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Summary 
 
Percutaneous coronary intervention (PCI) improves the blood supply to the heart 
by unblocking narrowed coronary arteries. Implantation of a coronary stent is 
usually required to scaffold the artery and improve long-term vessel patency. 
Drug-eluting stents (DES) have been developed to decrease the incidence of stent 
renarrowing, known as in-stent restenosis (ISR), the main limitation of bare 
metal stents (BMS). DES release potent drugs into the artery wall to inhibit cell 
division and attenuate ISR. However, this strategy can also impair vascular 
healing and increase the risk of stent thrombosis, which is a serious concern. 
Novel approaches to this problem are urgently required. Oxidative stress reflects 
a state in which reactive oxygen species (ROS) prevail over antioxidant defences. 
PCI causes a major release of ROS from the injured artery wall and these 
molecules appear to play an important role in critical signalling pathways 
involved in vascular repair. Numerous animal studies have found that oral 
antioxidants may reduce ISR and improve healing, yet these strategies have not 
been effective in humans. Stent-based delivery of antioxidants may offer more 
efficacious, targeted protection against oxidative stress than oral administration. 
The role of oxidative stress in endothelial repair mediated by bone marrow-
derived endothelial progenitor cells (EPCs) in patients with coronary heart 
disease is also poorly defined. The main aims of this thesis were: to determine 
the in vitro effects of oxidative stress on key aspects of thrombosis and vascular 
healing; to evaluate a novel antioxidant-eluting stent in an in vivo porcine model; 
and to examine the relationship between oxidised low-density lipoprotein 
(oxLDL), EPCs and coronary endothelial function in patients with stable angina. 
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Oxidative stress, generated by the xanthine/xanthine oxidase reaction, inhibited 
whole blood aggregation in a concentration-dependent fashion. This was 
probably due to an excess of ROS which impaired, rather than stimulated, 
thrombosis. Healthy endothelial cells (ECs) also inhibited whole blood 
aggregation, but this was not mitigated by oxidative stress. EC migration was 
assessed using an in vitro endothelial wound scratch assay. Oxidative stress was 
highly toxic to ECs and inhibited migratory activity. Nitrone D, a novel spin 
trapping antioxidant, was evaluated for its suitability as a novel DES coating. 
Nitrone D displayed weak antithrombotic effects, but markedly inhibited EC 
migration. Nitrone D was therefore unsuitable for a DES that was intended to 
improve re-endothelialisation.  
 
Oral probucol has established efficacy in animal models of restenosis, but not in 
humans. Probucol has been successfully incorporated as a dual DES coating with 
rapamycin in clinical trials. Succinobucol is a novel derivative of probucol with 
more potent antioxidant, anti-inflammatory and antiproliferative effects. A novel 
polymer-free succinobucol-eluting stent (SES) and succinobucol/rapamycin-
eluting stent (SRES) were developed and compared to a commercially available 
polymer-free rapamycin-eluting stent (RES) and BMS. Pharmacokinetic studies 
demonstrated optimal drug elution from the SES. However, in a porcine coronary 
model, the SES significantly increased neointimal thickness and aggravated ISR. 
The RES reduced neointimal thickness non-significantly, whereas the SRES 
caused no difference in neointimal thickness, compared with the BMS. The SES 
was associated with greater inflammation and persistent fibrin deposition around 
the stent struts, which are signs of defective healing. There were no significant 
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differences in endothelial regeneration between the groups. Subsequent cell 
culture studies found that succinobucol was toxic to ECs and smooth muscle 
cells. In the clinical study, circulating levels of EPCs were strongly correlated 
with coronary endothelial function, which is a novel finding. Plasma oxLDL 
levels were not correlated with EPCs or coronary endothelial function.  
 
In conclusion, ROS reflect a large array of molecules released after PCI that are 
multi-faceted regulators of platelets and vascular cells. As such, they represent a 
complex target for novel DES technologies. Excessive ROS may inhibit 
thrombus formation and delay re-endothelialisation. However, potent 
antioxidants delivered to injured arterial tissue after PCI may not necessarily 
encourage the physiological processes required to accelerate vascular repair. At 
high dose, local delivery of antioxidants may actually promote inflammation and 
aggravate ISR. Although oxLDL is known to induce endothelial dysfunction, it is 
not correlated with the number of circulating EPCs. These findings underline the 
complicated role of oxidative stress in vascular repair after PCI. Further studies 
are required to clarify whether antioxidants will ever provide advantages over 
existing options in the rapidly evolving field of interventional cardiology. 
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1.1 Preamble 
 
Coronary heart disease (CHD) is the leading cause of death and disability in the 
developed world. In 2007, the age-standardised mortality rates from CHD in 
Scotland were 89 per 100 000 men and 30 per 100 000 women, which are the 
highest in the United Kingdom (UK) (1). Although the incidence of CHD has 
decreased over the past decade, the economic burden is huge, costing the UK 
around £9.0 billion a year in 2006 (1). As a result, much effort is directed 
towards the development of effective, safe and lasting treatments for CHD.  
 
Initial management of CHD includes lifestyle modification and drug therapy 
which aim to reduce myocardial ischaemia and prevent myocardial infarction. 
Despite these measures, many patients remain symptomatic and therefore 
mechanical methods of improving coronary artery blood flow have been 
developed (coronary revascularisation). The earliest attempts to achieve coronary 
revascularisation led to the introduction of coronary artery bypass graft surgery 
(CABG), in which autologous venous and arterial grafts are used to bypass 
coronary artery stenoses or occlusions. CABG requires a general anaesthetic and 
is a major open heart operation, with a modest but appreciable early post-
operative risk of death (1-2%), a typical hospital stay of several days and a 
rehabilitation period of several months.  
 
Percutaneous coronary intervention (PCI) offers an alternative and much less 
invasive method of coronary revascularisation. It is performed under a local 
anaesthetic and involves percutaneous access to the coronary arteries via a 
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catheter which usually enters the circulation via the radial or femoral artery. 
Placement of a thin guide wire into a diseased coronary artery allows the passage 
of specialised equipment which is used to dilate a stenosis by inflation of a 
balloon catheter and ideally, deployment of an endovascular stent. PCI is capable 
of reopening a narrowed or blocked coronary artery (or coronary artery bypass 
graft), restoring normal epicardial blood flow and more importantly, re-
establishing normal myocardial perfusion. Patients undergoing PCI typically 
require minimal preparation, recover within hours and can often be discharged on 
the day of the procedure. Although procedural mortality associated with PCI is 
very low (0.1%), many patients suffer from progressive renarrowing or sudden 
blockage of the stent, therefore, the probability of requiring repeat 
revascularisation after PCI is currently higher than that after CABG (2). The 
natural history of PCI since inception has proven that refinement of technology 
can help to improve this situation, but current devices have brought with them 
their own limitations. Consequently, the discovery of novel approaches to 
improve the performance of stents remains crucial to the future development and 
success of PCI.  
 
1.2 PCI 
 
1.2.1 Historical aspects 
In 1964, Dotter and Judkins were first to report a new percutaneous technique to 
treat lower limb arteriosclerotic disease (3). However, it wasn’t until 1979 that 
Gruntzig et al. (4) published the first case series of 50 patients in whom 
percutaneously introduced inflatable balloon catheters were used to treat 
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coronary artery stenoses. The success of early balloon coronary angioplasty was 
tempered by the relatively high incidence of acute vessel closure and chronic 
renarrowing (restenosis), which often led to recurrent symptoms and a 
requirement for repeat procedures. In 1985, Palmaz et al. published the 
successful use of an endovascular metallic stent to prevent acute vessel recoil and 
limit late negative remodelling after balloon dilatation in dogs (5). The following 
year, Sigwart and Puel reported the first case series of patients who received self-
expandable stainless steel stents to treat ilio-femoral and coronary artery disease 
after failed balloon angioplasty or CABG (6). Due to the major reduction in the 
rate of restenosis and requirement for repeat revascularisation, there was a 
massive expansion in the use of coronary stents worldwide. By the end of the 
1990s, stents had become integrated into almost all PCI procedures. Like other 
modern medical treatments, PCI was subject to critical assessment of efficacy 
and cost-effectiveness and in 2000 the National Institute of Clinical Evidence 
published a report supporting the routine use of stents during PCI (7). The British 
Cardiovascular Intervention Society have reported national audit data showing 
that uptake of PCI to treat CHD has increased exponentially over the past twenty 
years, with 83 130 PCI procedures (1 345 PCI per million) performed in 105 
centres in the UK in 2009, producing a ratio of PCI to CABG in excess of 3:1. 
(Figure 1.1) (8). 
 
1.2.2 Clinical evidence 
In patients with stable angina, PCI is effective mainly to reduce symptoms. A 
systematic review of 6 prospective randomised controlled trials of PCI versus  
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Figure 1.1 PCI versus CABG frequency in the UK. 
An exponential rise in PCI procedures has occurred since the early 1990s, whereas the 
number of CABG operations has remained fairly constant. 
 
medical therapy in stable angina confirmed an improvement in symptoms and 
quality of life, but no significant differences in the subsequent risk of death or 
myocardial infarction (9). The majority of trials included in this review were 
performed in the 1990s, when most patients received balloon angioplasty only. 
The routine use of stents has considerably reduced the requirement for repeat 
revascularisation compared to balloon angioplasty, however a major randomised 
controlled trial in 2 287 stable angina patients failed to demonstrate a reduction 
in death or myocardial infarction, compared to optimal medical therapy (10). 
This trial was limited by the exclusion of high risk patients and crossover to 
revascularisation in around 30% of the medical therapy group during the course 
of the study. A large meta-analysis comparing PCI versus CABG in stable angina 
has yielded no difference in mortality or myocardial infarction, especially when 
stents are utilised (11).  
 28 
 
PCI can also be used to treat acute coronary syndromes, such as unstable angina 
or acute myocardial infarction. After non-ST elevation myocardial infarction 
(NSTEMI), an early invasive revascularisation strategy incorporating PCI or, to a 
lesser extent CABG, has been shown to prevent subsequent myocardial 
infarction and recurrent angina (12). Five year follow up data from a large UK 
randomised clinical trial has shown that high risk patients with non-ST elevation 
myocardial infarction achieve an overall mortality benefit with the routine use of 
invasive management (13). PCI for the treatment of ST elevation myocardial 
infarction (STEMI) has clear benefits compared with drug therapy and is now the 
preferred reperfusion strategy in the UK. A systematic review of the evidence for 
PCI to treat STEMI has demonstrated reductions in death, myocardial infarction 
and stroke, compared with thrombolytic drugs (14).  
 
1.2.3 Coronary stents 
The introduction of coronary stents to improve the performance of balloon 
dilation alone has been a major advance. The basic form of an uncoated coronary 
stent is known as a bare metal stent (BMS). The stent must be biologically inert 
and ideally provide a non-thrombogenic surface for blood flow. It must possess 
good radial strength to scaffold the artery reliably; however it must also be 
conformable to tortuous coronary anatomy and vessel irregularities. The field of 
stent design is continually evolving, although most BMS consist of a stainless 
steel or cobalt chromium tube into which laser guided cuts are made. The 
unexpanded stent is pre-mounted onto an angioplasty balloon catheter and is 
visible fluoroscopically during transit through the coronary circulation. When the 
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stent is optimally positioned over a coronary stenosis, the stent is deployed by 
inflating the balloon to high pressure (e.g. 14 atmospheres). The balloon is then 
fully deflated by applying negative pressure, which leaves the stent fully 
expanded against the artery wall before the balloon catheter can be withdrawn.  
 
Stents compress the fissured intima against the underlying media, reducing the 
propagation of arterial dissection after balloon dilation. Moreover, by scaffolding 
the artery, the lumen is protected from acute elastic recoil and chronic negative 
remodelling of the artery, which are the main causes of restenosis following 
balloon angioplasty (15). Due to their superior efficacy compared with balloon 
angioplasty alone, stents are now utilised in over 90% of PCI procedures (8). 
However late luminal loss is not abolished by stenting. Renarrowing still occurs 
and is caused primarily by excessive growth of neointimal tissue as a response to 
the deep vessel wall injury resulting from stent struts and the presence of a 
foreign body. This phenomenon is known as in-stent restenosis (ISR), which 
occurs to a greater extent than after balloon angioplasty and an example is shown 
in Figure 1.2. 
 
1.2.4 In-stent restenosis 
ISR occurs in 10-50% cases, depending on various stent, lesion and patient 
characteristics (16). The main predictors of ISR are the presence of diabetes 
mellitus, the treatment of long coronary lesions and small vessel diameter. ISR 
usually presents as a recurrence of stable angina symptoms but in around 10% of 
cases it can present as an acute coronary syndrome (17).  
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Figure 1.2 Angiographic illustration of ISR. 
An angiogram of the right coronary artery (RCA) shows a coronary catheter (C) placed 
at the ostium of the RCA, following injection of radio-opaque contrast. The magnified 
insert on the right demonstrates a previously implanted stent in the proximal segment of 
the artery (position of struts indicated by broken parallel lines) which has developed 
partial obstruction. This is due to encroachment of the lumen by neointimal tissue, 
causing ISR (visualised as a loss of contrast density within stent). 
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The process of ISR resembles the natural wound healing process following 
vessel injury, typically occurring over several weeks to months. An integrated  
view of the molecular and cellular events leading to ISR has been proposed by 
Welt and Rogers (18). Stent deployment causes severe endothelial denudation, 
which leads to platelet and fibrin deposition on the injured artery wall. Activated 
platelets expressing adhesion molecules, such as P-selectin, attach to circulating 
leucocytes via platelet receptors, such as P-selectin glycoprotein ligand. 
Leucocytes roll along the injured wall and then bind tightly to the surface 
through the leucocyte integrin Mac-1 (CD11b/CD18) class of adhesion 
molecules via direct attachment to the platelet receptor glycoprotein 1bα 
(GP1bα) and through cross-linking with fibrinogen to the GPIIbIIIa receptor. 
Under the influence of chemokines, such as monocyte chemoattractant protein-1 
(MCP-1), interleukin-6 (IL-6) and IL-8, released from vascular smooth muscle 
cells (SMCs) and resident macrophages, leucocytes infiltrate the artery wall. 
Growth factors such as fibroblast growth factor (FGF), platelet-derived growth 
factor (PDGF), insulin-like growth factor (IGF), transforming growth factor-β 
(TGF-β) and vascular endothelial growth factor (VEGF) are released from 
platelets, leucocytes and SMCs, which stimulate SMCs to proliferate and migrate 
from the media into the neointima. Ongoing SMC proliferation, macrophage 
infiltration and extracellular matrix production cause neointimal hyperplasia 
(NIH); the pathognomic feature of ISR. Although the luminal renarrowing due to 
elastic recoil and negative remodelling common after balloon angioplasty is 
prevented by the stent struts, the neointimal response is exaggerated and 
proportional to the degree of stent injury (19). Endothelial repair involves 
endothelial cell (EC) migration, which may be the critical and rate-limiting 
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initiating step, followed by EC proliferation (20). As the denuded endothelium 
regenerates, it completely recovers the neointimal surface, allowing the vessel to 
resume normal function.  
 
1.2.5 Endothelial regeneration 
The vascular endothelium lines the circulatory system throughout the body and 
provides a highly selective permeability barrier to contain the blood within the 
vascular space. The endothelium is integral to the control of several key vascular 
functions and provides extensive signalling capabilities to other cells via the 
release of cytokines and growth factors. Delayed or incomplete healing of the 
endothelium after PCI is undesirable for a number of reasons.  
 
First, the early regrowth of a functional endothelial layer is capable of 
attenuating NIH, the principle cause of ISR. After injury, ECs regulate SMC 
proliferation by the release of well-characterised growth promoters and inhibitors 
(21). Damage to the endothelium results in the activation of SMC proliferation, 
whereas repair of the endothelium leads to the reversal of this process and 
restoration of SMC quiescence (22). Endothelial progenitor cells (EPCs), derived 
from the bone marrow, also appear to contribute to endothelial regrowth, and 
intravenous transfusion of EPCs has been shown to reduce NIH in a mouse 
model of arterial injury (23). An early pilot study in patients using stents coated 
with anti-CD34 antibodies to target EPC surface antigens (Genous™ Bio-
engineered R stent, OrbusNeich, Hong Kong) demonstrated clinical efficacy with 
a low incidence of ISR (24). However, more recently the Genous™ stent was 
associated with a poor performance in lesions at higher risk of ISR, with 
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antirestenotic efficacy approaching that of a BMS, albeit with no cases of stent 
thrombosis (25). Gene transfer of VEGF in a rabbit model of balloon injury has 
inhibited NIH in some cases (26), but not in others (27), and the role of catheter-
based local VEGF gene delivery after human PCI is under investigation (28). A 
strategy utilising VEGF gene-eluting stents may be effective if the results of a 
promising rabbit study can be reproduced (29), although one clinical study had 
disappointing results (30). 
 
Second, the regeneration of the endothelium is crucial to restore normal vascular 
tone through the action of a number of vasoactive substances, including nitric 
oxide (NO) and prostacyclin. Coronary endothelial dysfunction is characterised 
by a reduction in NO bioavailability and is a recognised precursor to the 
development of coronary artery disease and subsequent vascular events (31). 
Therefore, it is conceivable that persistent endothelial dysfunction after PCI 
would increase the risk of late procedural complications.  
 
Finally, and particularly after stent deployment, regrowth of a functional 
endothelium is fundamental to luminal patency. An intact endothelial monolayer 
provides a non-thrombogenic surface for blood flow and acts as the primary 
regulator of haemostasis and thrombosis. The endothelium also serves as a non-
permeable barrier between circulating platelets and agonists, such as collagen, 
widely present in coronary plaque and artery wall, which profoundly stimulate 
platelet aggregation. The endothelium restricts exposure of blood coagulation 
factors to the subendothelial layer, which is rich in tissue factor, the primary 
trigger of the coagulation system. ECs themselves directly inhibit thrombosis via 
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the antiplatelet effects of released NO (32), prostacyclin (33) and CD39, an ecto-
ADPase (34). Endothelial-derived heparan sulfate, thrombomodulin and tissue 
factor pathway inhibitor are inhibitors of coagulation (35). The endothelium also 
regulates the endogenous fibrinolytic system by the release of endothelial tissue 
plasminogen activator (tPA), which plays a significant role in thrombus 
dissolution during acute coronary syndromes (36). Thus, in the milieu of an 
intrinsically thrombogenic metal stent, an absent or functionally deficient 
endothelium significantly impairs the natural defence of the stented coronary 
artery against acute occlusion, an event known as stent thrombosis. 
 
1.2.6 Stent thrombosis 
Implantation of a coronary stent immediately creates an intensely prothrombotic 
environment, which can lead rapidly to stent thrombosis (figure 1.3). As well as 
denuding the endothelium and exposing the intimal contents, the stent itself is 
highly thrombogenic. Platelet activation and aggregation are unavoidable 
consequences of arterial injury and preventative measures must be employed to 
prevent stent thrombosis. Improved operator technique and newer equipment 
have reduced the incidence of acute stent thrombosis, but the greatest impact has 
been made by the adoption of intensive adjunctive antithrombotic regimens. This 
usually includes at least two different antiplatelet drugs (aspirin, clopidogrel and, 
in high risk cases, a glycoprotein 2B/3A inhibitor) and intravenous anticoagulant 
therapy (heparin or bivalirudin). Despite this, stent thrombosis remains one of the 
most serious and life-threatening complications of PCI. Stent thrombosis is often 
a catastrophic clinical event, resulting in a large myocardial infarction with a 
high risk of death (37).  
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Figure 1.3 Angiographic illustration of stent thrombosis. 
A, Coronary angiogram with a coronary catheter (C) placed at the ostium of the right 
coronary artery (RCA) with a stenotic lesion (L) in the proximal segment.  
B, Angiographic result following dilation of the lesion and coronary stent implantation. 
C, Repeat angiogram several days later shows an early stent thrombosis (ST) with 
occlusive thrombus blocking the stent, which caused a large inferior myocardial 
infarction. D, Final angiographic result after the stent thrombosis has been treated using 
thrombus aspiration and further stenting. 
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Overall, the risk of stent thrombosis is related to a large number of patient, 
procedural and stent factors (Figure 1.4). Premature discontinuation of 
antiplatelet drug therapy is the strongest predictor of stent thrombosis and 
patients with renal failure, diabetes or acute coronary syndrome are also at higher 
risk (38;39). Patients undergoing non-cardiac surgery after coronary stenting are 
at greatly increased risk of stent thrombosis and associated cardiovascular 
complications during the first two months after PCI (40) and therefore non-
cardiac surgery should be deferred for several months unless absolutely 
necessary. A recent study showed no difference in the rates of stent thrombosis 
between BMS and drug-eluting stents (DES) in the early post-operative period, 
although important data on antiplatelet prescribing in either group were not 
reported (41). It is now recommended that dual antiplatelet therapy is continued 
where possible during the perioperative period to mitigate against the risk of 
stent thrombosis, unless there is an unacceptable risk of serious bleeding (42), 
such as neurosurgery. 
 
Figure 1.4 Risk factors for stent thrombosis. 
LV, left ventricular; RVD, reference vessel diameter. 
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In randomised clinical trials, stent thrombosis typically occurred after 
approximately 1-2% of PCIs (43;44). However, observational data from patient 
registries suggests the incidence of stent thrombosis in real world populations 
may be higher. Combined data from two large European centres (including 8 146 
patients) reported a 3 year incidence of angiographically proven stent thrombosis 
of 3%, occurring at a constant rate of 0.6% per year after the first year. (39). A 
registry of 5 842 ST-elevation myocardial infarction patients reported a 3.5% 
incidence of angiographically confirmed stent thrombosis within a month of 
primary PCI, of which half occurred during the first 24 hours (45). This 
discrepancy underlines the differences in patient populations selected for 
randomised clinical trials compared with contemporary clinical practice, with the 
latter group having more severe underlying disease, greater comorbidity and 
more complex PCI, increasing the risk of stent thrombosis (39). 
 
In order to more accurately quantify the incidence of stent thrombosis across 
different populations and make comparison between studies, the Academic 
Research Consortium (ARC) have introduced a classification system which has 
standardised the reporting of such events (46), the true incidence of which may 
be underestimated if based solely on angiographic confirmation (43). Definite 
stent thrombosis requires the presence of an acute coronary syndrome with 
angiographic or post-mortem evidence of thrombus or occlusion. Probable stent 
thrombosis includes unexplained death within 30 days of the procedure or acute 
myocardial infarction involving the vessel territory of the implanted stent without 
angiographic confirmation. Possible stent thrombosis includes all unexplained 
deaths occurring at least 30 days after the procedure. Using this classification 
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system, the cumulative rate of definite and probable stent thrombosis probably 
more accurately reflects and is now commonly used to approximate the incidence 
of stent thrombosis in research studies.  
 
Stent thrombosis is also categorised as early, occurring between 0-30 days (this 
can be sub-classified further into acute within 24 hours and subacute after 24 
hours); late, occurring between 31 days and 1 year; or very late, occurring more 
than 1 year after stent implantation (46). This distinction is important because 
stent thrombosis may occur at different time periods after PCI due to different 
pathophysiological processes.  
 
The first month after PCI represents the period when patients are at greatest risk 
of stent thrombosis (39). Early stent thrombosis is often associated with a 
procedural or technical problem with the stent. In an intravascular ultrasound 
(IVUS) registry of 53 patients with definite early stent thrombosis, 94% of cases 
demonstrated at least one abnormality on the original IVUS at the time of index 
PCI, such as undersizing of the stent, strut malapposition to the surrounding 
artery wall, edge dissection, thrombus formation or untreated disease at the 
inflow or outflow of stent (47). A registry of 201 early stent thromboses after ST-
elevation myocardial infarction discovered that unrecognised dissection, stent 
undersizing and small stent diameter were the strongest predictors for acute stent 
thrombosis (45). Lack of dual antiplatelet therapy or non-cardiac surgery are 
major risk factors for subacute stent thrombosis (38;41;45). The distinction 
between BMS and DES does not appear to play an important role in early stent 
thrombosis, as even BMS require at least one month to re-endothelialise and 
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therefore are both at increased risk of stent thrombosis during this time period, 
particularly if other risk factors are present. Late stent thrombosis occurs less 
frequently than early stent thrombosis although early discontinuation of 
antiplatelet therapy remains an important trigger (38;48). More complex PCI 
such as bifurcation stenting is also associated with higher risk during this period 
(38). Very late stent thrombosis, occurring at least one year after stenting, usually 
reflects impaired endothelial healing or persistent drug/polymer toxicity. The risk 
of stent thrombosis for BMS during this period is relatively low, because the 
stent struts are generally covered with new endothelial and neointimal tissue. The 
limitations of DES with regard to suboptimal healing and their increased risk of 
very late stent thrombosis will be discussed in more detail in section 1.2.7. A 
Japanese registry of 294 212 PCI procedures (exclusively sirolimus-eluting 
stents) yielding 611 ARC-definite stent thromboses confirmed previous studies 
that the majority of events occur within the first month after stenting (49). 
Characteristic factors predicting stent thrombosis after one month (late or very 
late stent thromboses) versus early stent thrombosis included haemodialysis, end-
stage renal disease, chronic total occlusions and age <65 years. Exploratory 
analyses demonstrated some differences in patient characteristics between late 
and very late stent thrombosis groups, with older age, lower body mass index and 
greater burden of vascular disease or diabetes more prevalent in patients with late 
as opposed to very late events, suggesting that comorbidity is a more prominent 
factor during the late period whilst usually receiving dual antiplatelet therapy. 
The one year mortality rate after late stent thrombosis appears to be higher than 
after acute or very late events (45;49), probably due to differences in presentation 
and important clinical factors as described above. 
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1.2.7 Drug-eluting stents 
Implantation of a metal stent into a diseased coronary artery has provided the 
cardiologist with a unique opportunity to deliver drugs directly into the 
surrounding artery wall in an attempt to modify the maladaptive thrombotic and 
hyperplastic responses to vessel injury and improve clinical performance. Local 
drug delivery from a DES aims to reduce the toxicity and compliance issues 
related to systemic administration. In order to control the drug release from the 
stent platform, the drug is eluted in a pre-specified pattern. To achieve this, the 
active drug is commonly carried by a polymer. The ideal polymer is biologically 
inert and should not promote inflammation or hypersensitivity because this may, 
in itself, lead to ISR or stent thrombosis (50).  
 
Clinical efficacy of first generation DES 
The first DES introduced to clinical practice was the sirolimus-eluting stent. 
Sirolimus (also known as rapamycin) is a natural macrocyclic lactone, which is a 
product of the bacterium Streptomyces hygroscopicus. Sirolimus acts by 
inhibiting the mammalian target of rapamycin (mTOR). It has significant anti-
inflammatory and immunosuppressive effects and is used to prevent rejection 
after organ transplantation. Recognition of its potent antiproliferative properties 
led to clinical studies, which confirmed its efficacy as an antirestenotic stent 
coating. The Cypher® stent (Cordis, Johnson and Johnson) is a commercially 
available sirolimus-eluting stent and utilises a stainless steel stent and permanent 
polymer to control drug release. Early human experience with both slow and fast 
release profiles for the sirolimus-eluting stent was favourable, demonstrating 
long term efficacy in the prevention of NIH, particularly with the slow release 
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version which is currently used in clinical practice (51). There have been many 
large randomised controlled trials comparing sirolimus-eluting stents with BMS 
in stable CHD. Early trials such as RAVEL (52) and SIRIUS (53) were first to 
report. In a subsequent meta-analysis, it was found that sirolimus-eluting stents 
led to an impressive reduction in ISR in the first year compared with BMS, from 
37% to 6% respectively (54). In addition, large improvements in target lesion 
revascularisation were found comparing sirolimus-eluting stents with BMS, from 
19% to 4% respectively. Up to a year, there was no difference in the incidence of 
myocardial infarction or death in patients with the sirolimus-eluting stent. It was 
worth noting that these trials involved relatively low risk patients and lesions, 
often in the absence of multiple medical comorbidities or presence of multivessel 
disease, which is misrepresentative of contemporary interventional practice. The 
real world effectiveness of sirolimus-eluting stents has been examined in 
prospective registries, and these have shown repeat revascularisation rates of up 
to 10% within a year in more complex cases (55). 
 
Paclitaxel-eluting stents were next to show encouraging results. Paclitaxel is an 
anticancer drug which also has potent antiproliferative effects. Paclitaxel-eluting 
stents are currently marketed as the Taxus® stent (Boston Scientific). The main 
source of evidence came from the TAXUS trial program (56). Paclitaxel is also 
carried in a permanent polymer, and both slow and moderate release profiles 
have been studied. Although both DES provided excellent suppression of NIH, 
the slow release Taxus® is currently the only commercially available version. A 
meta-analysis of the TAXUS program demonstrated a reduction in ISR using the 
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Taxus® from 24% to 7%, and reductions in target lesion revascularisation from 
12% to 3%, compared with BMS (54).  
 
A comprehensive meta-analysis of all randomised trials and observational studies 
of first generation DES (sirolimus- or paclitaxel-eluting stents) in which greater 
than 100 patients were enrolled with at least one year follow-up was performed 
by Kirtane et al. (57). This demonstrated that in randomised trials (9 470 patients 
in 22 studies), first generation DES led to a significant reduction in target vessel 
revascularisation compared with BMS (hazard ratio, 0.45; 95% CI, 0.37 to 0.54), 
with no significant differences in mortality or myocardial infarction. When all 
observational studies were analysed (182 901 patients in 34 studies), DES were 
associated with a similar reduction in target vessel revascularisation (hazard 
ratio, 0.54; 95% CI, 0.48 to 0.61), but also a significant reduction in mortality 
(HR, 0.78; 95% CI 0.71 to 0.86) and myocardial infarction (HR, 0.87; 95% CI, 
0.78 to 0.97), compared with BMS. Whilst accepting the potential for selection 
bias and residual confounding of observational data, this suggests that real-world 
use of DES retains efficacy outside of the carefully selected populations of 
randomised controlled trials and may be responsible for a lower rate of adverse 
cardiac events in higher risk patients with more complex CHD, compared with 
BMS. In the UK, DES are used in greater than 60% of PCI procedures, 
especially in diabetic patients and those patients with long or narrow coronary 
lesions, where the risk of ISR is higher and efficacy of DES greater in absolute 
terms (8).  
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Limitations of the first generation DES 
First generation DES limit ISR by inhibiting the cell cycle of proliferating cells. 
Sirolimus-eluting stents also reduce MCP-1 and IL-6 expression (58), and 
paclitaxel is known to influence inflammatory cell adhesion (59). However, 
whilst they are designed to arrest vascular SMC growth, it is not surprising that 
these potent antiproliferative compounds also have long-term effects on other 
nearby cells. Importantly, paclitaxel inhibits EC migration, whereas both 
paclitaxel and sirolimus inhibit EC proliferation (60). Sirolimus also inhibits 
proliferation of EPCs (61). These toxic effects are evident in pathological 
examinations of sirolimus- and paclitaxel-eluting stents, which frequently show 
evidence of poor healing, characterised by persistent fibrin deposition and 
incomplete re-endothelialisation (62). In addition, chronic eosinophilic 
infiltration (hypersensitivity), probably due to the polymer, may be seen and 
these findings have been closely linked to stent thrombosis. As well as impairing 
the endothelium regrowth, both sirolimus- and paclitaxel-eluting stents induce 
endothelial tissue factor expression which promotes a thrombogenic environment 
(63). Angioscopic examination of the sirolimus-eluting stent in situ has 
visualised incomplete healing and exposed stent struts persisting at a time when a 
BMS has fully re-endothelialized, and this may be associated with subclinical 
thrombus formation (64-66). Sirolimus- and paclitaxel-eluting stents may also 
lead to an increased risk of late acquired malapposition (67); a finding which 
may predict stent thrombosis (47). The sirolimus-eluting stent has been shown to 
cause endothelial vasomotor dysfunction in the adjacent vessel segments (68), 
indicating functional impairment resulting from DES implantation. 
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Owing to suboptimal endothelial regeneration after DES treatment, combined 
antiplatelet therapy with aspirin and clopidogrel is extended by at least several 
months during the perceived re-endothelialisation period. If prolonged dual 
antiplatelet regimes are used, DES do not appear to increase the risk of stent 
thrombosis at 12 months compared with BMS (69). However, as follow-up 
continues beyond a year, there is concern that first generation DES may present 
an increased risk of late myocardial infarction and death, a clinical surrogate of 
stent thrombosis (70;71). Although complete patient level meta-analyses of the 
randomised trials with first generation DES demonstrated no overall difference in 
cardiovascular events compared with BMS, there is an increased risk of late stent 
thrombosis (72). Therefore, there is now a considerable need to ensure the next 
generation of DES are effective and safe, and that means ensuring the 
endothelium is able to regenerate in a timely fashion. 
 
Recent developments in DES and polymers 
Following the introduction of the sirolimus- and paclitaxel-eluting stents and 
especially since the reporting of late stent thrombosis, there has been interest in 
testing novel DES with alternative biological profiles. By modifying the 
chemical structure of sirolimus (rapamycin) slightly, it is possible to create 
derivatives with improved tissue absorption and differential effects on cell 
proliferation. Zotarolimus is a highly lipophilic sirolimus analogue with 
antiproliferative and anti-inflammatory properties. A zotarolimus-eluting stent 
has been tested as part of the Endeavor® stent program (Medtronic Vascular), 
utilising a cobalt alloy stent platform and biocompatible phosphorylcholine 
polymer. The zotarolimus-eluting stent effectively reduced ISR compared with 
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BMS (73), but led to higher rates of ISR and repeat revascularisation compared 
with first generation sirolimus-eluting stents (74). The thin-strut permanent 
fluoropolymer-based everolimus-eluting cobalt chromium stent (Xience V®; 
Abbott Advanced Cardiovascular Systems) has excellent efficacy in terms of 
reducing the incidence of ISR compared with BMS (75) and paclitaxel-eluting 
stents (76). 3 year randomised clinical trial data involving 1 302 patients in the 
SPIRIT II and SPIRIT III randomised trials reported a significant reduction in 
myocardial infarction and target lesion revascularisation in the everolimus-
eluting Xience V® stent group compared with the paclitaxel-eluting Taxus® 
stent group. The cumulate rates of ARC-defined definite or probable stent 
thromboses were 1.2% in the everolimus-eluting stent patients versus 1.9% in 
paclitaxel-eluting stent patients, which was not significant  (77). 
 
Polymers used to coat the stent and act as a drug delivery mechanism for 
biologically active agents vary in suitability, with some causing a considerable 
increase in neointima formation in animal models (78). Although 
phosphorylcholine (which occurs naturally in red blood cell membranes) is 
thought to be a highly biocompatible polymer, its clinical use in DES 
(specifically zotarolimus-eluting Endeavor® stents) has been associated with 
increased rates of ISR compared with other durable polymeric DES platforms 
(73;74), most likely due to excessively rapid drug release. Furthermore, similar 
neointimal responses to BMS have been reported in some cases (79). A 
preclinical comparison of a phosphorylcholine versus a fluorinated copolymer 
(as found on everolimus-eluting Xience V® stents) in rabbit iliac arteries has 
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reported that the extent of re-endothelialisation and inflammatory response was 
similar (80).  
 
Localized hypersensitivity reactions in the artery wall associated with long-term 
exposure to first generation DES polymers (62) have prompted attempts to 
provide effective drug elution without the use of a permanent polymer. One such 
development is the introduction of the bioabsorbable polymer, which degrades 
over 6-9 months, removing the chronic stimulus for polymer-induced 
inflammatory reactions after drug elution is complete. An everolimus-eluting 
stent with a bioabsorbable polymer (polylactic acid, which degrades into carbon 
dioxide and water) has undergone investigation, and early trials demonstrate a 
reduction in the incidence of ISR compared with BMS (81;82). Excellent 
efficacy and safety data have also been reported in the LEADERS randomised 
trial of a biolimus-eluting stent (Biomatrix™; Biosensors International) which 
also utilises a biodegradable polylactic acid polymer (83) and showed non-
inferior efficacy to the polymeric sirolimus-eluting Cypher® stent. Although an 
optical coherence tomography substudy of the LEADERS trial demonstrated 
improved strut coverage in the Biomatrix™ compared with the Cypher® stent 
(84), a clear reduction in the risk of stent thrombosis using biodegradable stent 
polymers has not yet been shown.  
 
Polymer-free DES technology 
The ideal DES situation may be the carriage and controlled release of a drug 
from a stent without the necessity of a polymer, thereby obviating all potential 
toxicity. It has been shown in rabbit iliac artery stenting that whilst omission of a 
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polymer altogether may attenuate the neointimal suppression achieved by a DES 
(likely due to accelerated drug release), it may allow improved re-
endothelialisation and reduced local arterial inflammation (85). Reasonable 
results were demonstrated by a non-polymer paclitaxel-eluting stent (86;87). If 
non-polymer DES can achieve improved control of drug elution, equivalent to 
polymeric DES, then improved efficacy would be expected. The Yukon® 
(Translumina®, Germany) stent platform incorporates a microporous surface to 
improve drug release characteristics and has been tested extensively as part of the 
ISAR-TEST clinical trial program. An early randomised clinical study by Dibra 
et al. initially showed that the surface modification of the Yukon® stent alone 
caused a trend to reduced ISR compared with smooth surface uncoated stents, 
suggesting that the microporous stent surface was highly biocompatible and 
suitable for DES investigation (88). A polymer-free rapamycin-eluting Yukon® 
stent was subsequently tested in the randomised controlled ISAR-TEST study in 
450 patients and found to have equivalent efficacy to the permanent polymer 
paclitaxel-eluting Taxus® stent (89). Later studies compared the polymer-free 
Yukon® rapamycin-eluting stent with more effective DES platforms. Two year 
follow-up data from the ISAR-TEST-3 clinical study has shown that whilst that 
the polymer-free Yukon® rapamycin-eluting stent was associated with greater 
late loss in the first year, its efficacy was equivalent to both permanent polymer 
(Cypher®) or biodegradable polymer rapamycin-eluting stents after two years, 
due to late “catch-up” luminal loss in the polymer-based platforms (90). Further 
modification of the polymer-free Yukon® rapamycin-eluting stent has been 
investigated, leading to the incorporation of the antioxidant probucol as a dual 
stent coating. The addition of probucol has been shown to retard rapamycin 
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release analogous to that of a permanent polymer (91). A polymer-free Yukon® 
dual rapamycin/probucol-eluting stent (dual-DES) has delivered excellent 
clinical results as part of the ISAR-TEST-2 randomised clinical trial. This study 
in 1 007 patients found that the dual-DES led to significantly lower rates of ISR 
and target lesion revascularisation than the Endeavor® zotarolimus-eluting stent 
and a trend to lower rates compared with the Cypher® sirolimus-eluting stents 
after two years follow-up (92). Exploratory analysis of this study showed that the 
extent of late clinical restenosis (target lesion revascularisation between 1 and 2 
years) was significantly greater in the Cypher® group, compared with the 
polymer-free dual-DES. Similar to previous trials, there was no significant 
difference in death, myocardial infarction or stent thrombosis, although these 
studies are not individually powered to detect differences in these outcomes. 
 
Perhaps the final frontier for stent-based drug delivery is the fully bioabsorbable 
DES, so long as the mechanical properties of metal stents can be successfully 
reproduced (93). A landmark clinical study of a fully bioabsorbable everolimus-
eluting stent utilising a polylactic acid polymer reported promising results, 
although the mean in-stent late loss of 0.48 mm and diameter stenosis of 27% 
after two years is inferior to contemporary DES (94). Future refinement of the 
bioresorbable scaffold is likely to allow these devices to compete with the next 
generation of metal stent based devices. 
 
To summarise the DES story so far, the uptake of evolving technology has led to 
major improvements allowing the provision of lasting percutaneous coronary 
revascularisation for patients with CHD. Improvements in stent design and 
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incorporation of novel drugs and polymers with improved efficacy and 
biocompatibility have resulted in rates of ISR much lower to that first witnessed 
using BMS. In terms of antiproliferative drugs, limited preclinical data suggests 
that everolimus (95;96), tacrolimus (97;98) or biolimus (99) may have superior 
effects on EC biology compared with sirolimus. Increasing experience with 
biodegradable and polymer-free DES has hinted that the risk of late “catch up” 
restenosis and very late stent thrombosis (both occurring after one year) may be 
lower with these platforms. However, there is currently no consistent data yet to 
prove that either second or third generation DES result in lower rates of hard 
clinical events such as stent thrombosis, myocardial infarction and death. 
Evaluation of aggregate long-term efficacy and safety data from large-scale 
randomised trials of these newer DES is awaited with interest. 
 
1.3 Oxidative stress 
 
1.3.1 Oxidative stress and cardiovascular disease 
Reactive oxygen species (ROS) are highly reactive molecules released from the 
artery wall and circulating cells that have a profound impact on many biological 
processes. Increased production of ROS is a characteristic feature of several 
cardiovascular diseases such as atherosclerosis, hypertension and diabetes 
mellitus. ROS are capable of oxidising other substances by becoming reduced 
themselves. Oxidative stress is a phenomenon which describes the net influence 
of oxidants such as ROS over antioxidant defences. Oxygen is an abundant 
molecule found in humans and the relatively stable oxygen molecule can 
undergo univalent reduction to form the superoxide anion (O2-), a powerful ROS 
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and a major component of oxidative stress. The formation of O2- occurs through 
the action of a number of enzymes, the foremost of which is believed to be 
nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide phosphate 
(NADH/NADPH) oxidase. This enzyme is active in ECs, vascular SMCs, 
leucocytes and platelets, often as a response to vascular injury. 
 
Other enzymes contributing to oxidative stress include xanthine oxidase (XO), 
which generates O2- by catalyzing hypoxanthine and xanthine to uric acid, nitric 
oxide synthase (NOS), which generates the free radical NO from L-arginine and 
the lipoxygenases, which oxidise polyunsaturated fatty acids to hydroperoxy 
fatty-acid derivatives. Oxygen can also be converted into O2- nonenzymatically 
as a result of electron transfers in the mitochondrial electron transfer chain (100). 
O2- can be dismutated to form another biologically active ROS, hydrogen 
peroxide (H2O2) through the action of superoxide dismutase (SOD). H2O2 can be 
decomposed into water and oxygen by the enzyme catalase. Other highly 
influential ROS include peroxynitrite (ONOO-), which is formed by the reaction 
between O2- and NO, and the hydroxyl anion (OH-), which is generated by the 
reaction between O2- and H2O2. Both ONOO- and OH- anions are very strong 
oxidants.  
 
Oxidative stress is critically involved in the pathophysiology of atherosclerosis 
(Figure 1.5) (101). Circulating low density lipoprotein (LDL) in the blood is 
oxidised by ROS to form oxidised low-density lipoprotein (oxLDL). OxLDL is 
capable of causing damage to the vascular endothelium and this promotes the 
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Figure 1.5 Oxidative modification hypothesis of atherogenesis. 
Circulating monocytes in the bloodstream are drawn into the subendothelial space and 
become macrophages. Native LDL is taken up and oxidised by ROS such as O2- released 
from local vascular SMCs, ECs and macrophages. Macrophages take up oxLDL to 
become foam cells, which are precursors to atherosclerotic development. OxLDL causes 
endothelial dysfunction and injury which encourages monocyte recruitment and inhibits 
macrophage regress back into lumen. 
 
transport of lipoproteins into the artery wall to form the fatty streak (102). 
Oxidative stress, and in particular the activity of the ROS producing enzyme, 
NADPH oxidase, is an important contributor to coronary plaque instability, 
which can trigger acute coronary syndromes by leading to plaque rupture and 
resulting in thrombotic occlusion of the artery (103).  
 
1.3.2 Antioxidants and cardiovascular disease 
In response to numerous different ROS found in biological systems, cells have 
evolved to develop potent defensive antioxidant strategies. Endogenous 
antioxidant enzymes include SOD, catalase, glutathione peroxidase and glucose-
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6-phosphate dehydrogenase. Non-enzymatic antioxidants include glutathione, 
ascorbate (vitamin C), α-tocopherol (vitamin E) and high-density lipoprotein 
(HDL). 
 
Given that oxidative stress is a hallmark of many cardiovascular disease 
processes, much work has been done to determine if oral supplementation of 
antioxidants can prevent clinical events such as myocardial infarction and 
cardiovascular death. Some early trials showed promising results. In addition to 
its antiplatelet and anti-inflammatory actions, Vitamin E reduces the oxidation of 
LDL and is perhaps the most widely tested antioxidant therapy in clinical studies 
(104). The Cambridge Heart Antioxidant Study (CHAOS) randomised 2 002 
patients with proven CHD to oral vitamin E or placebo and demonstrated a 
reduction in the primary endpoint of cardiovascular death or non-fatal 
myocardial infarction (105). However, the encouraging results of CHAOS have 
not been confirmed in larger randomised studies. In the 9 541 patient Heart 
Outcomes Prevention Evaluation (HOPE) trial, vitamin E failed to reduce 
cardiovascular events in patients with high cardiovascular risk (106). Similarly, 
negative results were reported using Vitamin E in the post-myocardial infarction 
GISSI-Prevenzione trial (107) and the Heart Protection Study (HPS), which 
investigated the use of a combination of antioxidant vitamins for primary and 
secondary prevention (108). 
 
The failure of systemic antioxidants to reduce cardiovascular events in clinical 
trials has been discussed widely and some authors speculate on an inability to 
target therapies to population subtypes with enhanced oxidative stress such as 
 53 
diabetics or end-stage renal disease (109). Others suggest that more potent 
antioxidants are required to demonstrate clinical benefit (110). Crucially, very 
few studies have evaluated oxidative status at a cellular level in treated patients, 
instead opting to supplement antioxidants without confirming antioxidant 
efficacy. Nevertheless, on the basis of current evidence, oral antioxidant 
supplementation is not recommended for the prevention of cardiovascular events. 
The local delivery of antioxidants directly to the vascular wall represents an 
opportunity to achieve high concentration at the intended site of action with 
relatively few side-effects, although this technique is currently poorly studied.  
 
1.3.3 Oxidative stress and PCI 
Evidence for increased oxidative stress following PCI 
Inflation of an angioplasty balloon to high atmospheric pressure to dilate a 
stenotic coronary artery with deployment of a metal stent causes extensive 
mechanical trauma to the artery wall, resulting in marked vessel injury. As a 
result, the artery releases a large amount of ROS. 
 
Ex-vivo rabbit artery rings subjected to balloon injury demonstrated immediate 
release of ROS as a result of vessel wall NADPH oxidoreductase activity (111). 
The release was proportional to degree of injury and not prevented by prior 
removal of the endothelium or antagonism of other ROS generating sources such 
as XO, NOS or mitochondrial electron transport. Another study demonstrated 
that ex-vivo porcine coronary artery segments continue to release large amounts 
of O2- for at least several days after in vivo balloon injury (112). O2- production 
was essentially abolished after pretreatment of the artery ring with the NADPH 
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oxidase inhibitor, diphenyleneiodonium (DPI), again underlining the 
predominance of this enzyme in ROS generation after balloon injury.  
 
A method for in vivo estimation of oxidative stress as a result of PCI in humans 
involves simultaneous assay of coronary sinus blood, which provides venous 
drainage for the heart. Compared to upstream left main coronary artery blood, 
isoprostanes (end-products of ROS mediated-lipid peroxidation) are increased 
(113). Coronary angioplasty in humans also causes an acute increase in plasma 
levels of oxidised lipoproteins (114;115). The acute increase in oxidative stress 
following PCI may be partly responsible for impaired microcirculatory function 
after stent deployment. In a study of stable angina patients, the administration of 
intravenous ascorbic acid was shown to decrease the release of oxidative 
biomarkers (8-hydroxy-2-deoxyguanosine and 8-iso-prostaglandin F2alpha) and 
improve angiographic evidence of myocardial perfusion following elective PCI 
(116), although no differences in clinical outcome were detected. 
 
The influence of oxidative stress on cellular processes after PCI 
It is clear that oxidative stress is enhanced after arterial injury and, by influencing 
multiple signalling pathways of vascular repair, it appears to play an important 
role in the regulation of NIH (117). Early transient exposure to oxidised 
glutathione, a recognised consequence of oxidative stress, is capable of 
amplifying cell proliferation and NIH, which is sustained for weeks after arterial 
balloon injury and mediated through a redox-active metal-dependent pathway 
(118). The activation of the transcription factor nuclear factor κB (NF-κB) is 
enhanced by redox processes after injury (111) and this may have a lasting effect 
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on the gene programme involved in NIH, including expression of vascular cell 
adhesion molecule-1 (VCAM-1), MCP-1 and other pro-inflammatory factors 
(119;120). ROS also serve as second messengers to activate many intracellular 
proteins and enzymes, including the epidermal growth factor receptor (EGFR), c-
Src, p38 mitogen-activated protein kinase (MAPK), Ras and Akt/PKB, which 
suggests a significant role in the regulation of vascular SMC growth and 
migration, modification of extracellular matrix and modulation of EC function 
(121). The response of vascular SMCs to PDGF, which includes tyrosine 
phosphorylation, MAPK stimulation, DNA synthesis and chemotaxis, is at least 
partly dependent on elevated intracellular levels of the ROS, H2O2 (122). The 
prominent influence of oxidative stress on NIH after vascular injury is matched 
by a major involvement in the regulation of endothelial recovery. OxLDL formed 
by the oxidative modification of native LDL in the bloodstream is widely present 
in coronary artery lesions. Atherosclerotic plaques enriched with high levels of 
oxLDL are more likely to become unstable (123), and plasma oxLDL is acutely 
elevated after PCI (115). oxLDL is toxic to EPCs (124), which are likely to 
suffer from impaired antioxidant defences in the presence of atherosclerosis 
(125). oxLDL is also a potent inhibitor of EC migration and this occurs via an 
O2- dependent mechanism (126). As a result, oxLDL may influence healing of a 
stent deeply embedded in coronary lesions so that the rate of endothelialization is 
suboptimal, even after BMS. The inhibitory effect of oxLDL on EC migration in 
culture is blocked by the antioxidant vitamin E (127). Uptake of the lipophilic 
antioxidants probucol and vitamin E, both stimulate EC proliferation in culture 
(128) and are protective against the harmful effects of other ROS (129). NO 
released by the endothelium encourages migration and growth of ECs (130), and 
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endothelial NOS (eNOS) expression is increased in regenerating endothelium 
following injury (131). However, in situations where there is major oxidative 
stress, such as PCI, there may be widespread scavenging of NO by released ROS, 
such as the reaction of NO with O2- to form ONOO-, one of the most potent 
endocellular oxidants (132). The protective effect of NO on endothelial 
regeneration may be lost and, instead, ONOO- produced, which is harmful to 
ECs (133). These findings support a role for antioxidant therapy delivered to the 
site of arterial injury to defend the regenerating endothelium against the 
deleterious effects of oxLDL, O2-, ONOO- and other toxic ROS, whilst allowing 
NO to establish a protective effect on the endothelial healing process. 
 
Inhibition of thrombus formation and promotion of endothelial regeneration after 
PCI is highly preferable to reduce the risk of stent thrombosis. The underlying 
pathophysiology of arterial thrombosis is intrinsically linked to oxidative stress 
(134). Primarily, ROS inactivate NO, which has important antiplatelet actions 
(32). Vitamin E supplementation in healthy individuals has been shown to inhibit 
platelet aggregation (135). It has also been shown to decrease oxidative stress, 
increase platelet NO release, delay intra-arterial thrombus formation (136) and 
improve fibrinolysis via a reduction in plasminogen activator inhibitor activity 
(137). The antioxidant, N-acetyl-cysteine has been shown to reduce the 
procoagulant response following aortic balloon injury by decreasing bound 
thrombin activity and platelet adhesion (138). Other antioxidant compounds have 
been shown to inhibit platelet aggregation. A series of caffeic acid anilides 
exhibited potent anti-oxidative activities and inhibited arachidonic acid-induced 
platelet aggregation (139). Pomegranate juice, a natural source of antioxidants, 
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inhibited human platelet aggregation in response to collagen (140). Antioxidant 
flavonoids from black tea were found to decrease platelet aggregation in healthy 
human subjects (141). DPI, an inhibitor of NADPH-oxidase, also inhibits platelet 
aggregation (142). 
 
Despite the relative wealth of in vitro and animal data implying the importance 
of oxidative stress and the ability of some antioxidants to influence critical 
molecular and cellular vascular pathophysiological processes, less impressive 
results have been witnessed in human studies with no consistent evidence that 
these compounds have the capacity to influence hard clinical outcomes such as 
myocardial infarction or cardiovascular death.  
 
1.3.4 Antioxidants and PCI 
Much of the experimental data supporting the role of antioxidants to inhibit NIH 
and improve endothelial repair has been reinforced by several in vivo studies 
suggesting that strategies to decrease oxidative stress can reduce restenosis and 
encourage re-endothelialization after PCI (Table 1.1). As the major source of 
ROS after balloon injury is via NADPH oxidase, inhibitors of this enzyme have 
been tested and found to reduce NIH in animal models (143;144). Delivery of 
extracellular SOD gene therapy to the artery wall after balloon denudation of the 
rabbit aorta reduced NIH and improved endothelial recovery (145). Another 
study in atherosclerotic rabbit iliac arteries showed that gene transfer of SOD and 
catalase dramatically reduced ROS release from the artery wall after balloon 
angioplasty (146). This was accompanied by less neointimal inflammation and  
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Table 1.1 Main antioxidant studies for restenosis and re-endothelialisation. 
Study 
(ref) 
Anti-
oxidant 
Species and dose Main findings 
Jacobson et al. 
(143) 
NOX 
inhibitor 
Rat carotid balloon injury  
IP minipump 
Reduced NIH (p<0.05) 
Dourron et al. 
(144) 
NOX 
inhibitor 
Rat carotid balloon injury 
Gene transfer 
Reduced NIH (p<0.05) 
Laukkanen et al. 
(145) 
SOD Rabbit aortic balloon injury 
Gene transfer 
Reduced NIH, improved  
re-endothelialisation (both p<0.001) 
Durand et al. 
(146) 
SOD/CAT Rabbit iliac balloon injury 
Gene transfer 
Reduced restenosis, improved  
re-endothelialisation (both p<0.05) 
Schneider et al.  
(147) 
Probucol Pig coronary balloon injury 
Oral 2 g/day 
Reduced NIH (p=0.007) 
Miyauchi et al. 
(148) 
Probucol Rabbit carotid balloon injury 
Oral 1.3 g/day 
Reduced NIH (p<0.05) 
Lau et al.  
(149) 
Probucol Rabbit aortic balloon injury 
Oral 0.75% wt/wt 
Reduced NIH, improved  
re-endothelialisation (both p<0.05) 
Tanous et al. 
(150) 
Probucol Rabbit aortic stent  
Oral 1% wt/wt 
Reduced NIH and restenosis (both p<0.05), 
improved re-endothelialisation (p=0.008) 
Tardif et al.  
(151) 
Probucol Human PTCA  
Oral 1 g/day 
Reduced restenosis (improved remodelling) 
(p=0.003) and repeat PTCA (p=0.009) 
Yokoi et al.  
(152) 
Probucol Human PTCA  
Oral 1 g/day 
Reduced restenosis (p<0.01) 
Sekiya et al. 
 (153) 
Probucol Human coronary stent  
Oral 500 mg/day 
Reduced restenosis rate (17% vs 32%, 
p=NS), with cilostazol (p<0.05) 
Kim et al.  
(154) 
Probucol Human coronary stent  
Oral 500 mg/day 
Reduced restenosis rate (21% vs 24%, 
p=NS) 
Wakeyama et al. 
(155) 
Probucol Human coronary stent  
Oral 500 mg/day 
Reduced NIH (<0.001) and reduced 
restenosis (p=0.1)  
Tardif et al.  
(156) 
Probucol Human coronary stent  
Oral 1 g/day 
Increased follow up LA (p<0.05) due to 
greater acute gain 
Nunes et al.  
(157)  
Probucol Human coronary stent  
Oral 1 g/day 
No effect on NIH or restenosis 
Kim et al.  
(158) 
Probucol Pig coronary DES  
Stent delivery 
No effect on NIH or restenosis 
Tardif et al.  
(156) 
AGI-1067 
(succinobucol) 
Human coronary stent  
Oral 280 mg/day 
Increased follow up LA (p<0.05) due to 
greater acute gain 
Kim et al.  
(158) 
Carvedilol Pig coronary DES  
Stent delivery 
Reduced NIH (p=0.004) and reduced 
restenosis (p=0.002) 
NOX, NADPH oxidase; IP, intraperitoneal; CAT, catalase; PTCA, percutaneous 
transluminal coronary angioplasty; LA, lumen area. 
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reduced restenosis, with improved re-endothelialization and endothelial function. 
However, there is no data yet to suggest that incorporation of gene transfer to 
reduce restenosis in humans is a viable option and therefore these studies have 
poor applicability. Most techniques to deliver gene-based therapy during 
angioplasty rely on infusion of active treatments directly into the artery wall and 
therefore have significant practical limitations, compared with DES. Despite 
some evidence that NO encourages EC growth in vitro, L-arginine (a NO 
precursor) had no effect on re-endothelialization in denuded rabbit iliac arteries, 
although it effectively inhibited neointimal growth (159).  
 
Early trials of probucol administration in animal models of balloon angioplasty 
demonstrated a reduction in NIH and restenosis (147;148). Probucol restricts the 
severity of NIH by inhibiting vascular SMC proliferation via enhanced G1/S-
phase growth arrest and improving endothelial healing (149). A major 
mechanism by which probucol mediates these beneficial effects is believed to be 
via up-regulation of heme oxygenase-1, which induces SMC apoptosis (by 
producing heme breakdown products carbon monoxide, biliverdin and bilirubin) 
and promotes EC function (160). In keeping with these findings, supplementation 
of probucol inhibited NIH and improved re-endothelialisation in a rabbit model 
of aortic balloon injury (149). Owing to the positive animal studies, probucol has 
now been extensively tested in clinical trials, perhaps more than any other 
antioxidant compound. The Multivitamins and Probucol (MVP) trial and 
Probucol Angioplasty Restenosis trial (PART) both reported a clear reduction in 
restenosis after coronary angioplasty (151;152). However, a subsequent IVUS 
substudy of the MVP trial showed that the beneficial effect of probucol was 
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related to improved post-angioplasty remodelling, rather than suppression of NIH 
(161).  
 
Investigation in the stent era has continued with a variety of clinical trials 
examining the effects of oral probucol on ISR. Oral probucol approximately 
halved ISR rates in one clinical trial, although the effect was only significant 
when the drug was combined with the phosphodiesterase inhibitor, cilostazol 
(153). A trend to inhibit ISR was reported in another clinical study (162); 
however, the trial design was criticised due to inadequate preloading of oral 
probucol, which accumulates slowly in tissues and is usually commenced four 
weeks before the procedure. A clinical trial designed to determine the effect of 
candesartan and probucol on ISR found no benefits from angiotensin receptor 
blockade; however, using probucol, there were significant reductions in 
angiographic late loss and NIH by IVUS analysis (155).  
 
The large Canadian Antioxidant Restenosis Trial (CART-1) was a multi-centre, 
double-blind, placebo-controlled randomised trial in 305 patients comparing oral 
administration of probucol, succinobucol (AGI-1067) or placebo after PCI (156), 
involving stents in 85% of patients. Succinobucol is a novel probucol derivative 
with superior pharmacokinetic, antioxidant and anti-inflammatory properties 
compared with probucol (163-165). It has been shown to prevent atherosclerosis 
in animal models (164;166) and is discussed in more detail in Chapter 5. Two 
weeks prior to PCI, patients were assigned to one of the 5 treatment groups 
(probucol 500 mg twice daily, succinobucol 70 mg, 140 mg, 280 mg once daily 
or placebo)  and treated for 2 weeks before and 4 weeks after PCI. Angiographic 
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follow-up with baseline and 6-month IVUS examinations was performed to 
evaluate the efficacy of each group. Positive results were reported, with greater 
stent luminal area present in the highest dose of succinobucol and probucol 
groups, compared with placebo after 6 months. There was a significant dose-
response relationship for succinobucol, suggesting a true biological effect. 
Although CART-1 is often cited to provide evidence that succinobucol and 
probucol are both capable of reducing ISR, no statistically significant difference 
was demonstrated for this end-point unless compliant patients were analysed 
separately. Furthermore, detailed IVUS analysis showed clearly that 
supplementation of neither oral succinobucol nor probucol caused inhibition of 
neointimal growth and the advantages in final luminal area were due to greater 
acute luminal gain at the time of the index PCI. The underlying mechanism for 
this effect was not clear but speculatively may have been related to improved 
endothelial function of the diseased segment or favourable alterations in plaque 
composition due to antioxidant pre-treatment, allowing greater luminal gain at 
the time of balloon dilation and stent deployment. CART-2 was a subsequent 
IVUS study originally designed to investigate the effect of oral succinobucol 280 
mg once daily on ISR following PCI, however due to considerable difficulties 
with the technical quality of serial IVUS examinations, the trial was altered to 
examine the effect of succinobucol on coronary plaques in adjacent segments. 
Although atherosclerosis regression was evident in the succinobucol group, this 
effect was not significantly different from placebo (167). Taking the data from 
the CART-1 and CART-2 clinical studies and that of the ISAR-TEST clinical 
research program into consideration, succinobucol is unlikely to be an 
efficacious oral antirestenotic agent in clinical practice but may provide 
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advantageous if successfully incorporated in a fully biocompatible DES or 
potentially as a dual coating with a recognised inhibitor of restenosis (such as 
rapamycin) to improve its performance, similar to the probucol/rapamycin dual 
DES, and this strategy appears to merit further exploration. 
 
In more recent clinical study, oral probucol failed to reduce ISR following PCI, 
as determined by IVUS (157). This result should be viewed with some caution 
because confounding factors known to increase the risk of ISR were present in 
the probucol group, such as the treatment of significantly smaller vessels and a 
higher incidence of diabetes and acute lesions. A rabbit study which looked 
specifically at the effects of probucol on healing after stent injury reported a 
considerable improvement in stent endothelialization, accompanied by a 
reduction in NIH and less evidence of stent thrombosis (150). In this trial, oral 
probucol therapy also reduced leucocyte accumulation around the stent struts, 
suggesting its anti-inflammatory effects may exert a significant role in 
suppression of NIH, at least in animals.  
 
These studies testing the ability of antioxidants to reduce restenosis after balloon 
angioplasty or stenting have generally relied on oral administration. Studies 
which consistently demonstrated the most impressive reductions in ISR were 
performed in animals, where oral regimens are possible at a dose not possible in 
clinical practice. The application of stent-based delivery of antioxidants may 
provide an ideal opportunity to achieve optimal local tissue concentration, whilst 
minimizing toxic systemic side-effects. Such work has been performed with 
carvedilol, a β-blocker with potent antioxidant activity. It has been shown that 
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implantation of a carvedilol-coated stent in a porcine model was capable of 
inhibiting ISR and providing complete re-endothelialization (158). The same 
study failed to demonstrate a beneficial effect from a probucol-coated stent, 
although there were concerns about adequate drug delivery in this study.  
 
Given the broadly favourable preclinical data for high-dose oral antioxidant 
supplementation after coronary angioplasty and the modest effect of oral 
antioxidants evident in humans, the challenge of future trials is likely to focus on 
the incorporation of novel potent antioxidants into contemporary DES 
technology, which will provide targeted delivery and increased local tissue 
concentration without the potential drawbacks of systemic toxicity and 
administration, mirroring the successful development of other potent 
antiproliferative agents delivered via DES. 
 
1.4  Preclinical models of restenosis 
 
Several animal models have played a pivotal role in preclinical studies to 
examine the biological events resulting from PCI and to test the efficacy and 
safety of stents prior to investigation in human studies.  
 
1.4.1 Murine models 
Murine models of arterial injury and restenosis are favoured by cost-
effectiveness and ease of handling and housing, as well as providing a relatively 
accessible way to examine the influence of a wide variety of molecular 
biomarkers. The rat carotid model for restenosis was developed following 
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extensive use as a model for human atherosclerosis. Whilst these models have 
provided extensive data on the effects of endothelial denudation on SMC 
proliferation and inflammatory responses (168), the cumulative shortcomings of 
the murine models are significant. The effects of arterial injury cause a modest 
neointimal response in rodents and critically, results in these models have failed 
to consistently replicate the effect of test compounds in human studies, most 
notably the effect of angiotensin-converting enzyme inhibitors (169).  
 
1.4.2 Hypercholesterolaemic rabbit iliac model 
The rabbit iliac model has been used extensively to study atherosclerosis and 
restenosis. Rabbits are readily susceptible to dietary increases in cholesterol 
which leads to rapid atherosclerotic development, which is similar but not 
identical to that found in humans. Important differences exist in the histological 
composition and behaviour of atheromatous lesions in the rabbit model compared 
with humans, leading to limitations in the translation of data into clinical studies. 
An important criticism of this model for assessment of restenosis therapies is that 
the abundant foam cells and extracellular matrix generated by the 
hypercholesterolaemic state are not heavily involved in human neointimal 
formation. Nevertheless, despite these caveats, the rabbit iliac stenting model 
remains a relatively cost-effective way to assess the efficacy of antiproliferative 
drugs and has provided valuable data on the relative safety and toxicity of DES 
in the past decade (85;170). 
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1.4.3 Porcine coronary artery model 
Early pig models were able to demonstrate that the acute trauma related to 
coronary angioplasty was responsible for severe injury and provocation of the 
restenotic cascade in humans (171;172). The response of healthy porcine 
coronary arteries to overstretch injury closely replicates that found in human 
restenosis. Stent injury in the porcine coronary artery leads to thick neointimal 
development within 28 days, identical to human restenotic tissue. Coronary 
artery anatomy is similar to humans and therefore allows the use of human 
catheterisation equipment to accurately reflect clinical practice. The flow 
dynamics of the porcine coronary vasculature closely parallels that of humans, 
enabling a more reliable estimate of drug pharmacokinetics to take place. The 
disadvantages of the pig model are higher costs compared to smaller animals 
with related housing practicalities and expenses. Other considerations in the pig 
are potential differences in the inflammatory reactions to stent injury, which may 
display excessive granulomatous or eosinophilic infiltrates (173). Crucially, the 
effects of DES in the porcine model have been most predictive of their effects in 
humans, providing the strongest rationale for testing novel devices in this species 
(174). The pig coronary artery model has therefore become the standard model 
for the preclinical evaluation of DES (175). 
 
1.5 Hypothesis and aims 
 
The current literature indicates that oxidative stress may play a substantial role in 
modifying platelet and cellular responses following PCI. The events leading to 
ISR and stent healing are complicated and not completely understood, but 
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oxidative stress appears be involved in a number of important aspects. This thesis 
will investigate the effect of oxidative stress on several key processes closely 
involved in the response to arterial injury and the ability of antioxidants to 
favourably modify vascular healing. Specific approaches to decrease the impact 
of ROS will be tested, although it is appreciated that focussing on one particular 
antioxidant strategy may be insufficient to totally eliminate the effects of 
oxidative stress during vascular repair, as other oxidative pathways may remain 
active. As this may limit efficacy after PCI, complementary antiproliferative 
strategies in addition to a purely antioxidant approach may be considered. 
 
The first part of the thesis will focus on in vitro aspects occurring immediately 
after stent deployment. The effect of abundant ROS released after PCI may 
directly promote blood aggregation which could contribute to a higher risk of 
early stent thrombosis, the period at greatest risk because the stent has not yet 
endothelialised. Enhancement of platelet aggregation in human whole blood by 
locally released oxidants may increase the risk of myocardial infarction, carrying 
a substantial risk of death. This thesis will therefore examine the direct effect of 
ROS on blood aggregation and also whether ROS influence the antithrombotic 
properties of the endothelium, which is responsible for rapidly recovering the 
stent surface and providing protection against stent thrombosis. The direct effect 
of ROS on the migration of healthy ECs will also be investigated, as this may 
indicate that locally increased oxidative stress has the capacity to impair 
endothelialisation of stents, thereby exacerbating the risk of stent thrombosis and 
also promoting the rapid growth of neointimal tissue, which is known to be 
inhibited by regenerated endothelium. 
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In vivo testing will provide the basis for the second part of this thesis. I will 
evaluate the ability of a novel potent antioxidant loaded on a DES to offer 
improved healing and reduced neointimal thickening in a preclinical model of 
restenosis, using the pig coronary artery overstretch injury method. This is likely 
to provide valuable information on the potential for antioxidant DES to 
outperform other novel DES in clinical studies. The highly biocompatible 
polymer-free microporous Yukon® stent platform will be used to avoid the 
negative impact of persistent polymers on arterial healing and minimise the 
likelihood of late “catch-up” restenosis or aggravated inflammation. This stent 
platform will also enable “in-house” individualised DES coating and is already 
supported by large-scale clinical research studies (ISAR program, Munich Heart 
Centre). Scarce data exists reporting the effectiveness of an antioxidant-eluting 
stent approach in a preclinical or clinical research setting. I hypothesise that 
delivery of a suitable, potent antioxidant from a polymer-free DES may be able 
to achieve local suppression of oxidative stress, thus inhibiting platelet 
aggregation and neointimal growth, and accelerating re-endothelialisation, with 
minimal systemic toxicity (figure 1.6). These attributes may reduce the risk of 
ISR and stent thrombosis. 
 
The final part of the thesis will investigate more broadly the influence of 
circulating ROS on another important aspect of stent healing and the risk of 
thrombosis. As described already, it is now recognised that regrowth of 
functional endothelium is supported by the mobilisation and homing of EPCs to  
sites of endothelial damage. This systemic mechanism of vascular restoration  
 
 68 
 
Figure 1.6 The potential role of antioxidants after PCI. The endothelium prevents 
thrombosis via the actions of prostacyclin (PGI2), ADPase, tPA and NO, prevents 
contact between blood and the subendothelial layer (rich in procoagulant materials), and 
inhibits NIH. First-generation DES inhibit NIH, but impair re-endothelialisation. PCI 
injury causes major O2- release (primarily via NOX), which impairs re-endothelialisation 
and promotes NIH. Antioxidants may limit NIH and reduce thrombosis by accelerating 
re-endothelialisation and scavenging O2-. 
 
may constitute an important component of re-endothelialisation after arterial 
injury secondary to PCI (176). The relationship between systemic levels of 
oxidative stress in the bloodstream, which is elevated due to PCI, on this 
endothelial repair system is not well known. The potential for circulating EPCs 
to maintain coronary endothelial function in patients with CHD is also poorly 
recognised. This thesis will therefore investigate the correlation between plasma 
levels of oxLDL (a major component of oxidative stress in humans), the number 
of circulating EPCs and endothelial function in patients with CHD. Patients with 
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stable angina already scheduled for PCI will be recruited to facilitate invasive 
testing of their coronary endothelial function at the time of their planned 
coronary intervention and also to provide access to patient blood from a 
population with significant CHD undergoing PCI.  
 
To summarise, the overall aims of this thesis are: 
 
1 Using human whole blood and cultured porcine ECs, to investigate 
the influence of oxidative stress and antioxidants on WBA, the EC-
platelet interaction and EC migration.  
 
2 Using an in vivo model of porcine coronary stent implantation, to 
determine whether a novel antioxidant-eluting stent leads to reduced 
NIH and improved healing. 
 
3 In patients with angina, to determine whether plasma levels of oxLDL 
are associated with impaired endothelial repair (reduced circulating 
EPCs), impaired coronary endothelial function or increased whole 
blood aggregation. 
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Chapter 2 
 
The effect of oxidative stress on whole blood aggregation 
and the endothelial cell-platelet interaction 
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2.1 Introduction 
 
Oxidative stress is recognised as an important mediator of atherothrombotic 
events in cardiovascular disease (134). The classic paradigm is the formation of 
platelet-rich thrombus overlying a region of injured or dysfunctional 
endothelium. In addition to many other factors, oxidative stress participates in 
the regulation of platelet activation and thrombus formation. The effects of ROS 
on thrombus formation are of direct clinical relevance to PCI, which is known to 
stimulate the release of ROS from the surrounding vascular wall. The direct 
effects of ROS on platelet function are reportedly varied. Previous platelet assays 
in healthy individuals have reported both pro- and anti-aggregatory effects when 
platelets are exposed to exogenous ROS (177). Platelets themselves also generate 
ROS and this appears to be of significant relevance during recruitment, adhesion 
and aggregation (178). 
 
Although there is good evidence that oxidative stress damages the endothelium 
in vivo, which predisposes individuals to thrombosis, the close interactions 
between ROS and ECs are not completely understood. Healthy ECs inhibit 
thrombosis (179), but the direct actions of ROS on ECs may influence their 
antithrombotic properties, which may elevate the risk of stent thrombosis. 
 
WBA offers the most physiological setting in which to examine platelet-
mediated thrombus formation. Furthermore, it closely replicates the milieu in 
which clinical thrombosis occurs, where other blood constituents including 
erythrocytes (180), leucocytes (181) and plasma-derived substances (182;183) 
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are involved. ECs are thought to inhibit platelet aggregation by release of NO 
(32), prostacyclin (33), and the activity of endothelial ectonucleotidases (184), 
although in the presence of heightened oxidative stress, some of these effects 
may be deficient. My aims were to quantify the effects of ROS on WBA and to 
assess the influence of ROS on the EC-platelet interaction in patients with CHD. 
 
2.2 Methods 
 
2.2.1 Chemiluminescence 
Lucigenin chemiluminescence (CL) was used in non-biological samples to 
confirm generation of ROS (specifically superoxide anion, O2-) as a consequence 
of the X/XO reaction (185). 900 µl phosphate buffered saline (PBS) was added to 
a clear plastic sample cuvette. This was prewarmed at 37 ºC for 5 minutes in an 
incubation chamber. 100 µl lucigenin solution (Sigma-Aldrich, Dorset, UK) was 
prepared in distilled water and added to the cuvette with the test substance(s). As 
lugenin may itself interfere with O2- generation (186), a range of lucigenin 
concentrations were tested and the concentration producing the least additional 
chemiluminescence signal was used for subsequent experiments. The cuvette was 
transferred immediately to a chemiluminometer (Berthold, Germany). The delay 
was set to 10 seconds and the chemiluminescence signal was recorded after 120 
seconds in relative light units per seconde (RLU/s). Xanthine (Sigma-Aldrich, 
Dorset, UK) was dissolved in 10 mM NaOH and XO (Sigma-Aldrich, Dorset, 
UK) was dissolved in PBS. 
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2.2.2 Study population for WBA 
This study was approved by the West Glasgow and University of Strathclyde 
ethics committees. All participants were provided with a Participant Information 
Sheet (PIS) and gave their informed written consent. Preliminary WBA 
experiments were performed on venous blood donated by healthy human 
volunteers, recruited from the University of Strathclyde cardiovascular 
laboratory. In order to examine the effect of oxidative stress in a population 
closely matched to those undergoing PCI, adult patients with symptomatic stable 
CHD who were referred to the Western Infirmary Glasgow for out-patient 
cardiology appointments were recruited. All patients were over age 18 and 
receiving chronic oral aspirin therapy. Patients were excluded if there was a 
history of myocardial infarction within 3 months, if they were unable to give 
informed consent or if they were taking any other antithrombotic therapy.  
 
2.2.3 Whole blood aggregometry 
After recruitment, venous blood was withdrawn into vacuum filled plastic 3.5 ml 
Vacuette® tubes (Greiner Bio-One, Austria) containing 3.2% sodium citrate 
(0.109 mol/L). Four Vacuette® tubes (approximately 14 ml) of whole blood were 
collected from each donor or patient. Unless used to assess WBA over time, 
blood was tested within 3.5 hours of venepuncture. WBA was measured using an 
impedance aggregometer (Chrono-log, Model 590) and impedance was recorded 
using a dual channel chart recorder (Kipp & Zonen, BD 41). 500 µl citrated 
whole blood was diluted 1:1 with 500 µl normal saline to a total volume of 1 ml 
in a plastic sample cuvette. A stir bar was added to the cuvette, placed in the 
device reaction well and prewarmed for 5 minutes at 37 ºC, with a stirring speed 
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of 900 rpm. An electrode containing two fine palladium wires was inserted. The 
platelets in the whole blood adhered to the wires, forming a uniform platelet 
monolayer. A small voltage difference was applied across the wires, and the 
electrical impedance was measured. In the absence of aggregating agonist, the 
impedance between the two wires became constant after 2 minutes, producing a 
stable baseline which constituted zero. The aggregometer was then calibrated to 
20 ohms (Ω) equivalent to 40 mm deflection using the chart recorder controls. 
When an agonist was added to the cuvette, platelets in the blood were activated 
and started to aggregate, coating the palladium wires on the electrode and 
causing a corresponding increase in electrical impedance. This change in 
impedance was directly proportional to the extent of aggregation and was 
measured in Ω on the chart recorder set at 2 cm/min and followed for 5 minutes 
after addition of agonist. Collagen and adenosine diphosphate (ADP) (Labmedics 
Limited, Manchester, UK) were used as platelet agonists in all experiments. For 
X/XO experiments, individual aggregation values were calculated as a 
percentage of aggregation compared to control conditions, for both agonists and 
blood was incubated with the test substance(s) for 1 minute prior to addition of 
each agonist. 
 
2.2.4 EC culture  
Freshly removed pig hearts were obtained from a local abattoir within 2 hours of 
slaughter. The pulmonary artery was removed and pinned to a Sylgard coated 
block. Using a sterile scalpel blade, porcine pulmonary artery ECs were scraped 
gently from the luminal surface of the main pulmonary artery, under a sterile 
hood. ECs were transferred to a 15 ml tube of large vessel EC growth medium 
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package (basal medium, growth supplement and antibiotic [TCS Cellworks, 
Buckinghamshire, UK]). The cell suspension was centrifuged at 10,000 rpm for 5 
minutes. The supernatant was removed and the ECs were resuspended in 1 ml 
fresh growth medium. This was added to T-25 cell culture flasks (Nunc, 
Kamstrupvej, Denmark) with additional growth medium and cultured in an 
incubator at 37 ºC in a humidified atmosphere of 5% CO2. Growth medium was 
replaced every two days and ECs were transferred to T-75 flasks when 90% 
confluence was reached. Fresh growth medium was prepared once weekly. All 
ECs were used from passages 2 to 4. 
 
2.2.5 EC-platelet interaction 
ECs were collected from the flasks by removal of growth medium and addition 
of 2 ml TrypLE Express (Invitrogen Corporation, Paisley, UK) to detach the 
cells. Following 15 minutes, the cell suspension was transferred to centrifuge 
flasks and spun in a centrifuge (Mistral 1000, MSE centrifuge) at 10,000 rpm for 
5 minutes. The supernatant was removed and the pellet of cells resuspended in 1 
ml blank EC growth medium. The number of ECs in 1 ml suspension was 
counted using a haemocytometer. 1 x 105 ECs were added to the sample cuvette 
using an appropriate volume of cell suspension and made up to 500 µl with 
normal saline, to which 500 µl whole blood was added. In control experiments, 
an equivalent volume of blank growth medium was added to the cuvette in place 
of cell suspension. WBA was tested as previously described and the effect of 
ECs was determined in the absence and presence of X/XO and following 5 
minutes pre-treatment of ECs with 100 µM Nω-nitro-L-arginine methyl ester (L-
NAME) (Sigma-Aldrich, Dorset, UK), an inhibitor of NOS. 
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2.2.6 Statistical analysis 
The SD of pilot WBA data under control conditions was found to be 25%. A 
sample size of 14 patients was calculated to provide 80% power to detect a 
treatment difference at a two-sided 0.05 significance level, if the true difference 
between groups was 40%. All data are expressed as mean ± SEM unless 
otherwise stated. Groups were compared by independent samples t test or 
repeated measures analysis of variance and post-hoc Dunnett’s test. Statistical 
analysis was performed using the SPSS statistical software package 14.0 for 
Windows (SPSS Inc., Chicago, IL, USA).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 77 
2.3 Results 
 
2.3.1 Lucigenin concentration-response  
The effect of 5 µM, 50 µM and 250 µM lucigenin on chemiluminescence was 
examined. This represents a range of concentrations which have the potential 
influence baseline ROS production and redox-recycling, however minimal 
effects are previously reported for 5 µM (185). 5 µM lucigenin in the absence of 
X/XO caused very low chemiluminescence (62 ± 2 RLU/s). In the presence of 
100 µM X and 10 mU/ml XO, both higher doses of lucigenin (50 µM and 250 
µM) caused significantly increased chemiluminescence, compared to 5 µM 
lucigenin (p < 0.001) (Figure 2.1). 5 µM lucigenin was therefore used for all 
subsequent chemiluminescence experiments, as this gave the least assay 
interference, as previously confirmed (185). 
 
Figure 2.1 The effect of lucigenin on chemiluminescence. Chemiluminescence 
(CL) using different concentrations of lucigenin, in the presence of a constant 
concentration of 100 µM X and 10 mU/ml XO (n = 4), * p < 0.001 vs. other groups. 
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2.3.2 Confirmation of O2- production by X/XO 
There was a highly significant positive correlation (r = 0.94, p = 0.006) between 
chemiluminescence and XO concentration in the presence of a constant 
concentration of 100 µM X (Figure 2.2). 50 U/ml SOD completely abolished 
chemiluminescence in the presence of 100 µM X and 10 mU/ml XO (p < 0.001), 
indicating that O2- was the principal active molecule generated under the 
conditions of these experiments (Figure 2.3). 
 
 
Figure 2.2 The effect of X/XO on chemiluminescence. CL due to increasing XO 
concentration (log 10 scale) in the presence of a constant concentration of 100 µM X (n 
= 2), r = 0.94, p = 0.006. 
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Figure 2.3 The effect of SOD on X/XO-induced chemiluminescence. CL due to 
100 µM X and 10 mU/ml XO with the effect of 50 U/ml SOD (n = 4-8), * p < 0.001 vs. 
control. 
 
2.3.3 Baseline characteristics of WBA participants 
Venous blood was withdrawn from 12 healthy donors and used for preliminary 
experiments. 8 (67%) donors were male and the mean age was 30.5 years (SD 
9.2). No donor had a significant past medical history or was taking regular 
medication. The baseline characteristics of 23 recruited patients are shown in 
Table 2.1. There was a high prevalence of additional cardiovascular risk factors 
and regular medications prescribed. As patients were tested on the day of 
recruitment, all patients were taking regular aspirin. No patient was taking 
clopidogrel or any other antithrombotic medication. 
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Table 2.1 Baseline characteristics of WBA patients 
 Prevalence, 
(n = 23) 
Patients’ characteristics  
Age, mean (SD), y 62.7 (8.9) 
Male, n (%) 17 (73.9) 
Current smoker, n (%) 6 (26.1) 
Hypertension, n (%) 11 (47.8) 
Hypercholesterolaemia, n (%) 15 (65.2) 
Diabetes mellitus, n (%) 10 (43.4) 
Family history of premature CHD, n (%) 8 (34.8) 
Previous myocardial infarction, n (%) 9 (39.1) 
Previous stroke, n (%) 1 (4.3) 
Previous PCI or CABG, n (%) 7 (30.4) 
Multivessel disease, n (%) 13 (56.5) 
Preserved LV function, n (%) 18 (78.3) 
Heart failure, n (%) 3 (13.0) 
Drug treatment  
Aspirin, n (%) 23 (100.0) 
Clopidogrel, n (%) 0 (0.0) 
Statin, n (%) 22 (95.7) 
ACE inhibitor or ARB, n (%) 17 (73.9) 
Beta-blocker, n (%) 17 (73.9) 
Calcium channel blocker, n (%) 9 (39.1) 
Diuretic, n (%) 5 (21.7) 
Nitrate, n (%) 17 (73.9) 
Nicorandil, n (%) 11 (47.8) 
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2.3.4 WBA intra-individual variability 
Preliminary evaluation was performed on a single donor blood sample to assess 
the intra-individual variability of WBA. 6 experiments were performed within 
one hour of venepuncture using 3 µg/ml collagen as agonist. Agreement between 
replicates was excellent, as shown in Figure 2.4 (mean 13.67 Ω, SD 0.5164). 
 
 
Figure 2.4 Intra-individual variability of WBA (n = 6). 
 
2.3.5 WBA agonist concentration-response 
A range of collagen and ADP concentrations were tested to assess the 
concentration-response for each agonist, using donor blood. The EC50 for 
collagen was found to be 3 µg/ml (Figure 2.5) and for ADP was 5 µM (Figure 
2.6). The EC50 agonist concentrations were used for all subsequent experiments 
to study the potential of ROS to modify aggregation in either direction without 
the limitation of testing near minimal or maximal conditions. Therefore, although 
maximal impedance values for each agonist were different due to their different 
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activation mechanisms, agonist concentrations were matched for the level of 
activation of their respective receptors. 
 
 
Figure 2.5 WBA concentration-response curve for collagen (n = 7). 
 
 
 
Figure 2.6 WBA concentration-response curve for ADP (n = 5). 
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2.3.6 WBA time-response 
Due to the serial nature of experiments performed on each blood sample, I 
assessed the variation in WBA over time, for each agonist. WBA was tested 
under identical conditions using donor blood at intervals of up to 6 hours 
following venepuncture. There was a slight trend for collagen-induced WBA to 
decrease after 6 hours although this was not statistically significant (Figure 2.7). 
ADP-induced WBA showed minor variation over time, although there was no 
significant change in aggregation between 1 and 4 hours (Figure 2.8). 
 
Figure 2.7 WBA time-response curve for collagen (3 µg/ml, n = 5), p = NS. 
 
 
Figure 2.8 WBA time-response curve for ADP (5 µM, n = 4), p = NS. 
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2.3.7 Comparison of WBA between donors and patients 
There was no significant difference in WBA between donor blood and patient 
blood, for each agonist. Under identical control conditions, WBA was 15.9 ± 1.5 
Ω for donor blood (n = 12) compared with 15.4 ± 0.8 Ω for patient blood (n = 23) 
in response to 3 µg/ml collagen (p = NS). WBA was 7.8 ± 1.5 Ω for donor blood 
(n = 10) compared with 9.3 ± 0.9 Ω for patient blood (n = 23) in response to 5 
µM ADP (p = NS). 
 
2.3.8 Effect of X/XO on WBA  
The effect of oxidative stress on WBA in 14 CHD patients was determined using 
the X/XO reaction. The concentration of X was kept constant at 100 µM, 
whereas the concentration of XO was tested at 10, 50 and 100 mU/ml to 
engender incremental levels of oxidative stress, previously confirmed using 
chemiluminescence. ROS produced by X/XO caused a concentration-dependent 
inhibition of WBA in CHD patients compared to control, for both collagen 
(Figure 2.9) and ADP (Figure 2.10). 100 µM X and 100 mU/ml XO inhibited 
WBA in response to collagen by 28.9% (95% CI 15.9% - 41.8%, p < 0.001) and 
in response to ADP by 36.0% (95% CI 9.6% - 62.4%, p = 0.005). The effect in 
patients with diabetes mellitus did not differ significantly from the effect in 
patients without diabetes mellitus (n = 7, data not shown). A smaller number of 
identical experiments were performed using healthy donor blood, which also 
demonstrated concentration-dependent inhibition of WBA, which was significant 
at the highest dose of XO (n = 4, data not shown). 
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Figure 2.9 The effect of X/XO on WBA in response to collagen. X (µM) + XO 
(mU/ml) caused a concentration-dependent inhibition of WBA in response to 3 µg/ml 
collagen in CHD patients (n = 14), * p < 0.05 vs. control. 
 
 
Figure 2.10 The effect of X/XO on WBA in response to ADP. X (µM) + XO 
(mU/ml) caused a concentration-dependent inhibition of WBA in response to 5 µM ADP 
in CHD patients (n = 14), * p < 0.05 vs. control. 
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2.3.9 EC-platelet interaction  
The effects of ECs on WBA in 9 CHD patients are shown in Figures 2.11 and 
2.12. The addition of 1 x 105 cultured ECs caused a significant decrease in WBA 
in response to collagen by 31.2% (95% CI 12.2% - 50.2%, p < 0.01) and ADP by 
31.6% (95% CI 2.5 - 60.7%, p < 0.05). The inhibitory effect of ECs on WBA 
remained significant after pre-treatment of ECs with the combination of 100 µM 
X and 10 mU/ml XO, in response to collagen (29.1% [95% CI 10.1% - 48.1%, p 
< 0.01]) and ADP (32.6% [95% CI 3.4 - 61.7%, p<0.05]). However, pre-
treatment with 100 µM L-NAME attenuated the inhibitory effect of ECs, which 
was no longer statistically significant in response to either collagen (21.6% [95% 
CI -7.2% - 50.5%, p = NS]) or ADP (9.2% [95% CI -44.7% - 63.1%, p = NS]).  
 
Figure 2.11 The effect of ECs alone and after pretreatment with X/XO or L-NAME 
on WBA in response to collagen. Cultured ECs inhibited WBA in response to 3 µg/ml 
collagen. This effect was not affected by 100 µM X and 10 mU/ml XO but was no 
longer significant after pre-treatment of ECs with 100 µM L-NAME (n = 9), * p < 0.05 
vs. control. 
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Figure 2.12 The effect of ECs alone and after pretreatment with X/XO or L-NAME 
on WBA in response to ADP. Cultured ECs inhibited WBA in response to 5 µM ADP. 
This effect was not affected by 100 µM X and 10 mU/ml XO but was no longer 
significant after pre-treatment of ECs with 100 µM L-NAME (n = 9), * p < 0.05 vs. 
control. 
 
2.4 Discussion 
 
After arterial injury or atherosclerotic plaque rupture, circulating platelets adhere 
to the damaged vessel wall and become activated by agonists in the extracellular 
matrix such as collagen, von Willebrand factor and fibrinogen. Other agonists 
such as ADP, thrombin, adrenaline and platelet activating factor potentiate the 
platelet response. Once activated, platelets release granules containing cytokines 
and growth factors which lead to a cascade of events resulting in platelet 
aggregation, formation of a platelet plug and in some cases vessel occlusion, 
causing a myocardial infarction or stroke. Recently, evidence has accumulated 
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that ROS are heavily involved in the regulation of platelet function, although 
their precise role is complex (177).  
 
Clarifying the actions of ROS on WBA in patients with symptomatic CHD 
extends our understanding of the pathophysiology of acute thrombosis, which in 
patients who have undergone PCI is associated with a very high mortality (38). 
This chapter investigated the direct effects of oxidative stress on human whole 
blood, which has direct relevance to PCI as large amounts of ROS are released 
from the artery wall during this period and may be implicated in stent 
thrombosis. The greatest influence of ROS on the stent-vessel wall interaction is 
likely to be derived from locally generated ROS as a result of arterial injury 
(principally via NOX) but also from elevated systemic levels of circulating ROS, 
which are increased in patients with CHD. 
 
2.4.1 Preliminary results 
My initial experiments confirmed that the X/XO reaction was generating ROS 
within the time frame of WBA. The potential interference of lucigenin used in 
these experiments was minimal, due to the very low concentration used, which 
has been shown to exert only minor effects on O2- production (185). 5 µM 
lucigenin was associated with very low chemiluminescence in my experiments. I 
demonstrated that the WBA assay was reliable and consistent, with a low intra-
individual variability. All samples were tested within a time frame that I have 
shown to have no impact on WBA. Notably, WBA was not significantly different 
between healthy donors and patients. I propose that the administration of chronic 
aspirin therapy negated the increased platelet aggregation likely to be present in 
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CHD patients compared with healthy individuals on no antithrombotic therapy. 
The lack of difference supported the translation of preliminary methodological 
data to the patient population.  
 
2.4.2 Effect of ROS on platelet aggregation 
One of the primary purposes of the current study was to examine, for the first 
time, the effects of exogenous ROS on WBA in patients with clinically proven 
CHD. My results have shown that ROS, generated by the X/XO reaction, cause a 
concentration-dependent inhibition of WBA in these patients. This reduction in 
aggregation is demonstrated in response to the biologically relevant agonists, 
collagen and ADP. Whilst I have confirmed using chemiluminescence that O2- is 
generated by X/XO, this reaction also leads to the downstream production of the 
highly reactive molecule, H2O2 (187), which plays a significant role in the 
modulation of platelet function. Additionally, although resting platelets do not 
produce NO, intracellular NO is formed following stimulation with platelet 
agonists (188), and this can react with O2- to produce ONOO- (132), a potent 
oxidant and additional contributor to platelet aggregation (189). I propose that 
these secondary molecules may have played a major role in the inhibition of 
WBA in these experiments. 
 
The reported effects of ROS on platelet function are variable and depend on a 
variety of factors, especially the type and concentration of ROS and the milieu in 
which it acts. Using washed platelets in buffer, exposure to ROS generated by 
X/XO led to irreversible aggregation to subthreshold levels of ADP, although 
there was no effect on collagen-induced platelet aggregation (190). In another 
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study, collagen (but not ADP or thrombin) induced O2- release from platelets, 
which stimulated ADP-dependent platelet recruitment to preformed thrombus, 
but did not in itself cause platelet aggregation (190). Others have shown that 
addition of X/XO to washed platelets led to release of the surrogate marker 
serotonin, thought to occur as a result of platelet aggregation, whereas exposure 
of platelets to X/XO also lowered the threshold for thrombin-induced 
aggregation (191). This effect was blocked by SOD suggesting that O2- was the 
relevant molecule involved. The O2- generator pyrogallol increased thrombin-
induced platelet aggregation, an effect which was also blocked by SOD (192), 
and increased arachidonic acid-induced platelet aggregation, an effect which was 
inhibited by dipyridamole (193). Put together, these data suggest the more likely 
effect of O2- on isolated platelets is pro-aggregatory, albeit mild in some cases. 
 
Importantly, the addition of X/XO to platelets in platelet rich plasma (PRP) has 
led to different results compared to those found in isolated platelets. In healthy 
volunteers, X/XO led to potent inhibition of platelet aggregation in response to 
ADP, collagen and U-46619 (a thromboxane mimetic) (194). These findings 
were attributed to the abolition of the second wave release reaction with an 
overproduction of H2O2, stimulation of guanylate cyclase and an increase in 
cGMP. This inhibitory effect on platelet aggregation was blocked by catalase, 
but not by SOD, which suggested that H2O2 was the crucial inhibitory ROS. The 
inhibitory effect of H2O2 on ADP-induced aggregation has been confirmed in 
other studies (195;196). There have been reports that lower concentrations of 
H2O2 have the capacity to enhance subthreshold collagen and arachidonic acid-
induced aggregation, but not ADP-induced aggregation (197;198). The influence 
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of ONOO- on isolated platelets has been varied, causing either pro-aggregatory 
(199) or anti-aggregatory effects (200;201), but studies in PRP show that ONOO- 
consistently inhibits collagen, ADP, and thrombin-induced aggregation 
(199;202). Subsequent reports suggested that the NO-dependent inhibitory 
effects of ONOO- occurred at lower concentrations than the pro-aggregatory 
effects (203). 
 
Taking all of these data into consideration, the actions of ROS on platelet 
function are diverse, depending on the molecule involved, and concentration-
dependent. Furthermore, assessment of platelet function must take into account 
the environment in which aggregation is stimulated. Although washed platelets 
suspended in buffer can provide information on the specific effects of substances 
on isolated platelets, a more physiological environment can be simulated in 
plasma or whole blood, which allow other blood constituents and endogenous 
antioxidants to be represented which may antagonise the stimulation of platelets 
induced by ROS (204).  
 
The key finding from my results is that oxidative stress (generated by X/XO) 
caused a concentration-dependant inhibition of platelet aggregation in whole 
blood derived from patients with CHD. I propose that this was caused by the 
generation of secondary inhibitory ROS such as H2O2 and ONOO-, possibly 
related to endogenous substances present in whole blood. The main goal of 
future studies would be to confirm the precise species involved, the mechanism 
and the importance of this effect with reference to the levels of oxidative stress 
present in clinical situations such as PCI. A closer estimate of the potential 
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mechanism of this effect could be assessed by studying the effects of SOD given 
prior to X/XO, thereby removing the effects of O2- and causing generation of 
H2O2. Catalase could be used to specifically assess the loss of H2O2 from the 
system. In addition, other specific scavengers of secondary ROS including 
ONOO- could be used to clarify the influence of these molecules.  
 
2.4.3 Effect of ROS on the EC-platelet interaction 
I demonstrated that healthy ECs maintain the ability to inhibit WBA derived 
from patients with CHD. ECs are thought to inhibit thrombosis predominantly 
through the actions of NO, prostacyclin (205) and the activity of an endothelial 
ecto-ADPase present on the surface of ECs, identified as CD39 (206;207). It was 
reported that depolarization of ECs led to O2- production, which inactivated the 
ecto-ADPase, thereby decreasing the inhibitory properties of ECs on ADP-
induced aggregation, (208). Therefore it was expected that ROS would at least 
partly neutralise the inhibitory effect of healthy ECs on WBA by opposing the 
effects of NO and/or endothelial ecto-ADPase. However, I have demonstrated 
that the addition of exogenous ROS using X/XO failed to influence the inhibitory 
properties of healthy ECs. This may have resulted from an overall equilibrium of 
negative and positive effects on blood aggregation. The X/XO reaction may have 
produced ROS such as O2-, which inactivated NO and endothelial 
ectonucleotidases (actions that would promote aggregation), but also produced 
H2O2 and ONOO-, leading to inhibitory effects. To explore this further, I have 
shown that the inhibitory effect of healthy ECs is decreased by the pretreatment 
of ECs with L-NAME. This supports the notion that isolated removal of EC-
derived NO from the blood decreases its anti-aggregatory capacity, which 
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implies an increased risk of thrombosis where endothelial dysfunction and 
reduced NO bioavailability occurs. 
 
2.4.4 Limitations 
 
Well recognised limitations exist concerning the translation of this work to the 
clinical field. It is unclear how the addition of exogenously derived ROS relates 
to the extent and nature of ROS release following PCI. The main source of ROS 
after PCI is generation via NOX, the output of which may differ significantly 
from the X/XO reaction. The effects of ROS on blood aggregation have been 
investigated in isolation and subsequently in the presence of healthy ECs, rather 
than in the presence of damaged endothelium and the presence of a foreign body, 
as is present after coronary stenting. We must accept that the applicability of 
these in vitro studies to the clinical scenario of early stent thrombosis may be 
limited. Porcine rather than human ECs were used to replicate the effect of 
human endothelium due to cost constraints, but it seems unlikely that the effect 
would have been significantly different if human ECs had been used. 
 
2.4.5 Conclusions 
ROS generated by X/XO produce a concentration-dependent inhibition of WBA 
in patients with CHD. This concurs with previous studies in healthy individuals 
using X/XO as a source of ROS and is likely to be a result of highly reactive 
molecules such as H2O2 and ONOO-, which share inhibitory properties that 
appear to predominate over O2-, which tends to promote aggregation. Healthy 
ECs maintain their physiological role to inhibit platelet-derived thrombus 
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formation in blood derived from atherosclerotic human populations, even after 
short term exposure to ROS. This suggests that strategies to preserve endothelial 
function and improve re-endothelialisation are likely to be beneficial after PCI. 
However, persistent endothelial dysfunction or patchy endothelial regrowth due 
to persistent drug or polymer effects after PCI is likely to diminish the capacity 
of the endothelium to generate NO, which could put patients at greater risk of 
stent thrombosis. 
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Chapter 3 
 
The effect of oxidative stress 
on endothelial cell migration 
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3.1 Introduction 
 
After PCI, the migration of ECs to reconstitute the denuded endothelium is a 
crucial process that occurs early after vessel trauma. In the rat carotid balloon 
injury model, the endothelium regenerates at approximately 2-3 mm per week 
(209), depending on the degree of injury, with more severe cases taking longer. 
Deeper medial injury encourages more SMCs to migrate to the neointima, which 
inhibit the migration and proliferation of ECs in that area (210). Endothelial 
regrowth is specific to the species involved. For instance, stent healing in pigs is 
slower than in rats but still occurs around six times faster than in humans (174). 
Identifying the factors controlling the movement of these vital cells is paramount 
to understanding the mechanisms that contribute to ISR. Besides a central role in 
modulating vascular tone and haemostasis, regeneration of confluent 
endothelium provides an impermeable barrier between medial SMCs and 
circulating growth factors. ECs also produce a number of growth-promoting and 
growth-inhibitory factors which regulate SMC proliferation. Healthy ECs 
maintain the quiescence of SMCs by releasing NO (211). Hence, regeneration of 
the endothelium significantly influences the extent of neointimal formation.  
 
ECs themselves are stimulated to a lesser degree, or inhibited, by many 
substances that stimulate SMC migration, such as angiotensin-II (212), serotonin, 
noradrenaline and IL-1 (213). Factors that promote EC migration include VEGF 
(214), platelet-derived EC growth factor (PD-ECGF) (215), oestradiol (216), 
oxytoxin (217), ACE inhibitors (212), heparins (218), endothelins (219), 
thrombin (220), tPA (221), high density lipoprotein (222) and shear stress, which 
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increases EC migration onto metallic stent surfaces (223). NO appears to exert a 
biphasic effect on EC migration. Acute release of NO, generated by eNOS, 
reportedly promoted EC migration towards angiogenic factors, such as VEGF 
(224), endothelin (130) and substance P (225). NO appeared to exert its 
stimulatory effect on EC migration through activation of soluble guanylyl 
cyclase mechanisms (226). On the other hand, others have observed that chronic 
basal endogenous NO release inhibited EC migration (227), an effect which was 
matched by other NO donors (228). Since the recognition that endothelial 
recovery may reduce ISR and lower the risk of stent thrombosis, more attention 
has been re-focussed on revascularisation devices which might accelerate EC 
regrowth (229;230). The effect of ROS on EC migration is not well defined and, 
given that oxidative stress is a major consequence of PCI, requires further 
evaluation. Therefore, the aim of this study was to investigate the effect of ROS 
generated by X/XO on EC migration, using a scratch wound assay. The effect of 
the antioxidant, probucol, on EC migration would also be evaluated. 
 
3.2 Methods 
 
3.2.1 EC culture 
The method for EC cell culture is described in detail in section 2.2.4. Briefly, 
porcine pulmonary artery ECs were removed from fresh pig hearts and cultured 
in large vessel EC growth medium. ECs were maintained at 37°C in a humidified 
atmosphere of 5% CO2, and used from passages 2 to 4. After obtaining sufficient 
quantities, the ECs were collected from T-75 flasks using TrypLE Express and 
seeded in 6 well plates.  
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3.2.2 EC migration assay 
EC migration was measured by the scratch wound method as described by Bürk 
(231). Once grown to confluence in 6 well plates, ECs were made quiescent by 
exchanging the serum-containing growth medium with serum-free medium, 
followed by the addition of 1 mg/ml gelatin. The ECs remained in serum-free 
medium for 24 hours. Following this, a wound was made in the EC monolayer by 
pressing a rigid razor blade down on the well. The blade was gently drawn across 
the base of the well, scraping the ECs to one side (Figure 3.1). Care was taken to 
avoid reusing a damaged blade which had developed gaps in the cutting edge, 
otherwise lines of ECs would remain attached to the well, perpendicular to the 
wound. After a successful razor scrape, the detached cell debris and medium 
were aspirated and disposed of. Serum-free medium with 1 mg/ml gelatin was 
replaced and the test substance(s) was added using a pipette. The ECs were 
incubated for a further 24 hours. For each well, 2 adjacent regions consisting of 
1,300 µm lengths of razor wound in the centre of the microscopic field were 
examined and the number of cell nuclei that had crossed the starting line 
produced by the razor scrape was counted. Well plates were fixed and stained 
using modified Wright-Giemsa stain. Images of migrating ECs were captured 
using an inverted microscope (Nikon) and attached digital camera 
(CoolSNAP™-Pro, Media Cybernetics). Representative photomicrographs have 
been enhanced digitally for graphical purposes. 
 
3.2.3 Cell treatments 
EC migration was tested under control conditions, after exposure to oxidative 
stress using different X and XO concentrations with and without the antioxidant, 
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probucol, and with probucol alone. Control cells were always treated with the 
relevant vehicles alone. X and XO were dissolved in 10 mM NaOH and PBS, 
respectively and probucol was dissolved in PBS.  
 
3.2.4 Statistical analysis 
All data are expressed as the mean number ± SEM of ECs which had migrated 
across the 1.3 mm starting line after 24 hours. All experiments were performed in 
duplicate, on at least 2 different cell isolates. Groups were compared using a t-
test or repeated measures analysis of variance with post-hoc Dunnett’s test. 
Statistical significance was confirmed at p < 0.05. Statistical analysis was 
performed using the SPSS statistical software package 14.0 for Windows (SPSS 
Inc., Chicago, IL, USA). 
 
 
 
Figure 3.1 Razor scrape EC migration assay. Confluent cultured ECs before (A) 
and after the razor scrape wound at 0 hours (B). 
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3.3 Results 
 
3.3.1 General toxicity of X/XO to ECs 
Severe generalised toxicity was encountered when ECs were exposed to 
conditions of oxidative stress, using X/XO. Multiple populations of cultured ECs 
were exposed to X/XO for 24 hours and, even at relatively low concentrations, 
ECs detached from the base of the well, rendering the migration assay 
impossible. ECs remained adherent to the base in the presence of X/XO vehicles. 
Extensive concentration ranging experiments were performed and eventually it 
was found that the highest concentration of X/XO which allowed ECs to remain 
consistently attached to the base of the well was 1 µM X + 0.1 mU/ml XO (Table 
3.1). The tolerability of serum-fed ECs to X/XO was considerably better than 
that of quiescent ECs. 
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Table 3.1 Toxicity of X/XO to cultured ECs after 24 hours. 
Xanthine (µM) Xanthine oxidase (mU/ml) Serum medium Quiescent medium 
100 10   
100 2.5   
100 1 ND  
10 10   
10 2.5   
10 1   
5 2.5 ND  
2.5 2.5   
1 10 ND  
1 2.5 ND  
1 1  / 
1 0.1   
 
Key:  = ECs remained attached to plate 
 = ECs detached from plate 
 / = Variable detachment of ECs 
 ND = Not done 
  
3.3.2 Effect of low concentration X/XO on EC migration 
1 µM X and 0.1 mU/ml XO inhibited EC migration significantly compared with 
vehicle solutions (11.5 ± 0.5 vs. 27.5 ± 1.0 migrating cells/wound, respectively 
[p < 0.01]), as shown in Figure 3.2. The addition of 20 µM probucol did not 
influence the effect of X/XO significantly (13.4 ± 0.4 migrating cells/wound, p = 
NS, probucol vs. X/XO).  
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Figure 3.2 The effect of X/XO with and without probucol on EC migration. 
Representative photomicrographs of control (A), 1 µM X and 0.1 mU/ml XO (B) and 1 
µM X + 0.1 mU/ml XO with 20 µM probucol (C) in the scratch wound assay. D, X/XO 
inhibited EC migration compared with vehicle, an effect which was not altered 
significantly by 20 µM probucol (n = 2), * p < 0.01 vs. control. 
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3.3.3 Effect of probucol on EC migration 
Given that probucol did not appear to protect ECs against X/XO, 20 µM 
probucol alone was tested to determine whether it would have an effect on EC 
migration in isolation. There was no significant difference between probucol 
vehicle and 20 µM probucol (13.4 ± 3.7 vs. 10.4 ± 2.2 migrating cells/wound, 
respectively, [p = NS]).  
 
 
 
Figure 3.3 The effects of probucol alone on EC migration. Representative 
photomicrographs of vehicle (A) and 20 µM probucol (B) in the scratch wound assay.  
C, There was no significant difference between groups (n = 3), p = NS. 
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3.4 Discussion 
 
3.4.1 General cytotoxicity of oxidative stress to cultured ECs 
I found that oxidative stress, applied exogenously using the X/XO reaction, 
caused severe toxicity to cultured ECs, leading to widespread cell detachment 
within 24 hours. Direct observation of well plates containing X/XO revealed that 
detachment started within an hour of exposure to X/XO and was virtually 
complete within 8 hours. Although I did not directly prove that cell detachment 
was a consequence of cell death, this was highly probable because floating cells 
displayed severe morphological changes and general cellular debris was evident 
on the surface of the culture medium. The cytotoxicity of X/XO was very severe 
in quiescent ECs, whereas serum-fed ECs had greater tolerance. Toxicity seemed 
more dependent on XO concentration than xanthine concentration, because 
serum-fed ECs retained adherence by reducing the XO concentration from 10 
mU/ml to 2.5 mU/ml, whereas they showed persistent detachment when xanthine 
concentration was lowered from 100 µM to 10 µM. I have already demonstrated 
in Chapter 2 that 100 µM X + 10 mU/ml XO produces significant quantities of 
ROS. Thus, I propose that a high concentration of ROS in the cell culture 
medium, released by the X/XO reaction, was responsible for EC death. 
 
3.4.2 Effect of oxidative stress on EC migration 
Unfortunately, the migration experiments were severely hampered by the 
somewhat unexpected severe cytotoxicity of X/XO. Nevertheless, migration of 
ECs appeared to be significantly inhibited in the presence of exogenous oxidative 
stress generated by X/XO, within 24 hours. Investigating the underlying 
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mechanism for this effect fell outside the time frame for this work, however, 
future experiments could investigate whether ROS generated by X/XO deactivate 
molecular signalling pathways involved in normal migratory activity. The effects 
of SOD and inhibitors of NOX may help clarify the specific role of O2- in EC 
migration. Given that EC motility is reliant on NO production, attempts could 
also be made to eliminate NO from the cell culture using NOS inhibitors to 
examine its effect on migration. The effects of antioxidants to oppose these 
negative effects could also be tested.  
 
Previous work by other groups also merits consideration. A large proportion of 
published work regarding the negative influence of oxidative stress on EC 
migration has surrounded oxLDL, which acts as a key oxidant in vivo. 
Overwhelming evidence exists to support the role of oxLDL in atherosclerosis 
(232) and the triggering of acute coronary syndromes (233), therefore it is not 
surprising that EC function is a target for its pathological actions. Given that 
repair of injured blood vessels is dependent on EC migration following arterial 
injury, the effect of oxLDL on this phenomenon is likely to be important after 
PCI. OxLDL increases intracellular ROS production by ECs (234). Murugesan et 
al. (235) found that oxLDL markedly reduced EC migration using a razor wound 
assay and this effect was concentration- and oxidation-dependent. In this work, 
the antimigratory activity of oxLDL was not reliant on mortal cell injury, since 
migration was re-established after removal of oxLDL from the culture. Chavakis 
et al. (236) also reported that oxLDL inhibited VEGF-induced EC migration, 
without inducing apoptosis or necrosis. This observation was associated with 
dephosphorylation of the serine/threonine kinase Akt/protein kinase B, which led 
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to deactivation of eNOS and a reduction in NO generation, thus inhibiting a 
process which is partly NO dependent (237).  
 
More evidence that ROS are pivotal in inhibiting EC migration by oxLDL has 
been provided by van Aalst et al. (126), and this work also provides an important 
insight into my results. As in other studies, the antimigratory effects of oxLDL 
on ECs was demonstrated using the razor scrape assay. Inhibition of EC 
migration was also confirmed using other agents known to stimulate ROS 
production (lysophosphatidylcholine and naphthoquinones). In this study, the 
effect of oxLDL was blocked by the presence of SOD or NADPH oxidase 
inhibitors (DPI, quinacrine and hydralazine). It was not affected by mannitol or 
glutathione, which inactivate OH- anions, or catalase, which scavenges H2O2. 
These data suggest that oxLDL inhibits migration of ECs by causing the release 
of O2-, produced enzymatically by NADPH oxidase. This, in turn, supports the 
proposal that the antimigratory effects of X/XO on ECs observed in my study 
may have been mediated by O2-.  
 
Interestingly, direct administration of H2O2  (10-50 µM) had no effect on EC 
migration, however higher concentrations (> 100 µM) caused ECs to lift off the 
plate (126). This probably explains the general cytotoxicity of the X/XO reaction 
in my study, which is known to produce large quantities of H2O2 (238). The 
inability of H2O2 to inhibit EC migration suggests that different ROS may lead to 
cell death compared to those that modulate motility. ONOO-, which is created by 
the rapid reaction between NO and O2-, has been shown to impair actin 
polymerisation and inhibit movement of neutrophils and fibroblasts (239;240), 
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therefore it could also affect ECs. However, the importance of this potent 
oxidising substance in my study, or that of others, with regard to EC migration 
has not been established. 
 
3.4.3 Effect of probucol on EC migration 
I found that 20 µM probucol had no effect on EC migration in this assay. 
Moreover, I have shown that probucol at the same concentration was unable to 
preserve EC migration in the presence of X/XO. This was interesting, since some 
data already exists to support the use of probucol to encourage endothelial 
healing in animal models (data from Chapter 1, Table 1.1). Pre-incubation with 
probucol also reportedly provided ECs with protection against fatal oxidative 
injury (129). However, the inability of probucol to preserve EC migration in the 
presence of oxidative stress is in agreement with another study which utilised 
oxLDL as a source of ROS (127). In an identical fashion to my results, probucol 
led to minimal improvement in EC migration compared with oxidative stress. I 
propose that probucol is insufficient to oppose the inhibitory effects of excessive 
ROS on EC migration, possibly due to its delayed uptake into ECs (163;241) and 
poor solubility in aqueous solution.  
 
3.4.4 Limitations 
Significant limitations exist in this work and the presented data should be 
interpreted in this context. In a few cases, the razor scrape method caused 
marked damage to the EC monolayer, resulting in an irregular starting line and 
rendering some wells invalid for the EC migration assay. The severe generalised 
toxicity of X/XO severely limited the number of valid experiments, therefore the 
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number of different cell populations available for each group was low and only a 
single concentration of probucol was tested. The concentration of probucol 
chosen was however similar to that used in previous studies (127). Nevertheless, 
a concentration-response curve for probucol would have been valuable. It would 
have been interesting to confirm the nature and extent of general cell toxicity of 
X/XO using specific methods such as lactate dehydrogenase release assay or 
trypan blue staining (242). Confirmation that EC migration was abolished in the 
absence of cell death could have been tested by reseeding the ECs in standard 
growth medium to ensure their motility was re-established. However, even in 
those groups in which migration virtually ceased completely, cells maintained 
their normal appearance and adherence in contrast to the findings in chapter 5 
(Figure 5.2.1). Direct measurement of O2- production in the EC culture medium 
would have been valuable to quantify and characterise ROS generation by the 
X/XO reaction and the effect of probucol, although the former could be 
indirectly confirmed by chemiluminometry reported in Chapter 2.3.2. The 
observer performing microscopic examination of EC migration was not blinded, 
similar to previous work published in this area (126;127). The standard error 
within each group was relatively low, suggesting that the selection of analytical 
fields did not suffer from major variability. 
 
3.4.5 Conclusions 
Taken together, the results of this study and others indicate that oxidative stress 
is an important modulator of EC migration. The fact that ROS may inhibit EC 
migration has direct clinical relevance. In the setting of PCI, potential sources of 
ROS include oxLDL already present in atherosclerotic lesions and the 
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consequence of the procedure itself, which is known to generate ROS (243). 
Elevated levels of circulating and local ROS, especially O2-, could contribute to 
delayed stent healing after PCI. Retarded re-endothelialisation would be expected 
to encourage SMC proliferation and exacerbate neointimal thickening. 
Successful methods to reduce local levels of ROS, particularly O2-, may promote 
endothelial recovery and reduce ISR. Whilst this study provides no evidence that 
probucol is beneficial, the evaluation of more potent antioxidants with improved 
pharmacokinetic profiles to achieve this goal may present an important step 
towards the development of novel effective DES.  
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Chapter 4 
 
An in vitro evaluation of nitrone D 
as a potential novel DES coating 
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4.1 Introduction 
 
Nitrone-based antioxidants represent a family of electron paramagnetic 
resonance (EPR) spin-trapping agents, developed to trap ROS within biological 
tissues (244). Investigation of several novel nitrone-based compounds in human 
fibroblasts has suggested that the analogue, nitrone D, may possess the most 
favourable biological profile to take forward into preclinical assessment (245). 
The chemical structure of nitrone D is shown in Figure 4.1. Nitrone D is a highly 
lipophilic molecule which embeds deeply within biological membranes. This 
renders it potentially appealing as a therapeutic agent in atherosclerosis and other 
inflammatory conditions characterised by lipid peroxidation and heightened 
oxidative stress. Nitrone D has been shown to be a functionally effective 
antioxidant by providing protection to human fibroblasts against oxidative 
challenge with 150 µM H2O2 (245). Another important effect of nitrone D was 
the five-fold increase in relative SIRT 1 expression (245). SIRT 1 is a 
deacetylase protein which is implicated in a broad range of cellular functions 
(246;247). Importantly, SIRT 1 promotes EC proliferation and survival (248). 
Furthermore, upregulation of SIRT 1 appears to prevent oxidative stress-induced 
EC senescence, which may help to maintain a functional endothelium (249). 
Established DES coatings (sirolimus and everolimus) decrease SIRT 1 
expression and cause a senescent phenotype in ECs, an effect which was 
reversed by SIRT 1 overexpression (250).  
 
Bearing in mind these encouraging data, nitrone D was chosen as a potentially 
suitable DES coating for evaluation. First, I assessed the effect of nitrone D on 
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WBA to determine if it had favourable antithrombotic properties that would be 
attractive as a DES coating. As no data exists for the effects of nitrone-based 
antioxidants on platelet or blood aggregation, this would provide important 
safety data for a novel compound to be potentially used as a stent coating. If 
antithrombotic properties were identified, that may potentially inhibit early stent 
thrombosis and to some extent neointimal formation, although the antirestenotic 
efficacy of anticoagulant coated stents has been limited to date (251;252). 
Second, and more importantly, I set out to test the effect of nitrone D on 
migration of cultured ECs. If nitrone D were to display favourable characteristics 
in vitro, then it would be investigated as a DES coating in a preclinical in vivo 
model to assess whether it would improve endothelial regrowth, reduce ISR or 
lower the risk of stent thrombosis. 
 
 
Figure 4.1 The chemical structure of nitrone D.  
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4.2 Methods 
 
4.2.1 Chemiluminescence 
Lucigenin chemiluminescence was performed with nitrone D to establish that it 
was acting as an antioxidant, according to the method in Chapter 2.2.1. 
Antioxidant efficacy was assessed using 50 U/ml SOD as a positive control in 
the presence of 100 µM X and 10 mU/ml XO. 
 
4.2.2 Study population for WBA 
This study was approved by the West Glasgow and University of Strathclyde 
ethics committees. All participants were provided with a PIS and gave their 
informed written consent. All patients were recruited from adult patients with 
angiographic evidence of stable CHD, who attended the Western Infirmary 
Glasgow for out-patient cardiac appointments. All patients were over age 18 and 
receiving chronic oral aspirin therapy. Patients were excluded if there was a 
history of myocardial infarction within previous 3 months, they were unable to 
give informed consent or if they were taking any other antithrombotic therapy (as 
in Chapter 2). 
 
4.2.3 Whole blood aggregometry 
The method of WBA is described in Chapter 2.2.3. To assess the effect of nitrone 
D, blood was incubated with increasing concentrations of nitrone D (1-100 µM), 
for 1 minute prior to addition of each agonist. Finally, to assess the effect of 
nitrone D in the presence of oxidative stress, 100 µM nitrone D was given prior 
to adding 100 µM X and 10 mU/ml XO, 1 minute before the addition of agonist. 
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4.2.4 EC culture and migration assay  
The methods of EC culture and EC migration assay are described in Chapter 
3.2.1-3.2.2. EC migration after 24 hours was measured under control conditions 
and after exposure to 100 µM nitrone D. Control cells were treated with the 
relevant vehicle (PBS). 
 
4.2.5 Statistical analysis 
All data are expressed as the mean ± SEM, unless otherwise stated. For WBA, 
individual aggregation values were calculated as a percentage of aggregation 
compared to control conditions. For EC migration, the number of ECs that had 
migrated across the 1,300 µm starting line after 24 hours was counted. All EC 
migration experiments were performed in duplicate, on cultures derived from at 
least 2 different animals. Groups were compared using a t-test or repeated 
measures analysis of variance with post-hoc Dunnett’s test. Statistical 
significance was confirmed at p < 0.05. Statistical analysis was performed using 
the SPSS statistical software package 14.0 for Windows (SPSS Inc., Chicago, IL, 
USA). 
 
4.3 Results 
 
4.3.1 Confirmation of antioxidant activity of nitrone D 
The addition of 100 µM nitrone D prior to the reaction between 100 µM X and 
10 mU/ml XO abolished chemiluminescence in a similar fashion to 50 U/ml 
SOD, indicating that nitrone D was acting as an effective antioxidant (Figure 
4.2). 
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Figure 4.2 The effect of nitrone D on X/XO-induced chemiluminescence. CL due 
to 100 µM X and 10 mU/ml XO with the effect of 50 U/ml SOD and 100 µM nitrone D 
(n = 4), * p < 0.001 vs. control. 
 
4.3.2 Baseline characteristics of WBA patients 
The baseline characteristics of 10 patients included for WBA are shown in Table 
4.1. The prevalence of additional cardiovascular risk factors was high and most 
patients were taking standard drug therapy for CHD. As in Chapter 2, all patients 
were taking regular aspirin and no patient was taking clopidogrel or any other 
antithrombotic medication. 
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Table 4.1 Baseline characteristics of WBA patients 
 Prevalence, 
(n = 10) 
Patients’ characteristics  
Age, mean (SD), y 66.9 (10.0) 
Male, n (%) 9 (90.0) 
Current smoker, n (%) 3 (30.0) 
Hypertension, n (%) 4 (40.0) 
Hypercholesterolaemia, n (%) 5 (50.0) 
Diabetes mellitus, n (%) 5 (50.0) 
Family history of premature CHD, n (%) 3 (30.0) 
Previous myocardial infarction, n (%) 5 (50.0) 
Previous stroke, n (%) 0 (0.0) 
Previous PCI or CABG, n (%) 1 (10.0) 
Multivessel disease, n (%) 6 (60.0) 
Preserved LV function, n (%) 8 (80.0) 
Heart failure, n (%) 2 (20.0) 
Drug treatment  
Aspirin, n (%) 10 (100.0) 
Clopidogrel, n (%) 0 (0.0) 
Statin, n (%) 8 (80.0) 
ACE inhibitor or ARB, n (%) 6 (60.0) 
Beta-blocker, n (%) 8 (80.0) 
Calcium channel blocker, n (%) 4 (40.0) 
Diuretic, n (%) 6 (60.0) 
Nitrate, n (%) 6 (60.0) 
Nicorandil, n (%) 5 (50.0) 
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4.3.3 Effect of nitrone D on WBA  
The effect of nitrone D on WBA in CHD patients is shown in Figures 4.3 and 
4.4. Nitrone D caused a concentration-dependent inhibition of WBA compared to 
control, for both agonists. Although the effect of each individual dose fell short 
of statistical significance, a linear trend was evident for each agonist (both p < 
0.05 for trend). As in Chapter 2, 100 µM X and 10 mU/ml XO inhibited WBA 
non-significantly compared to control. However, in the presence of 100 µM X 
and 10 mU/ml XO, 100 µM nitrone D inhibited WBA significantly in response 
to collagen by 18.4% (95% CI 3.9%-33.0%, p < 0.05) and in response to ADP by 
39.0% (95% CI 0.2%-77.8%, p < 0.05).  
 
 
Figure 4.3 The effect of nitrone D on WBA in response to collagen. Nitrone D (1-
100 µM) caused a concentration-dependent inhibition of WBA in response to 3 µg/ml 
collagen in CHD patients (p < 0.05 for trend). 100 µM nitrone D and X/XO significantly 
inhibited WBA (n = 9), * p < 0.05 vs. control. 
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Figure 4.4 The effect of nitrone D on WBA in response to ADP. Nitrone D (1-100 
µM) caused a concentration-dependent inhibition of WBA in response to 5 µM ADP in 
CHD patients (p < 0.05 for trend). 100 µM nitrone D and X/XO significantly inhibited 
WBA (n = 7), * p < 0.05 vs. control. 
 
4.3.4 Effect of nitrone D on EC migration  
Initially, the effect of nitrone D alone on EC migration was studied (Figure 4.5). 
100 µM nitrone D caused a marked reduction in EC migration compared with 
control (1.1 ± 0.5 vs. 6.4 ± 1.8 migrating cells/wound, respectively [p < 0.01]). 
Given that nitrone D alone severely limited EC migration, its influence on the 
migration of X/XO-treated cells was not evaluated. 
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Figure 4.5 The effect of nitrone D on EC migration. Representative 
photomicrographs of vehicle (A) and 100 µM nitrone D (B) in the scratch wound assay. 
C, 100 µM nitrone D severely inhibited EC migration compared with control (n = 4), p < 
0.05 vs. control. 
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4.4 Discussion 
 
4.4.1 Nitrone D as an antioxidant 
Nitrone D was found to perform well as an antioxidant in chemiluminescence 
experiments. In the presence of X/XO, nitrone D was able to quench O2- from the 
surrounding environment in a similar fashion to SOD. 
 
4.4.2 Effect of nitrone D on WBA 
Although no individual concentration of nitrone D was found to inhibit WBA, 
there was a trend across the concentration range of an inhibitory effect, which 
may have reflected increasing antioxidant activity. Although antioxidants may 
suppress the pro-aggregatory effects of platelet-derived O2- (177), this effect was 
not confirmed by this study. When local oxidative stress was enhanced by X/XO, 
addition of 100 µM nitrone D led to a statistically significant reduction in WBA. 
As discussed in Chapter 2, the overall effect of exogenous ROS generated by 
X/XO in this assay is inhibitory, probably due to the relative over-production of 
anti-aggregatory ROS such as H2O2 and ONOO-, rather than O2-. I speculate that 
nitrone D may have been less protective against inhibitory ROS; thus, co-
administration of X/XO and nitrone D resulted in additive inhibitory effects on 
WBA, which became statistically significant. I have found no data to suggest that 
elevation of SIRT 1 or reduction in p16 and p21 gene expression (245) are 
alternative potential mechanisms of platelet inhibition, although this was unlikely 
given the time frame of the experiments. To my knowledge, the effect of nitrone 
D on platelet function has not previously been described. Therefore, this work 
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provided evidence that nitrone D is likely to have, at most, a minor inhibitory 
effect on WBA.  
 
4.4.3 Effect of nitrone D on EC migration 
Surprisingly, nitrone D (100 µM) caused a marked reduction in EC migration. In 
fact, migratory activity of ECs was virtually abolished by nitrone D. This was an 
unexpected finding and rendered nitrone D very unattractive as a novel DES 
coating, which would ideally accelerate endothelial regeneration. Although only 
a single concentration of nitrone D was tested, I speculate that concentrations 
less than 100 µM would not have been effective overall, since nitrone D was not 
toxic to human fibroblasts up to 300 µM and relatively high concentrations are 
desirable to trap ROS and the carbon-centred radicals resulting from them (245). 
Human fibroblasts grown in nitrone D had elevated SIRT 1 transcription, 
consistent with these cells being more adapted to growth and survival (245). 
Therefore positive effects were anticipated in this study, as SIRT 1 is emerging 
as a key protective regulator of ECs against oxidative stress (253;254). The 
reason(s) for the marked inhibitory effect of nitrone D on EC migration is 
unclear, but can be explored by considering the processes required for cell 
motility.  
 
Migration of ECs involves cytoskeleton reorganisation, extension of lamellipodia 
and filopodia, with formation and detachment of adhesions at the edges of the 
cell to facilitate movement. Nitrone D is known to reduce p21 expression in 
human fibroblasts (245) and this effect may be relevant to EC migration because 
previous data supports a role for p21 activated kinases in the coordination of 
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leading edge adhesion formation and contraction/detachment of the trailing edge 
of the cell (255). Another strong possibility was that the potent antioxidant 
properties of nitrone D were responsible for reduced EC migration. It is now 
recognised that ROS have a dual role in affecting cell migration, which can be 
stimulatory or inhibitory, depending on the type, amount and duration of 
exposure. Compelling studies by Moldovan et al. (256) and Ikeda et el. (257) 
found that ECs at the margins of a wound assay produce small amounts of ROS, 
which appear to be essential for normal migration. Normal cell motility in 
animals is based on changes in the actin cytoskeleton, which depends on the 
response to numerous signals (258). Actin polymerisation, necessary for 
cytoskeleton reorganisation, is mediated by targeted physiological release of O2- 
from ECs (256). Therefore, potent antioxidants acting deep within cells, such as 
nitrone D, could disturb this process and lead to impaired cell motility. In support 
of this, a SOD mimetic and inhibitor of NADPH oxidase both limited EC 
migration (256). A finely balanced redox state is likely to support EC movement 
which, like platelet aggregation, is reliant on physiological cellular ROS 
generation, but may also be disrupted by disproportionately high levels of 
oxidative stress present in pathological states.  
 
4.4.4 Limitations 
It would have been beneficial to test a variety of concentrations and construct a 
concentration-response curve for nitrone D in the EC migration assay. The effect 
of X/XO caused a lower chemiluminescence signal compared to the values in 
Chapter 2. This appeared to be due to considerable daily variability in the assay, 
which was unexplained. As a result, to maintain scientific validity, all 
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experiments for a given section were performed in succession on the same day 
and excellent reproducibility was achieved for identical conditions within each 
group. As in previous chapters, the relevance of in vitro assays in whole blood to 
the clinical setting is limited. Recent work has shown that some methods of in 
vitro platelet testing can predict clinical events after PCI and although supportive 
data is not available for WBA, this method correlates well with light 
transmission aggregometry (259), which does display some prognostic value 
(260). 
 
4.4.5 Conclusions 
Although I found that nitrone D displayed attractive properties by weakly 
inhibiting WBA, it caused a marked reduction in EC migration. This latter 
characteristic is highly undesirable as a potential DES coating because, if 
occurring in vivo, it could significantly impair endothelial healing. Given that 
promotion of re-endothelialisation was a primary objective of this research 
project, nitrone D was no longer considered suitable as a potential novel 
antioxidant DES coating. 
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Chapter 5 
 
The effects of a succinobucol-eluting stent 
in a porcine coronary model 
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5.1 Introduction 
 
The advent of DES has enabled a vast array of compounds to be tested as local 
treatments after stent deployment in a bid to modify arterial healing. The primary 
objective of early DES was to inhibit neointimal hyperplasia and resulting ISR, 
the main drawback of BMS. This goal has largely been achieved by the first 
generation of DES, now in widespread clinical use. However, whilst DES have 
successfully decreased the incidence of ISR, the polymers and drugs used as 
coatings can cause delayed arterial healing and inflammation, which both 
increase the risk of late stent thrombosis, a potentially life-threatening 
complication (261). Thus, much effort is now being directed towards the 
development of novel polymer-free DES using drugs which inhibit ISR, but also 
promote healing and reduce inflammation. 
 
Previous studies have shown that probucol can reduce ISR by inhibiting 
neointimal hyperplasia and improving re-endothelialisation after stent injury 
(150;155). Probucol is thought to mediate these beneficial effects via its 
antioxidant properties (148;262) and up-regulation of heme oxygenase-1, which 
induces vascular SMC apoptosis and promotes EC function (160). Unfortunately, 
in clinical trials, the effects of oral probucol have been less consistent 
(153;154;156;157). The efficacy of probucol as a DES coating has been 
evaluated in a preclinical model (263) and subsequently in the ISAR-TEST-2 
clinical trial, which showed that a non-polymer based dual probucol/rapamycin-
eluting stent was equivalent to a polymer-based rapamycin-eluting stent (264). 
This was remarkable, given that rapamycin is known to have superior effects if 
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delivered using a polymer (265). It is not clear whether probucol was exerting 
polymer-like properties or if it was directly beneficial to vascular healing. The 
efficacy of a probucol-eluting stent is currently unproven. 
 
Succinobucol is a novel compound designed to improve upon many of the 
chemical and pharmacological properties of probucol (Figure 5.1). It has several 
properties highly attractive as a novel DES coating. The introduction of a 
monosuccinate moiety onto a phenol group renders succinobucol slightly more 
hydrophilic than probucol. This leads to considerably enhanced cellular uptake 
compared with probucol, which suffers from poor bioavailability and requires 
preloading for several weeks (157;163). Succinobucol potently inhibits basal and 
H2O2-induced levels of ROS released from human ECs and monocytic cells in a 
concentration-dependent fashion, whereas probucol has a much weaker effect 
(163;166). Succinobucol also exerts antiproliferative effects on vascular SMCs, 
with 50% inhibition at 5 µM (165;166), compared with probucol which was 
shown to exert no significant effect on SMC proliferation up to 100 µM (165). 
Succinobucol also has important anti-inflammatory actions. In previous studies, 
succinobucol potently inhibited pro-inflammatory cytokine release by monocytes 
and the expression of several pro-inflammatory adhesion molecules, including 
vascular cell adhesion molecule-1 and MCP-1 (163-166), which may contribute 
significantly to neointimal development (266;267). The anti-inflammatory effects 
of probucol in these studies was greatly limited. These comparisons with 
probucol may partly explain the poor results of oral probucol in clinical studies 
(154;157) and the negative preclinical effects of a probucol-eluting stent (158). 
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Finally, succinobucol also reduces platelet aggregation, which may be beneficial 
in lowering the risk of early stent thrombosis (268).  
 
In the ARISE (Aggressive Reduction of Inflammation Stops Events) clinical 
trial, oral succinobucol reduced the incidence of myocardial infarction, stroke 
and diabetes mellitus (269). However, succinobucol caused more adverse effects 
than placebo, worsened lipid profiles and increased the incidence of atrial 
fibrillation. CART-1 tested oral succinobucol following coronary stenting, but 
the reduction in ISR was significant only if drug compliant patients were 
analysed separately (156).  
 
Succinobucol has never been evaluated as a DES coating and appears to offer 
significant advantages over probucol. It is possible that locally targeted therapy 
using stent-based delivery of succinobucol could improve efficacy and reduce 
systemic adverse effects. On the other hand, if negative cellular actions outweigh 
the beneficial effects of succinobucol, delivery of high concentrations into the 
artery wall may result in localised toxicity. The combination of succinobucol 
with a recognised inhibitor of ISR such as rapamycin may potentiate beneficial 
effects on neointimal formation and negate the proinflammatory effects of 
rapamycin on injured arterial tissue (170). There is also some evidence 
suggesting that oxidative stress may be linked to rapamycin resistance (270), 
therefore local application of an antioxidant may improve the efficacy of 
rapamycin. Finally, succinobucol may improve the elution profile of rapamycin 
in the absence of a polymer, by retarding drug release in a similar fashion to 
probucol (91) leading to improved efficacy. The aim of this study was to test 
 128 
whether succinobucol alone, or in combination with rapamycin, coated on a 
polymer-free DES would have a favourable effect on ISR and vascular healing 
after stent implantation. 
 
 
 
 
 
Figure 5.1 The chemical structure of probucol (A) and succinobucol (B). 
 
5.2 Methods 
 
5.2.1 Drugs 
Succinobucol ([butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-
hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-
dimethylethyl)phenyl]ester], previously known as AGI-1067), the monosuccinic 
acid ester of probucol, was synthesized by esterification of probucol (Sigma-
Aldrich, Poole, Dorset). The identity of succinobucol was confirmed by NMR 
spectroscopy and purity was in excess of 99%. Succinobucol is metabolically 
stable and no significant active metabolites are formed in vivo (271). Rapamycin 
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(sirolimus) is a macrocyclic triene antibiotic with potent antiproliferative, anti-
inflammatory and immunosuppressive effects. It forms a complex with FKBP12, 
which subsequently binds to and inhibits the molecular target of rapamycin 
(mTOR), causing arrest of cell proliferation. Rapamycin (purity ≥ 95%) was 
purchased from Cfm Oskar Tropitzsch (Marktredwitz, Germany). 
 
5.2.2 DES coating 
The Yukon® DES (Translumina, Hechingen, Germany) used in this study 
consisted of a pre-mounted, sandblasted 316L stainless steel microporous stent, 
which is designed for individualised and dose-adjustable on-site stent coating. 
The microporous stent surface enables increased drug deposition and improves 
the drug reservoir capacity, allowing for retarded drug release without recourse 
to a polymer (272). All stents were 3.5 mm diameter and 16 mm length. The 
BMS were uncoated versions of the Yukon® stent. All stent coating solutions 
consisted of drug(s) dissolved in 99.5% ethanol. Sterile stent cartridges were 
placed in the coating device (Figure 5.2) and connected to a 1 ml syringe which 
contained a predetermined volume of coating solution (0.33 ml for a 16 mm 
stent). Stent coating was achieved by a mobile ring containing 3 jet units, which 
allowed uniform spraying of drug solution onto the stent surface. The total time 
to spray coat the stent was approximately 6 minutes. The coating device dried the 
stent surface automatically by evaporating the ethanol with pressurised air (4-6 
atmospheres). When spray coating was complete, the stent cartridge was 
removed from the machine and set aside for use within 4 hours. In the absence of 
prior data, three succinobucol coating solutions: 0.5% (5 mg/ml), 1% (10 mg/ml) 
and 2% (20 mg/ml) were tested. The succinobucol concentration that produced 
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optimal strut coverage, using scanning electron microscopy (Hitachi S-4800), 
was selected for preclinical evaluation. The concentration of rapamycin coating 
solution (2%) was derived from favourable data using an identical Yukon® stent 
platform  (272;273). Three DES were evaluated: a succinobucol-eluting stent 
(SES); a rapamycin-eluting stent (RES); a dual succinobucol/rapamycin-eluting 
stent (SRES) and these were compared to an uncoated Yukon® stent (BMS).  
 
 
Figure 5.2 The DES coating device. Individualised, dose adjustable DES coating 
was achievable using a predetermined volume of coating solution which was sprayed via 
three mobile jet units onto the microporous stent surface under sterile conditions. 
 
5.2.3 Preoperative care and anaesthesia 
Male Large-White/Landrace pigs (approximately 10 weeks old, 20-25 kg) were 
allowed to acclimatise for at least a week before commencement of the study. 
Each pig was preloaded with oral aspirin 300 mg and oral clopidogrel 300 mg 3 
days prior to the procedure, followed by normal diet with supplementation of 
oral aspirin 75 mg and oral clopidogrel 75 mg daily for the remainder of the 
study. On the morning of the procedure, 2-3 stents were prepared for 
implantation. The pig was sedated by an intragluteal injection of 
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tiletamine/zolazepam (Zoletil®) 100 mg i.m. and a mixture of inhaled isoflurane 
(1–2%) in oxygen/nitrous oxide. Intravenous access was obtained via cannulation 
of the marginal ear vein and propofol (Rapinovet®) 30 mg i.v. was administered 
slowly over 1-2 minutes. Immediately, tracheal intubation was performed using a 
5.5 French veterinary tracheal tube. The tracheal tube was connected to the 
ventilator and general anaesthesia maintained throughout the procedure using a 
mixture of isoflurane (1–2%) in oxygen/nitrous oxide. Pigs were given 
buprenorphine (Vetergesic®) 0.15 mg i.m. for perioperative analgesia and 
ampicillin (Amfipen®) 350 mg i.m. as antibiotic cover. Electrocardiography 
leads were connected to three limbs for cardiac monitoring. 
 
5.2.4 In vivo stenting 
Heparinised saline (5,000 units heparin in 500 ml 0.9% saline) was used to flush 
all catheterisation equipment. The left groin area of the pig was sterilised using 
povidone-iodine (Betadine®) solution and the surgical field was prepared with 
sterile drapes. A 5 cm incision was made with a sterile scalpel and the 
subcutaneous tissue was divided. The underlying muscles were separated by 
blunt dissection to expose the left femoral neurovascular bundle. The left femoral 
artery was dissected carefully to separate it from the femoral vein and femoral 
nerve, which allowed a blunt suture holder to pass two absorbable sutures 
(Dexon™ II) around the femoral artery (Figure 5.3A). The femoral artery was 
accessed between the two sutures using a human transradial artery access kit 
(Arrow® International UK Ltd, Middlesex). Arterial puncture was confirmed by 
pulsatile arterial flow. The 0.025 inch soft tipped guidewire was passed through 
the needle into the arterial lumen, the needle was removed and a 6 French sheath 
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and dilator were placed over the wire. The wire and dilator were removed and the 
sheath was flushed with heparinised saline (Figure 5.3B).  
 
 
Figure 5.3 Intra-arterial access via the left femoral artery in the pig. A, Two sutures 
were placed around the femoral artery, which lies between the femoral vein and femoral 
nerve. B, The sheath was inserted after arterial puncture and wire access. 
  
Heparin 2000 units (100 units/kg) i.a. was administered via the sheath. Real time 
fluoroscopy (Siremobil 4N, Siemens) was used to image the catheterisation. A 
0.035 inch J-tipped guidewire was inserted into a 6 French coronary guiding 
catheter and both were advanced to the aortic arch. The guidewire was removed 
and the catheter was attached to a 3 port manifold, connected to an electronic 
pressure transducer, heparinised saline flush and radiographic contrast 
(Omnipaque 140, GE Healthcare), with a luer lock 10 ml syringe (BD 300-912) 
attached to the distal end for intra-arterial injection. The catheter tip was placed 
at the ostium of the left or right coronary artery, confirmed by contrast injection. 
Suitable guiding catheters were Judkins Right 3.5 or 3 for both coronary arteries 
or Judkins Left 3.5 or Amplatz Right 1 for difficult intubations. A 0.014 inch 
coronary guidewire was introduced and advanced to a distal portion of a major 
coronary artery. A Yukon® stent (type of stent was blinded to the operator) was 
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prepared by passively filling the stent balloon with 1:1 contrast:saline and 
advanced over the guidewire into a stable position in the proximal or mid 
coronary artery, avoiding major coronary branches. Balloon inflation was 
performed for 20 seconds, aiming for a stent:artery ratio of 1.1-1.2:1 (typically 9-
12 atmospheres), i.e. slight over-sizing. Appropriate injury was confirmed by 
angiography before the balloon and guidewire were removed (Figure 5.4).  
 
 
Figure 5.4 Angiograms of coronary stent implantation in the pig. A, Catheter in left 
main coronary artery and guidewire in distal left circumflex coronary artery. B, Inflation 
of balloon and stent deployment. C, Final angiographic result with slight oversizing of 
stent:artery ratio. All angiograms shown are right anterior oblique 30º projection. In this 
view, the left circumflex is medial to the left anterior descending coronary artery. 
 
This procedure was repeated in a total of 2-3 coronary arteries in order to implant 
2-3 stents per pig. Succinobucol was undetectable in blood samples 1 hour and 1 
day after stenting therefore implantation of multiple stent types in each animal 
was permitted in accordance with published guidelines (175). During the 
procedure, the pig received an intravenous saline infusion (approximately 250 
ml) to support blood pressure. The catheter and sheath were removed and 
haemostasis was achieved by manual pressure (10-20 minutes) or ligation of the 
femoral artery, if ongoing bleeding. The subcutaneous tissues were closed with 
 134 
absorbable sutures (Dexon™ II) and the skin was closed with non-absorbable 
sutures (Ethilon®). Anaesthesia was terminated and the pig was extubated. 
Adequate recovery was ensured and the pig returned to the pen. All premature 
and unexpected deaths were examined by post-mortem, gross evaluation and 
stent examination. Approval was granted by Strathclyde University Ethics 
Review Committee and all procedures were performed under Home Office 
Project Licence number 60/3410. 
 
5.2.5 Pharmacokinetic studies 
Drug loading of succinobucol was quantified by in vitro elution of the SES in 
pure ethanol, followed by HPLC analysis. To determine in vivo release 
characteristics of the SES, stents were harvested 1 hour, 1, 3, 7, 14 and 28 days 
after implantation. At the end of each predefined period, the pig was sedated and 
euthanized by a lethal dose of sodium pentobarbital (Euthatal®) 3000 mg i.v. 
The heart was removed via midline thoracotomy and placed in saline. The 
coronary arteries containing stents were carefully dissected from connective 
tissue. Stents were excised and surrounding arterial tissue was homogenised. 
Succinobucol in surrounding arterial wall and remaining on the stent was 
extracted into acetonitrile. Samples were chromatographed on a Sphereclone 
ODS (2) column (5 µm particle size, 150 × 4.6 mm [Phenomenex, UK]). 
Samples were injected using an autosampler and pump system (Gynotek 480) in 
20 µl aliquots, at a mobile phase flow rate of 1 ml/min acetonitrile:water 
(92.5:7.5). The detector (Detector 432, Kontron Instruments, UK) output was 
measured at a wavelength of 242 nm.  
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5.2.6 Tissue fixation and processing 
To determine efficacy, stents were harvested 28 days after stent implantation. At 
the end of the study period, each pig was sedated and euthanized as previously 
described. The heart was examined for gross evidence of myocardial infarction. 
The coronary arteries were dissected free from connective tissue and the stented 
segments were excised, including 3-4 mm of non-stented artery at each end. The 
segments were rinsed with saline to remove non-adherent clot. The specimens 
were fixed overnight in 10% formal saline, in an Eppendorf tube at 4 ºC, 
followed by dehydration in 100% acetone, overnight at 4 ºC. The specimens 
were then placed in glycol methacrylate (Technovit® 8100, Kulzer) infiltrating 
solution in an Eppendorf tube and left overnight at 4 ºC. The following day the 
specimens were removed and placed in a small plastic cylindrical tube, using 
circumferential foam padding to ensure correct orientation (distal end of the stent 
at the base of the tube). The tube was filled with Technovit® 8100 embedding 
solution and air bubbles were removed using forceps, before placing in the fridge 
to allow the plastic resin to harden. The Technovit® 8100 infiltrating and 
embedding solutions were made up according to the manufacturer’s instructions. 
This produced a small cylindrical block of plastic resin containing the stented 
coronary segment. All blocks were randomly labelled by an external observer 
with a numbered code, which was placed in a sealed envelope until the end of all 
data collection and analysis. 
 
5.2.7 Slide preparation 
Each resin block containing the stented artery segment was removed from the 
plastic tube using a scalpel. The distal end of the resin block was stuck to a glass 
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microscope slide using toughened acrylic adhesive (159-3991, RS). This 
produced superior bonding compared to Super Glue (Loctite®). Using a diamond 
edged rotary saw (Buehler Isomet® 1000), the slide was mounted on a chuck and 
a thin section cut 300-400 µm from the slide end. The new distal end of the resin 
block was then stuck to another slide with adhesive. This process was repeated to 
produce 6 good quality sections from the distal to proximal portion of the stent. 
Once cut, the sections were ground and polished by hand using a grinder/polisher 
(Buehler Metaserv® 2000) to reduce the thickness of the section to 10 µm and 
give a uniform surface for staining and microscopic evaluation. Sections were 
stained using haematoxylin-eosin and modified Carstairs’ stain. Images were 
acquired using a Leica DM LB2 microscope and Leica DFC320 digital camera. 
Blinded histological analysis was performed using computerized morphometry 
software (Image-Pro Plus, Cybernetics).  
 
5.2.8 Histomorphometric analysis 
Histomorphometric analysis was according to Schwartz et al. (274) (Figure 5.5). 
Neointimal thickness was calculated as the mean distance from each stent strut to 
lumen; neointimal area was calculated as stent area minus lumen area; diameter 
stenosis was calculated as 100 × (1 − lumen area / IEL area). Binary ISR was 
defined as ≥ 50% diameter stenosis. Stent endothelialisation score was defined as 
the extent of the circumference of the arterial lumen covered by ECs and graded 
from 1 to 3 (1 = 25%; 2 = 25% − 75%; 3 ≥ 75%). Inflammation was graded as 0, 
none; 1, scattered inflammatory cells; 2, inflammatory cells encompassing 50% 
of a strut in at least 25% to 50% of the circumference of the artery; 3,  
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Figure 5.5 Histomorphometry and injury score. Injury score was defined as 0, IEL 
intact, media compressed; 1, IEL lacerated, media compressed; 2, Media lacerated, EEL 
intact; 3, EEL lacerated. Stent struts are represented by rounded squares. 
 
inflammatory cells surrounding a strut in at least 25% to 50% of the 
circumference of the artery. The intimal fibrin content was graded as 0, no 
residual fibrin; 1, focal regions of residual fibrin involving any portion of the 
artery or moderate fibrin deposition adjacent to the strut involving < 25% of the 
circumference of the artery; 2, moderate fibrin involving > 25% of the 
circumference of the artery or heavy deposition involving < 25% of the 
circumference of the artery; 3, heavy fibrin deposition involving > 25% of the 
circumference of the artery. All sections were examined for presence of 
uncovered stent struts and evidence of in-stent thrombus was determined 
throughout the entire stent length. 
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5.2.9 WBA studies 
As succinobucol was to be used for the first time as a novel DES coating, its 
effect on WBA was investigated, primarily for safety purposes. This part of the 
study was performed following the premature death of two pigs, to ensure that 
succinobucol was not exerting a prothrombotic effect. WBA was performed 
according to the method described in section 2.2.3. The effect of succinobucol 
(1-100 µg/ml) on WBA was determined using fresh porcine blood, withdrawn 
from the main pulmonary artery immediately after euthanasia for 4 pigs. 1 µl of 
1, 10 and 100 mg/ml succinobucol (in 99.5% ethanol) was added to 1 ml of 
whole blood:0.9% saline (1:1), 1 minute prior to addition of agonist. 3 µg/ml 
collagen and 20 µM ADP were used as platelet agonists. A higher concentration 
of ADP was used in this study because pigs were taking clopidogrel, an ADP 
receptor antagonist. Vehicle (0.1% ethanol) had no effect on WBA. 
 
5.2.10 Cell culture studies 
Bovine pulmonary artery ECs, obtained from a local abbatoir, were seeded on to 
6 well plates (up to passage 4) and grown to 70% confluence. Succinobucol or 
probucol was added to each well at concentrations (1-20 µmol/L) that have 
previously been shown to inhibit SMC proliferation (149;165;166). An additional 
well received the maximum amount of vehicle (0.3% dimethyl sulphoxide). After 
24 hours, the well plates were inspected and photographed, taking account of any 
evidence of cytotoxicity. The medium was removed, and adherent cells were 
dislodged using trypLE Express (Invitrogen, UK). Trypan blue (0.07%) was 
added to the cell suspension and cells counted using a hemocytometer. The 
percentage of the counted cells not stained by trypan blue is reported as the 
 139 
percent viable cells. Identical experiments were performed using abbatoir derived 
bovine pulmonary artery SMCs, grown to 90% confluence. In additional 
experiments, 3-morpholinosydnonimine (SIN-1, a peroxynitrite donor) 0.2 µM 
was used to generate oxidative stress and administered to bovine aortic SMCs 
alone and in combination with succinobucol or probucol. Originally, the effect of 
succinobucol on cell proliferation was to be studied, however the 
proinflammatory actions of the SES found in vivo and the damaging effects noted 
in cell cultures led to a change in the protocol to address cytotoxicity and 
viability. 
 
5.2.11 Toxicology studies 
Given that succinobucol is a close analogue of probucol, which is known to 
prolong the QT interval, the effects of succinobucol on the surface 
electrocardiogram was assessed. 500 µg succinobucol (an approximation of the 
mass of drug carried on a SES) was infused into a coronary artery of a pig, not 
included in any other study. Electrocardiographic and haemodynamic monitoring 
was performed throughout, looking specifically for evidence of ischaemia, 
dysrhythmias or QT interval prolongation. Succinobucol concentration in the 
blood (withdrawn from the pulmonary artery) was measured 1 hour and 1 day 
after implantation of 2 SES, using HPLC. 
 
5.2.12 Statistical analysis 
Histomorphometric data for each stent was the mean of six sections from 
proximal to distal end. The endothelial score, inflammatory score and fibrin 
score were the mean of two sections per stent. Group means were calculated and 
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then compared by one-way analysis of variance and post-hoc Dunnett’s test. For 
WBA experiments, aggregation in response to ADP was severely reduced by 
clopidogrel, therefore values are absolute impedance. For the efficacy study, a 
sample size of 9 per group was calculated to provide 80% power to detect a 
treatment difference of 30% between groups at a two-sided 0.05 significance 
level, based on the assumption that the SD of the response variable (neointimal 
area) was 20% as shown by similar studies in the porcine model (58;272). All 
data are expressed as mean ± SEM unless otherwise stated. Significance was 
established by a value of p < 0.05. Statistical analysis was performed using the 
SPSS statistical software package 14.0 for Windows (SPSS Inc., Chicago, IL, 
USA). 
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5.3 Results 
 
5.3.1 Optimisation of SES coating 
0.5% (5 mg/ml), 1% (10 mg/ml) and 2% (20 mg/ml) succinobucol solutions in 
99.5% ethanol were sprayed onto a Yukon® stent and examined using scanning 
electron microscopy. 1% succinobucol coating solution produced a smooth 
uniform complete drug layer, optimal for the Yukon® DES delivery system and 
was therefore considered most appropriate for preclinical assessment (Figure 
5.6). 0.5% succinobucol produced incomplete strut coverage, with some areas of 
stent sparsely covered with drug. 2% succinobucol produced excessive coverage, 
with surplus drug deposition between struts and crystallisation of drug (10-25 µm 
diameter) present on the surface of the stent, which may become hazardous after 
balloon dilatation if distal embolisation were to occur. The coating device 
provided drug deposition on the exterior (abluminal) surface of the stent struts, 
whilst the interior (adluminal) surface remained essentially uncoated with drug 
(Figure 5.7). 
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Figure 5.6 A comparison of stent coverage for succinobucol coating solutions. A, 
0.5% succinobucol provided suboptimal coverage with drug (incomplete coverage areas 
are white). B, 1% succinobucol produced optimal strut coverage. C, 2% succinobucol 
caused surplus drug deposition and crystallisation (SEM, × 100 magnification). 
 
 
 
Figure 5.7 A comparison of uncoated and 1% succinobucol coated stents. A, BMS 
with microporous surface designed to act as a reservoir for drug deposition (insert: 
expanded BMS). B, 1% SES with smooth uniform drug layer (insert: SES with drug 
deposition on abluminal surface). Main figures (SEM, × 1000 magnification); inserts 
(SEM, × 100 magnification).  
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5.3.2 Drug loading of SES 
The total drug loaded on the SES using 1% succinobucol was measured in 4 
stents. The coating process produced a mass of 465 ± 61 µg succinobucol per 
SES. The drug loading of the RES using 2% rapamycin has been reported as 
producing 479 ± 26 µg rapamycin/cm2 (265), which is equivalent to 842.7 ± 46 
µg for a 3.5 mm × 16 mm stent.  
 
5.3.3 In vivo study plan 
6 pigs underwent coronary stenting to investigate in vivo pharmacokinetics of the 
SES and 19 pigs underwent coronary stenting as part of the in vivo efficacy 
study. The study plan is shown in Table 5.1. No pigs died prematurely during the 
pharmacokinetic study. There were 2 unexpected premature deaths during the 
efficacy study. One pig died the first night after successful implantation of a RES 
and SRES. Post-mortem examination identified no gross evidence of myocardial 
infarction, however careful dissection of the coronary arteries revealed occlusive 
stent thrombosis (Figure 5.8) in both stents. A second pig died on the operating 
table during recovery from general anaesthesia. Electrocardiographic monitoring 
displayed ventricular fibrillation during cardiac arrest (Figure 5.9). Post-mortem 
examination showed no gross cardiac abnormality, but there was evidence of 
occlusive stent thrombosis in both stents (SES and SRES). The diagnosis for 
both premature deaths was acute stent thrombosis (within 24 hours). 17 pigs 
completed the 28 day efficacy study and 41 stents were available for histological 
evaluation.  
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Table 5.1 In vivo study plan. Premature deaths are highlighted in grey (pig 2 and 5 
in efficacy study). Each pig received 2-3 stents. 
Pig LAD LCx RCA 
 
   
Pharmacokinetic study    
               1 (1 hour) SES SES SES 
               2 (1 day)  SES SES 
               3 (3 days) SES  SES 
               4 (7 days) SES SES  
               5 (14 days) SES  SES 
               6 (28 days) SES SES  
 
   
Efficacy study    
1 SES BMS  
2 SRES RES  
3 BMS  RES 
4 RES  BMS 
5 SES  SRES 
6  RES BMS 
7 BMS RES  
8 BMS  RES 
9 BMS RES  
10 RES SES  
11 RES SES  
12 SES SRES  
13 SES BMS RES 
14 BMS SES RES 
15 SRES SRES BMS 
16 SRES SES SRES 
17 SES SRES SRES 
18 SRES SRES SES 
19 SRES BMS SES 
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Figure 5.8 Fatal stent thrombosis in the pig. A, Gross cardiac specimen showing no 
evidence of myocardial infarction. B and C, Dissection of coronary artery revealed 
occlusive stent thrombosis. 
 
 
 
Figure 5.9 Ventricular fibrillation during cardiac arrest after stent implantation. 
The electrocardiograph shows 4 normal sinus beats followed by an R on T phenomenon 
inducing fatal ventricular fibrillation. 
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5.3.4 In vivo release profile of SES 
To determine in vivo release characteristics of succinobucol from the novel SES, 
13 SES were deployed in 6 pigs, using the techniques as previously described. 
Each pig received 2-3 stents in different coronary arteries (n = 2-3 for each time 
point) and specimens were harvested 1 hour, 1, 3, 7, 14 and 28 days after stent 
implantation. The SES provided sustained in vivo drug release for up to 4 weeks 
(Figure 5.10). 59.4% of the total succinobucol loaded on the SES was eluted 
during the first week and 81.0% was eluted after 28 days. This was very similar 
to the release profile of the RES, which retards drug release for greater than 3 
weeks, with around two-thirds released during the first week (272;273). 
Succinobucol concentration in coronary artery tissue immediately surrounding 
the stent was quantified at 1 hour, 1, 3, 7, 14 and 28 days after stent implantation 
(Figure 5.11). At 1 hour, succinobucol concentration in surrounding artery tissue 
was 22.4 ng/mg. At 1 day, succinobucol tissue concentration peaked at 825.9 
ng/mg. Succinobucol concentration in surrounding artery tissue was > 200 ng/mg 
for the remainder of the study. At 28 days, succinobucol tissue concentration was 
242.2 ng/mg.  
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Figure 5.10 In vivo release profile of SES. Succinobucol elution was controlled over 
4 weeks, with the majority of drug released in the first week. Data points represent % 
succinobucol released as a percentage of total drug loaded on the SES. 
 
 
Figure 5.11 Succinobucol tissue concentration after SES implantation. Succinobucol 
concentration in surrounding artery tissue peaked 1 day after implantation and was 
maintained for the duration of the study period (n = 2).  
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5.3.5 Efficacy results 
In total, 41 stents were implanted in the coronary arteries of 17 pigs for 
evaluation of efficacy at 28 days (BMS, n = 11; SES, n =10; RES, n = 10; SRES, 
n = 10). Representative photomicrographs from each group are shown in Figure 
5.12. 
 
Injury score 
There was no significant difference in injury score between groups (Figure 5.13).  
 
Vessel size 
EEL area was increased in the RES group, compared with all other groups (7.84 
± 0.30 mm2, 7.52 ± 0.28 mm2, 9.03 ± 0.30 mm2 and 7.61 ± 0.22 mm2 for BMS, 
SES, RES and SRES, respectively, p < 0.05). IEL area (6.74 ± 0.27 mm2, 6.35 ± 
0.30 mm2, 7.94 ± 0.29 mm2 and 6.56 ± 0.24 mm2) and stent area (6.35 ± 0.24 
mm
2
, 6.01 ± 0.27 mm2, 7.54 ± 0.29 mm2 and 6.29 ± 0.24 mm2) were also 
increased in the RES group (BMS, SES, RES and SRES, respectively, both p < 
0.05). Other group comparisons were not statistically significant. 
 
Medial area 
There was no difference in medial area at 28 days between groups (1.10 ± 0.06 
mm2, 1.17 ± 0.07 mm2, 1.10 ± 0.06 mm2 and 1.05 ± 0.06 mm2 for BMS, SES, 
RES and RSES, respectively, p = NS). 
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Figure 5.12 Representative photomicrographs of stent sections. BMS (A,B) had 
moderate neointimal formation; SES (C,D) had the most extensive neointima; RES (E,F) 
had minimal neointimal growth; SRES (G,H) had moderate neointima similar to BMS. 
A, C, E, G (× 2 magnification); B, D, F, G (× 10 magnification). 
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Figure 5.13 A comparison of injury score between groups. No significant 
differences were present (n = 10-11), p = NS. 
 
Neointimal area and thickness 
Neointimal area was increased significantly in the SES group, whereas there was 
a trend to decreased neointimal area in the RES group (Figure 5.14). Similar 
results were evident for neointimal thickness (Figure 5.15). There were no 
significant differences in neointimal area/medial area. Neointimal area/IEL area 
and neointimal area/EEL area were both increased significantly in the SES, 
compared with BMS (both p < 0.01). In all groups, the neointima was composed 
almost entirely of SMCs with inflammatory cells around the struts and little 
extracellular matrix (Figure 5.16). 
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Figure 5.14 A comparison of neointimal area between groups. Neointimal area was 
increased significantly in SES, compared with BMS (n = 10-11), * p < 0.01 vs. BMS. 
 
 
Figure 5.15 A comparison of neointimal thickness between groups. Neointimal 
thickness was increased significantly in SES, compared with BMS (n = 10-11), * p < 
0.01 vs. BMS. 
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Figure 5.16 Representative photomicrographs of stent sections (high power).  
A, Neointima (n) over stent struts (s) was made up predominantly of SMCs.  
B, Inflammatory cells (i) around a strut in SES. C, Thin endothelial monolayer (e) over 
the adluminal surface of a stent strut in RES. D, Uncovered strut with interruption of 
endothelium. E, Luminal thrombus (t) over an area of poor re-endothelialization.  
F, Fibrin (f) deposition around a strut in SES. All sections (× 20 magnification). 
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Diameter stenosis 
SES caused a significant increase in diameter stenosis, whereas the decreased 
diameter stenosis in the RES group was not significant (p = 0.17) (Figure 5.17). 
The rate of binary ISR (> 50% diameter stenosis) measured by histological 
analysis was 9.1%, 60%, 0% and 20% for BMS, SES, RES and SRES groups, 
respectively (p < 0.01). 
 
 
Figure 5.17 A comparison of diameter stenosis between groups. Diameter stenosis 
was increased significantly in SES, compared with BMS (n = 10-11), * p < 0.05 vs. 
BMS. 
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Lumen area 
The lumen area was increased significantly in the RES group and the decrease in 
lumen area in the SES group was of borderline significance (Figure 5.18). 
 
 
Figure 5.18 A comparison of lumen area between groups. Lumen area was increased 
significantly in RES and decreased of borderline significance in SES, compared with 
BMS (n = 10-11), * p < 0.05, ** p = 0.05 vs. BMS. 
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Endothelial regeneration 
28 days after implantation, all BMS and SES had an endothelial score of 3. Two 
RES and two SRES had an endothelial score of 2.5 (derived from mean of two 
sections per stent). This resulted in a small but non-significant reduction in 
endothelial score in both rapamycin groups (p = 0.30) (Table 5.2). The mean 
semiquantitative percentage of circumference covered by endothelium was 98.3 
± 1.0%, 98.3 ± 1.1%, 96.4 ± 1.8% and 96.0 ± 2.3% in BMS, SES, RES and 
SRES, respectively, p = NS. The rate of stents with any uncovered stent struts 
was 9.1%, 0%, 30% and 0% for BMS, SES, RES and SRES groups, respectively 
(p = 0.08).  
 
In-stent thrombus and fibrin deposition 
The rate of stents with in-stent thrombus was 27.3%, 10%, 20% and 20% for 
BMS, SES, RES and SRES groups, respectively (p = 0.81). Fibrin scores were 
markedly higher in both succinobucol groups (Table 5.2).  
 
Inflammation 
Inflammatory infiltrates present in the sections after 28 days were significantly 
increased in SES and significantly reduced in RES (Table 5.2). Inflammatory 
cells were most prevalent close to the stent struts (Figure 5.16). 
 
 
 
 
 
 156 
Table 5.2. Healing and inflammation. 
Group Endothelial 
Score 
Fibrin 
Score 
Inflammatory 
Score 
BMS (n=11)  3.00 ± 0.00   0.09 ± 0.20    1.96 ± 0.42 
SES (n=10)  3.00 ± 0.00   0.95 ± 0.69*    2.35 ± 0.41** 
RES (n=10)  2.90 ± 0.21   0.15 ± 0.24    1.55 ± 0.28** 
SRES (n=10)  2.90 ± 0.21   1.25 ± 0.83*    2.00 ± 0.00 
* p < 0.005 vs. BMS; ** p < 0.05 vs. BMS. 
 
5.3.6 In vivo toxicology of succinobucol 
500 µg succinobucol infused directly into the left anterior descending coronary 
artery over 10 minutes (50 µg/ml at 1 ml/min) was well tolerated with no 
evidence of ischaemia, thrombosis or QT prolongation. The infusion was 
repeated after BMS implantation (to induce endothelial injury) with no adverse 
effects. Vehicle (0.5% alcohol) was tested without incident. The SES caused no 
significant change in QTc interval (410.3 ± 14.5 ms before vs. 422.3 ± 7.5 ms 
after SES implantation, p = NS). No succinobucol was detected in blood samples 
obtained from the pulmonary artery 1 h or 1 day after deployment of 2 SES. 
 
5.3.7 Effect of succinobucol on WBA 
There was no significant effect of succinobucol (1-100 µg/ml) on WBA 
compared with control, in response to 3 µg/ml collagen (Figure 5.19) or 20 µM 
ADP in porcine blood (Figure 5.20). All pigs were treated with aspirin and 
clopidogrel. 
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Figure 5.19 The effect of succinobucol on WBA in response to collagen. 
Succinobucol (1-100 µM) had no effect on WBA in response to 3 µg/ml collagen in 
porcine blood (n = 4), p = NS. 
 
 
Figure 5.20 The effect of succinobucol on WBA in response to ADP. Succinobucol 
(1-100 µM) had no effect on WBA in response to 20 µM ADP in porcine blood (n = 4), 
p = NS. 
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5.3.8 Effect of succinobucol on cultured ECs and SMCs 
Succinobucol caused marked toxicity to cultured bovine pulmonary artery ECs 
and SMCs.  
 
EC culture 
After 24 hours, 1 µM succinobucol caused a few ECs to detach from the well 
plates in culture, whereas above 5 µM, succinobucol caused almost all ECs to lift 
off the plate (Figures 5.21). Trypan blue staining showed that adherent ECs 
remained viable up to 5 µM succinobucol. However, with higher concentrations 
of succinobucol, there was a significant decline in EC viability (Figure 5.22).  
 
SMC culture 
After 24 hours, 1 µM succinobucol caused a few cells to detach from the well 
plates in culture, whereas above 10 µM, succinobucol caused almost all SMCs to 
lift off the plate (Figures 5.23). The adherent SMCs had significantly reduced 
viability in 1, 5 and 20 µM succinobucol (Figure 5.24). Probucol was 
considerably less toxic to SMCs than succinobucol, with minor detachment of 
SMCs occurring only in 20 µM probucol (Figure 5.25). Probucol had no 
significant deleterious effect on SMC viability (Figure 5.26).  
 
Protection against SIN-1 
0.2 µM SIN-1 reduced viability of ECs and SMCs. 1 µM Succinobucol did not 
protect against SIN-1-induced toxicity, whereas 1 µM probucol provided some 
protection (Figure 5.27).  
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Figure 5.21 The effect of succinobucol on cultured ECs. After 24 hours, there was 
evidence of concentration-dependent cytotoxicity, resulting in total cell detachment in 
10 µM and higher concentrations of succinobucol (magnification ×100). 
 
 
Figure 5.22 The effect of succinobucol on the viability of adherent ECs. Cell 
viability was reduced at concentrations of 10 µM and higher (n = 4-6), * p < 0.05 vs. 
control. 
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Figure 5.23 The effect of succinobucol on cultured SMCs. After 24 hours, there was 
evidence of concentration-dependent cytotoxicity, resulting in total cell detachment in 
20 µM succinobucol (magnification ×100). 
 
 
Figure 5.24 The effect of succinobucol on the viability of adherent SMCs. Cell 
viability was reduced in 1 µM, 5 µM and 20 µM (n = 4-6), * p < 0.05 vs. control. 
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Figure 5.25 The effect of probucol on cultured SMCs. After 24 hours, there was 
maintained cell adherence with only minor cell detachment at the 20 µM probucol 
(magnification ×100). 
 
 
Figure 5.26 The effect of probucol on the viability of adherent SMCs. Probucol had 
no significant effect on the viability of remaining adherent SMCs (n = 4-5), p = NS. 
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Figure 5.27 The effect of succinobucol and probucol on SIN-1-induced toxicity. 
Succinobucol was unable to protect ECs and SMCs from SIN-1-induced toxicity, 
however probucol provided some protection (n = 4-5), * p < 0.01 vs. control, ** p < 0.05 
SIN-1 vs. SIN-1 + 1 µM probucol, p = NS all other comparisons. 
 
5.4 Discussion 
 
Since both oxidative stress (117;275;276) and inflammation (18;277) are 
responsible for increased neointimal formation, I chose to investigate the novel 
antioxidant and anti-inflammatory drug, succinobucol, coated on a stent, without 
a polymer to reduce the potential for adverse effects. Succinobucol reportedly 
had shown many properties which were extremely attractive as a potential DES 
coating. These included potent antiproliferative effects on SMCs (165;166), 
inhibitory effects on vascular inflammation (163-166), antiplatelet effects (268) 
and rapid uptake into cells (163), all of which were superior to probucol, the 
parent molecule with promising results for the prevention of ISR and promotion 
of endothelial healing, especially in animal models (149;150).  
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5.4.1 Effects of succinobucol 
Drug coatings were sprayed onto unexpanded stents on a balloon, therefore drug 
deposition occurred onto the abluminal surface, which is ideal for a modern DES. 
Preferential abluminal DES coating allows more targeted drug release into the 
artery wall, reduces systemic exposure and limits potentially unforeseen drug 
toxicity to the ECs which repopulate the adluminal strut surface. This technique 
is now specifically employed in several modern DES currently in clinical use 
(278-280). Stent-based delivery of succinobucol was optimally controlled in 
vivo, despite the absence of a polymer, with around two-thirds of the drug 
released during the first week. This matches closely the period after stent 
deployment when ROS are released in large quantities from the artery wall (243).  
 
However, surprisingly, local delivery of succinobucol increased inflammation 
and neointimal growth. Rate of ISR was also significantly increased in the SES 
group. Subsequently, succinobucol was found to destabilise cells in culture 
leading to cell detachment and loss of viability. However, cell toxicity in vitro 
was much less marked with probucol. Rapamycin is a potent inhibitor of SMC 
proliferation but has no deleterious effect on cell viability (281). I postulate that 
succinobucol exacerbated neointimal formation by causing direct cellular 
damage and inflammation, negating any putative local beneficial effects. 
Localised cellular deterioration and necrosis would have been likely to recruit 
inflammatory cells, as was observed. Degree of inflammation has been shown to 
correlate positively with neointimal growth (282) and this relationship has been 
reaffirmed by my results (Figure 5.28). Analysis of human peripheral artery  
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Figure 5.28 Scatter plot of inflammatory score and neointimal thickness. Neointimal 
thickness was strongly correlated with inflammatory score (r = 0.67, p < 0.001). 
 
atherectomy specimens demonstrated that macrophages and leucocytes account 
for almost a quarter of neointimal cells in cases of ISR (283). Coronary 
atherectomy specimens from several patients who had received the paclitaxel 
derivative, 7-hexanoyltaxol (QP2)-eluting polymer stents, which also increased 
ISR, displayed widespread inflammatory aggregates and fibrin deposition in a 
SMC-rich neointima (284). These histological findings are analogous to those 
found with succinobucol in this study. Thus, I propose that the accumulation of 
inflammatory cells around SES struts caused increased production of 
chemotactic cytokines and growth factors, which led to the proliferation of SMCs 
and increased neointimal formation. 
 
Succinobucol did not cause improved arterial healing, because increased fibrin 
and excessive inflammation around SES struts in vivo after 28 days are both 
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features of poor healing (274). Fibrin and platelet-rich thrombus adhere to 
metallic stent struts within hours of implantation. Normally, this progressively 
resolves over the following weeks, principally due to resorption by macrophages, 
which secrete a number of fibrinolytic enzymes (285;286). Near-total fibrin and 
thrombus resorption is a feature of complete arterial healing in both animal and 
human models. Increased fibrin deposition seen in both SES groups after 28 days 
in this study closely matched the late histological findings of other potent 
antirestenosis therapies that impede arterial healing, such as intracoronary 
radiation (287) and polymeric DES (62). Endothelial regeneration was difficult 
to assess in this model because, at the end of the study, the BMS were 
completely re-endothelialised. However, the toxic effects of succinobucol on 
cultured ECs suggest that endothelial healing was not accelerated by 
succinobucol. In fact, succinobucol may have worsened neointimal formation 
due to toxicity to ECs, which inhibit SMC proliferation (21;22). Although it has 
been shown that phenolic antioxidants can provide protection against oxidative 
stress, they can also lead to generation of secondary radicals that may modify 
important intracellular targets with the potential to cause pro-oxidant effects 
(288;289). This may also explain some of the unfavourable cellular responses 
identified in our study.  
 
In light of the poorly performing SES, one of the most obvious concerns related 
to possible “overdosing” of the SES on injured arterial tissue. A 1% 
succinobucol coating was selected for preclinical DES evaluation. This was 
based on the physical properties of the coating, rather than attempts to predict the 
coating concentration necessary to replicate previously published cell culture 
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data. The latter approach is not a common or straightforward method of DES 
development, since estimating the concentration of drug coating required to 
achieve a pre-specified local tissue concentration is fraught with difficulties. 
From prior in vitro studies, 10 µM succinobucol exerted potent antioxidant and 
anti-inflammatory effects, whereas 5 µM was ~50% inhibitory to SMC 
proliferation (165;166). Unfortunately, quantifying the concentration of drug 
coating required to obtain this narrow therapeutic range in target tissue would 
require evaluation of multiple coatings, with repeated measurement of 
succinobucol levels in the artery wall. The relationship between coating 
concentration, drug loading and target tissue concentration is dependent on 
multiple factors including stent surface affinity for drug, in vivo release kinetics 
and subsequent partitioning into local and distant tissues. This level of 
preparatory work has considerable resource demands, beyond the scope of this 
research, and its value has not been proven by other groups. Another potential 
method could utilise complex mathematical modelling, but this prediction is 
likely to be imprecise as the relationships may not be linear. In my view, in vitro 
techniques to simulate in vivo pharmacokinetics are of limited value, not least 
because most in vitro release kinetics are performed in aqueous solutions and the 
ability to replicate tissue absorption is greatly impaired. Ultimately, 1% 
succinobucol coating was chosen because it provided excellent coating of stent 
struts, no overspill onto the balloon and no areas of sparse deposition, which was 
present with lower concentrations. The local tissue concentration was quantified 
at various time points after SES implantation and this was compared to in-house 
cell culture experiments, which were performed after the in vivo study period, to 
provide supporting data. The succinobucol concentration measured in arterial 
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specimens throughout the 28 day study period (200-800 ng/mg, which is 
equivalent to 300 µM – 1.3 mM succinobucol) was around one hundred-fold 
greater than the concentration reported to cause antioxidant, anti-inflammatory 
and antiproliferative effects in previous studies (10 µM succinobucol is 
approximately 6 ng/mg tissue). However, 1-20 µM succinobucol was found in 
this study to cause severe toxicity to cells in culture. It was not possible to 
investigate the effects of much higher concentrations, which were measured in 
the arterial tissue, to cells in culture due to insufficient solubility. The mass of 
succinobucol loaded on the SES (~450 µg per stent) was similar to that of other 
drugs loaded on DES which are even more potent inhibitors of cell proliferation, 
but share similar release characteristics and tissue solubility. For instance, the 
tissue concentration of rapamycin measured after successful drug elution in a 
porcine model (272) was around one thousand-fold greater than that required to 
inhibit SMC proliferation (281;290), yet this stent is currently used in clinical 
practice. Similar findings were reported in another preclinical study of polymer-
based rapamycin (58), which provided positive data prior to clinical trials. It 
follows that adjustment of the coating concentration to target a narrow 
therapeutic range (effective in cell culture) is not a fundamental prerequisite for 
early DES development. It is clear, however, that drugs may differ considerably 
in their safety margins. In retrospect, I believe that inclusion of a “low dose” (e.g. 
0.1% or 0.5%) and “high dose” (e.g. 1%) SES would have been preferable and 
this is supported by recently updated consensus guidelines (175). 
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5.4.2 Effects of rapamycin 
The inhibition of neointimal growth by around a third with the RES in this study 
was very similar to previous preclinical data using an identical non-polymer stent 
platform (272) subsequently validated in a clinical trial (89), although this 
finding was not significant. No evidence of medial necrosis was evident in the 
RES group, but the extent of re-endothelialisation was reduced, albeit non-
significantly, consistent with previous reports (62). Inflammation was 
significantly reduced by the RES, which is in agreement with a similar study of 
the same stent with rapamycin at a lower concentration (272) and another study 
evaluating polymer-based rapamycin (58) in a porcine model. 
 
5.4.3 Effects of succinobucol/rapamycin combination 
When used in combination, the succinobucol coating impaired the antirestenotic 
effect of rapamycin. It is likely that the undesirable biological effects of 
succinobucol on the artery wall opposed the actions of rapamycin, although I 
cannot rule out the possibility that succinobucol impaired the delivery of 
rapamycin. In terms of neointimal growth, the dual DES performed similarly to 
the BMS. Persistent fibrin deposition was present, as in the SES group, 
indicating suboptimal arterial healing, but inflammation was no different to 
BMS, suggesting equipoise between the toxic proinflammatory effects of 
succinobucol against the anti-inflammatory action of rapamycin. 
 
5.4.4 Other predictors of neointimal growth 
The increase in EEL area identified in the RES group after 28 days may have 
been a chance finding. A possible confounding factor was increased rates of 
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(blinded) implantation of the RES into the RCA, which was a significantly larger 
vessel than the branches of the left coronary system (mean EEL was 7.86 ± 0.21 
mm2, 7.55 ± 0.23 mm2 and 8.77 ± 0.35 mm2 for LAD, LCx and RCA, 
respectively, p < 0.05). This discrepancy in vessel area may have confounded the 
results for the RES group, although injury scores were well matched. Without 
baseline measurements, it was not possible to determine the role of positive 
arterial remodelling, an uncommon sequela of DES implantation, however no 
cases of incomplete stent apposition occurred (291). Regardless of whether 
vessel enlargement was acquired or not, neointimal thickening was inversely 
correlated with EEL (r = -0.53, p < 0.001), confirming the relationship between 
smaller vessels and ISR (292). As expected, there was a positive correlation 
between injury score and neointimal thickening (r = 0.56, p < 0.001), but 
importantly, no relationship between vessel size and degree of injury (r = 0.01, p 
= 0.95). Injury scores were also closely matched between groups and < 20% of 
sections showed excessive injury, which is consistent with consensus 
recommendations (274). Overall the mean injury score was 1.61 (SD 0.19) which 
was appropriate for the porcine restenosis model.  
 
5.4.5 Premature deaths 
Two unexpected premature deaths occurred during the efficacy study. These 
were probably both caused by acute stent thrombosis. It is recognised that 
difficulties exist in diagnosing whether stent thrombosis occurred premortem or 
postmortem. Ventricular fibrillation was witnessed prior to the second death and 
this was probably the mode of death for the first pig that died suddenly, also 
within 24 hours. The occurrence of ventricular arrhythmias suggested 
 170 
unrecognised acute ischaemia, which was most likely due to stent occlusion. It 
was not possible to determine whether a particular type of stent was responsible 
for stent thrombosis due to the small number of events. Sudden death may be 
more common in drug-eluting stents, principally due to stent thrombosis (293), 
but importantly, the early mortality rate in this study was less than the suggested 
maximum of 15% for the porcine model (274). To show that succinobucol itself 
was not likely to be directly responsible for the premature deaths, rather than the 
stent procedure itself, it was found to be tolerated well when infused down the 
coronary artery and not found to be proaggregatory (or antiaggregatory) in vitro. 
 
5.4.6 Comparison with other studies 
In CART-1, although oral succinobucol improved coronary artery dimensions six 
months after coronary stenting, the drug failed to influence neointimal growth, as 
observed by intravascular ultrasound (156). The ability of oral probucol to reduce 
neointimal growth has been variable, with encouraging results in predominantly 
animal models (148-150;155;262), but negative reports in other studies 
(153;154;156;157;161;294). Other compounds released from DES have been 
shown to cause local cell toxicity and increased inflammation following coronary 
stenting. Polymeric paclitaxel (62;295) and sirolimus-eluting stents (62;272) are 
both associated with impaired healing, greater inflammation and persistent fibrin 
deposition after arterial injury. Despite these deleterious effects, both are widely 
used in clinical practice because of their ability to reduce ISR. Gold-coated stents 
increased ISR compared with BMS, despite encouraging early preclinical results 
(296). Aggravated neointimal growth and incomplete healing was caused by an 
actinomycin-eluting stent (174), as was found in this study. The effects of the 
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dual SRES contrasted markedly with the effects of a probucol/rapamycin stent on 
an identical platform, which reduced ISR comparably to a polymeric sirolimus-
eluting stent (264). The dual probucol/rapamycin stent also caused no increase in 
inflammation (263). Therefore, stent-based delivery of succinobucol in 
combination with rapamycin does not produce similar effects to probucol. This 
study suggests that a critical factor determining the efficacy of antioxidants used 
in DES is the balance of their local cellular actions and toxicity. It is also 
possible that the inferior results of the SRES group compared with the 
probucol/rapamycin stent may relate to more rapid tissue uptake of succinobucol 
compared with probucol, which could cause less retardation of rapamycin release 
from the stent. 
 
5.4.7 Study limitations 
This investigation of succinobucol coated stents after arterial injury used a 
standard preclinical model. It is possible that the effect of local delivery of 
succinobucol in human atherosclerotic coronary arteries would differ from the 
effect demonstrated in normal pig coronary arteries. Nevertheless, the 
morphological characteristics of neointimal growth in the porcine model are 
similar to that found in human coronary arteries (297). Further study is required 
to determine the concentration-response (particularly for low dose) and the long-
term effects of succinobucol loaded on a stent, although I think a beneficial 
action is unlikely. The pharmacokinetic profile of the SES was characterised by 
measurement of drug remaining on the stent at various time points and by 
estimation of drug levels in surrounding arterial tissue, as described by a recent 
consensus document for the preclinical assessment of DES (175). In vitro 
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estimation of drug elution was avoided due to the relative insolubility of 
succinobucol in aqueous solutions. An alternative method to determine drug 
release involves the use of radio- or fluorescent-labelling to measure the 
concentration of the succinobucol in blood or arterial segments adjacent to the 
implanted stent, but this was not possible due to resource demands. Drug 
concentration was not measured in downstream myocardium from the target 
artery or in other organs such as liver and kidney to assess the possibility of 
systemic effects. A very early time point (such as 7 days in the efficacy study) 
would have been useful to help determine stent thrombosis risk and the presence 
of early re-endothelialisation. This was not performed in this research to preserve 
group sizes, although smaller numbers (minimum 3 stents) are probably required 
for this endpoint. Further characterisation of the inflammatory cells (for instance, 
semiquantitative division into monocytes/macrophages, lymphocytes and 
neutrophils) may have helped to unravel the cellular and molecular mechanisms 
responsible for excessive neointimal growth caused by succinobucol. It would 
also have been beneficial to section the stents from both premature deaths in the 
efficacy study, as certain histological features are characteristic of premortem 
stent thrombosis (variegated platelet-fibrin, thrombus layering and adhesion to 
the artery wall, and presence of polymorphonuclear leucocytes (274)). 
 
5.4.8 Conclusions 
These data suggest that 1% succinobucol is not a favourable stent coating for 
clinical studies. After 28 days, the SES was associated with widespread 
inflammation, substantial late fibrin deposition and increased neointimal 
formation. This maladaptive tissue response is most likely related to localised 
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cell toxicity, increasing inflammation and impairing healing. The succinobucol 
coating also inhibited the effects of rapamycin from a polymer-free DES, thereby 
reducing its antirestenotic properties. More studies are required to determine the 
role of succinobucol and other antioxidant compounds for the prevention of ISR 
and promotion of stent healing.  
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Chapter 6 
 
The relationship between oxidised LDL, endothelial 
progenitor cells, coronary endothelial function and whole 
blood aggregation in patients with CHD 
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6.1 Introduction 
 
Vascular injury caused by PCI elevates oxidative stress (298;299) and leads to 
increased oxLDL in the blood (114;115), which can exacerbate endothelial 
dysfunction and impair arterial healing (102;236;300). The mechanisms by 
which oxLDL exerts these effects are not fully understood. The traditional 
paradigm of endothelial repair is based on the migration and proliferation of 
mature ECs from the wound edge to repopulate the site of injury. OxLDL 
inhibits EC migration (126;235;236) and therefore impairs this process. 
However, endothelial repair is also now thought to be regulated by mobilisation 
and homing of bone marrow-derived endothelial progenitor cells (EPCs) to sites 
of vascular damage, which have the potential to differentiate into ECs (176). 
Circulating levels of EPCs in blood are increased following several forms of 
endothelial injury including tissue ischaemia (301), myocardial infarction 
(302;303) and PCI (304). Mobilisation of EPCs is mediated by cytokines such as 
VEGF (305) and granulocyte macrophage-colony stimulating factor (GM-CSF) 
(301), and is thought to be dependent on NO (306). Circulating EPCs are 
augmented by measures which increase NO bioavailability, such as exercise 
(307) and drug therapy with statins (308;309) or ACE inhibitors (310). 
Conversely, the number of EPCs in the vasculature appears to correlate inversely 
with the presence of cardiovascular risk factors, which reduce NO bioavailability 
(311;312). Patients with stable CHD have fewer circulating EPCs than healthy 
controls (311;313;314), and lower levels are associated with worse 
cardiovascular outcome (315;316).  
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EPCs are more resistant than mature ECs to the toxic effects of oxidative stress, 
probably due to greater expression of potent antioxidant enzymes, including 
manganese SOD, catalase and glutathione peroxidase, which reduce intracellular 
levels of ROS (317;318). This defence mechanism may allow EPCs to proliferate 
and differentiate in areas of high oxidative stress, such as inflamed and ischaemic 
tissues. However, EPC function and survival remain susceptible to oxidative 
stress (319), and their antioxidant defences may be impaired in the presence of 
elevated C-reactive protein, a biomarker and active participant in atherosclerosis 
(125). The addition of oxLDL to cultured EPCs has been shown to impair EPC 
survival and function in a dose-dependent manner (124;320), an effect attributed 
to eNOS inhibition (321).  
 
Taken together, the in vivo relationship between oxLDL, EPCs and coronary 
endothelial function is likely to be a critical factor which can influence vessel 
healing. Oxidative stress, resulting in elevated oxLDL, may increase vascular 
damage and inhibit endothelial repair due to impaired EPC mobilisation and 
survival. This could exacerbate coronary endothelial dysfunction. As the 
endothelium modulates thrombosis and haemostasis, a defect in endothelial 
function may cause increased blood aggregability, which could increase the risk 
of stent thrombosis following PCI. A schematic diagram depicting these 
relationships is shown in Figure 6.1. 
 
Through these suggested interactions, systemic levels of oxidative stress are 
likely to contribute to the ability of injured arterial tissue to repair after PCI. 
Oxidised lipoproteins represent one of the major oxidative influences on the 
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vascular system, being potentially responsible for ongoing endothelial injury, 
inflammation and impairing healing. There is limited data supporting a direct 
link between whole blood aggregability and clinical thrombosis (322), however 
similar methods of platelet testing such as light transmission aggregometry have 
demonstrated prognostic value (260). The aim of this study was to investigate the 
in vivo relationships between plasma oxLDL levels, the number of circulating 
EPCs, coronary endothelial function and WBA in patients with symptomatic 
CHD. This information may provide indirect evidence as to whether elevated 
levels of oxidative stress (which is increased by PCI) could impair some of the 
mechanisms involved in arterial repair after stent injury, exacerbating endothelial 
dysfunction and rendering the stented artery more prone to thrombosis. 
 
 
Figure 6.1 The potential relationship between oxidative stress, EPCs, endothelial 
dysfunction and blood aggregation. Increased oxLDL may lead to fewer circulating 
EPCs, exacerbating endothelial dysfunction and causing increased blood aggregability. 
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6.2 Methods 
 
6.2.1 Study population 
The study was approved by the West Glasgow ethics committees. All 
participants were provided with a PIS and gave informed written consent. All 
patients were scheduled to undergo elective PCI for standard clinical indications. 
All patients were over age 18 and were receiving oral aspirin and clopidogrel 
therapy. The characteristics of each patient with respect to factors which can 
modify endothelial and platelet function were recorded. Patients were excluded if 
they had a history of myocardial infarction within 3 months, if they were taking 
any other antithrombotic therapy or if they were unable to give informed consent. 
On the same day, prior to angiography, venous blood was taken for immediate 
assay of circulating EPC levels and WBA. Plasma was stored at -70 ºC for 
subsequent oxLDL assay. 
 
6.2.2 OxLDL Assay 
OxLDL was detected by the commercial Mercodia solid two-site enzyme-linked 
immunoassay (Diagenics, Bletchley, UK). In this assay, two monoclonal 
antibodies were directed against separate antigenic determinants on the oxidised 
apolipoprotein B molecule. Samples were snap-thawed at 37 ºC for 3 minutes. 
All samples were run in duplicate on a single assay. The average coefficient of 
variation of the duplicates was 0.6%. The lowest sample value was 36 IU, which 
is above the lowest standard (10 IU). All samples were therefore within the 
sensitivity of the assay. 
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6.2.3 EPC Assay 
Quantification of EPCs was performed by fluorescent-activated cell sorting 
(FACS) analysis using a flow cytometer. 1 ml of EDTA anticoagulated blood 
sample was added to 100 µl of FcR Blocking Reagent (Miltenyi Biotec). After 
20 minutes of incubation, 20 µl of the blocked blood was added to 20 µl of anti-
VEGF receptor-2 (KDR) antibody with isotype control mouse IgG1-APC used as 
a control. The blood was incubated for 30 minutes on ice and sheltered from the 
light. 20 µl of 7-amino-actinomycin D (AAD) viability dye was added for the 
exclusion of nonviable cells. 20 µl of CD45-FITC/CD34-PE antibody 
combination was added and CD45-FITC/CTL-PE was used as a control. The 
solution was incubated at room temperature for 20 minutes, sheltered from the 
light. Diluted lysis buffer was made up by adding 400 µl 10× buffer to 3.6 ml of 
water. After 20 minutes incubation, 500 µl of buffer was added before a further 
10 minutes of incubation in the dark. 100 µl of fluorospheres was added to 
prepare the sample for FACS acquisition. Data was analysed using Cellquest™ 
Pro software (BD). Analytical gates were used to enumerate the total number and 
subsets of circulating cells. Samples were run until a total of 250,000 events were 
counted or after a 20 minute cut off. Data were stored for interpretation at the 
same time by one observer to remove bias. EPC concentration was calculated as: 
(No. CD34+KDR+ events × concentration fluorospheres)/total fluorospheres 
recovered. 
 
6.2.4 Whole blood aggregometry 
WBA was performed according to the method described in Chapter 2.2.3. 
Collagen (3 µg/ml) and ADP (20 µM) (Labmedics Limited, Manchester, UK) 
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were used as platelet agonists, within 3 hours of venepuncture. 20 µM ADP is 
commonly used to assess clopidogrel response (323). WBA was measured as 
absolute change in impedance 5 minutes after the addition of agonist, compared 
to baseline.  
 
6.2.5 Coronary endothelial function testing 
All vasodilator medication was withheld for 24 hours prior to testing. Coronary 
endothelial function was measured in a coronary artery without significant 
stenosis (< 40% diameter), not scheduled for PCI. This was done by the standard 
method of assessing the change in luminal diameter, using quantitative coronary 
angiography (QCA), in response to an intracoronary infusion of the endothelium-
dependent vasodilator, acetylcholine. In healthy arteries, acetylcholine causes 
release of NO from ECs, leading to vasodilation. In endothelial dysfunction, the 
NO response is blunted and the direct muscarinic smooth muscle response to 
acetylcholine predominates, causing paradoxical vasoconstriction (324). 
Following baseline coronary angiography, the optimal angiographic projection 
for the study artery was selected, avoiding overlapping side-branches. A 3 
French infusion catheter (Cook Medical, Limerick, Ireland) was placed into the 
proximal portion of the coronary artery to be studied via a standard 6 French 
guiding catheter. After intracoronary infusion of 0.9% saline as a control, 
endothelium-dependent vasomotion was assessed by serial infusions of 
acetycholine (Miochol-E, Novartis) in the following order: 10-6 M, 10-5 M and 
10-4 M. All infusions were given at a flow rate of 2 ml/minute for 2 minutes. 
Careful attention was paid to the dead space within the infusion equipment to 
ensure accurate delivery of acetylcholine. Assuming a mean coronary artery 
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blood flow of 50 ml/minute (325), the final blood concentration for each 
acetylcholine infusion was estimated at 4 × 10-8 M, 4 × 10-7 M and 4 × 10-6 M, 
which was appropriate for assessment of a range of vasomotor responses 
(recommended range 10-8 to 10-5 M) (326). At the end of each infusion, coronary 
angiography was recorded using non-ionic contrast medium (Omnipaque™, GE 
Healthcare) in the standard fashion. Serial angiograms were performed using 
identical projections, table height and magnification. The acetylcholine infusion 
was terminated if significant ischaemia or bradycardia were observed. 
Endothelium-independent vasomotion was then assessed by an intracoronary 
bolus injection of 400 µg isosorbide dinitrate. If required, a further dose of 
isosorbide dinitrate was administered to fully reverse any latent effects of 
acetylcholine, ensuring maximal coronary artery vasodilation, before a final 
angiogram was recorded. 
 
Quantitative Coronary Angiography 
Coronary angiograms were stored digitally at the Golden Jubilee National 
Hospital, Glasgow for subsequent analysis. An automated edge-detection 
software system (Centricity CA1000, GE Healthcare) was used to measure the 
luminal diameter of the coronary artery distal to the infusion catheter, at end 
diastole. The mean percentage change in luminal diameter compared to control in 
two distinct 5 mm segments was calculated for each patient following each 
infusion and after final nitrate injection (each analysis segment consisted of five 
separate measurements 1 mm apart). Each segment was easily identifiable by 
anatomical landmarks (such as side branches). Endothelial function was 
represented by the vasomotor response to the highest tolerated acetylcholine 
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concentration. One patient did not receive 10-4 M acetylcholine due to recurrent 
transient atrioventricular block. All other patients received all three 
concentrations of acetycholine. Negative changes in vessel diameter represent 
vasoconstriction, compared to control. All QCA analysis was performed by a 
single observer, blinded to all other study results. 
 
6.2.6 Statistical analysis 
A formal power calculation was difficult due to the exploratory nature of the 
study, however a sample size of 23 patients was estimated to provide 80% power 
to detect a relationship between the independent and the dependent variables at a 
two-sided 0.05 significance level, if the true change in the dependent variable is 
0.3 units per unit change in the independent variable. This was based on the 
assumption that the SD of the independent variable (oxLDL) is 0.3 and the SD of 
the dependent variable (endothelial function) is 0.15 (327). A previous small 
study reported a significant correlation between oxLDL and endothelial response 
to acetylcholine in 15 patients (328). All data are expressed as mean ± SEM 
unless otherwise stated. Correlations were performed using the Pearson 
correlation coefficient. Coronary responses for each infusion were compared 
using analysis of variance and post-hoc Dunnett’s test. Statistical analysis was 
performed using the SPSS statistical software package 14.0 for Windows (SPSS 
Inc., Chicago, IL, USA). 
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6.3 Results 
 
6.3.1 Baseline characteristics of patients 
The number of patents included in each part of the study is shown in Figure 6.2. 
23 patients consented to the study between June 2007 and April 2010. The 
endothelial function study was abandoned in one patient due to time constraints 
in the catheterisation laboratory. All 22 remaining patients underwent coronary 
endothelial function testing. OxLDL assay was performed in the first 14 patients, 
but was not available for the remaining patients. WBA assays were performed 
for all patients. Circulating numbers of EPCs were only available for 18 patients, 
due to technical problems with the assay. The baseline characteristics of the 
patients are shown in Table 6.1. All patients had chronic stable angina and were 
taking standard pharmacotherapy. There was a low prevalence of diabetes 
mellitus but high prevalence of other cardiovascular risk factors. Most patients 
had single vessel coronary artery disease. 
 
 
 
 
 
 
 
 
 
Figure 6.2 Patient flow diagram for study. 
23 patients  
consented to the study 
18 patients had  
EPC assay 
1 patient abandoned due 
to time constraints in 
catheterisation laboratory 
22 patients underwent endothelial 
function testing and provided  
venous blood sample 
22 patients had  
WBA assay 
14 patients had 
oxLDL assay 
4 EPC assay not 
performed 
2 machine breakdown,  
1 analysis error,  
1 late arrival of sample 
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Table 6.1 Baseline characteristics of endothelial study patients 
 Prevalence, 
(n = 22) 
Patients’ characteristics  
Age, mean (SD), y 61.5 (9.5) 
Male, n (%) 18 (81.8) 
Current smoker, n (%) 2 (9.1) 
Hypertension, n (%) 10 (45.5) 
Hypercholesterolaemia, n (%) 14 (63.6) 
Diabetes mellitus, n (%) 2 (9.1) 
Family history of premature CHD, n (%) 9 (40.9) 
Previous myocardial infarction, n (%) 7 (31.8) 
Previous stroke, n (%) 0 (0) 
Previous PCI or CABG, n (%) 0 (0) 
Single vessel disease, n (%) 18 (81.8) 
Preserved LV function, n (%) 21 (95.5) 
Heart failure, n (%) 0 (0) 
Drug treatment  
Aspirin, n (%) 22 (100) 
Clopidogrel, n (%) 18 (81.8) 
Statin, n (%) 21 (95.5) 
ACE inhibitor or ARB, n (%) 15 (68.2) 
Beta-blocker, n (%) 20 (90.9) 
Calcium channel blocker, n (%) 6 (27.3) 
Diuretic, n (%) 4 (18.2) 
Nitrate, n (%) 10 (45.5) 
Nicorandil, n (%) 3 (13.6) 
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6.3.2 Coronary endothelial function 
The mean vessel responses for each acetylcholine infusion and isosorbide 
dinitrate injection are shown in figure 6.3. The mean response to incremental 
concentrations of acetylcholine was progressive vasoconstriction, which was 
significant for the highest concentration (-1.64 ± 1.21%, -4.80 ± 1.84% and -
13.20 ± 3.33% for 10-6 M, 10-5 M and 10-4 M acetylcholine, respectively, p < 
0.001 for 10-4 M acetylcholine vs. control). The mean response to isosorbide 
dinitrate was 11.20 ± 2.50%, p = 0.001 vs. control). Figure 6.4 shows the mean 
endothelial function of two segments for each patient in order of the study 
performance. 
 
 
Figure 6.3 Mean vasomotor responses to acetylcholine infusion (concentration 
[M]) and isosorbide dinitrate. There was progressive vasoconstriction to serial 
acetylcholine infusions whereas administration of isosorbide dinitrate caused 
vasodilation (n = 22) * p < 0.001 vs. control, ** p = 0.001 vs. control. 
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Figure 6.4 Individual patient vasomotor responses to the highest concentration 
acetylcholine infusion in order of study. The group’s mean response was -13.20 (SD 
15.60) %. 
 
There was good agreement between the two segments analysed for each patient. 
The mean difference in endothelial function between the two segments analysed 
in each patient was 7.87 (SD 8.15) percentage points. 3 patients displayed 
vasoconstriction in one segment and vasodilation in the other segment. 
 
6.3.3 Adverse events 
Transient minor atrioventricular block was common (approximately one quarter 
of patients) during acetylcholine infusion, especially during the highest 
concentration, but this was usually short-lived (less than 10 seconds) after the 
infusion was stopped. Minor electrocardiographic evidence of ischaemia was 
uncommon and clinical ischaemia was rare (two patients complained of mild 
angina). Figure 6.5 shows an example of severe vasoconstriction in the left 
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anterior descending coronary artery in one patient who displayed marked 
electrocardiographic ischaemic changes during the highest acetylcholine dose, 
but this was quickly reversed with isosorbide dinitrate injection (serial 
angiography was successfully recorded). No serious complications were 
encountered. 
 
Figure 6.5 Angiographic example of severe coronary endothelial dysfunction. 
Progressive vasoconstriction of the left anterior descending artery after 0.9% saline (A), 
10-6 M acetylcholine (B); 10-5 M acetylcholine (C) and 10-4 M acetylcholine (D) 
infusions. Isosorbide dinitrate caused complete reversal of vasoconstriction (not shown). 
All angiograms shown are right anterior oblique 30º cranial projection. 
 
6.3.4 Correlations  
Endothelial function correlated significantly with the number of circulating EPCs 
(CD34+/KDR+ cells) (Figure 6.6). Patients with fewer circulating EPCs displayed 
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Figure 6.6 Scatter plot of EPC number and coronary endothelial function. 
Endothelial function is represented by % change in vessel diameter during highest 
acetylcholine concentration, compared to control. Endothelial function was strongly 
correlated with EPC number (CD34+/KDR+ cells) (r = 0.57, p = 0.01). 
 
more severe endothelial dysfunction. Stepwise multiple linear regression analysis 
demonstrated that this correlation was independent of age, gender, hypertension, 
hypercholesterolaemia, diabetes mellitus, current smoking, family history of 
premature CHD and total number of cardiovascular risk factors (p < 0.05). No 
other significant correlations were found between plasma oxLDL concentration, 
number of circulating EPCs (CD34+/KDR+ cells), number of circulating CD34+ 
cells, endothelial function or WBA, except for a highly significant positive 
correlation between WBA in response to collagen and WBA in response to ADP 
(Table 6.2). Figures 6.7 and 6.8 show the lack of correlation between plasma 
oxLDL and EPC or endothelial function, respectively. Endothelium-independent 
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vasodilation induced by isosorbide dinitrate injection showed no significant 
correlation with any parameter (data not shown). 
 
Table 6.2 Correlations between main study parameters. 
  oxLDL 
(IU) 
CD34 
/µl 
blood 
CD34+/ 
KDR+/ 
µl blood 
Endo. 
function 
WBA 
(collagen) 
WBA 
(ADP) 
oxLDL (IU) r 1 -0.134 0.197 0.452 -0.441 -0.369 
  p  0.648 0.519 0.105 0.114 0.194 
  n 14 14 13 14 14 14 
CD34+/µl blood r -0.134 1 0.329 -0.089 0.107 -0.294 
  p 0.648  0.273 0.763 0.715 0.308 
  n 14 14 13 14 14 14 
CD34+/KDR+/µl 
blood 
r 0.197 0.329 1 0.569* -0.185 -0.040 
  p 0.519 0.273  0.014 0.464 0.874 
  n 13 13 18 18 18 18 
Endo. Function r 0.452 -0.089 0.569* 1 -0.283 -0.028 
  p 0.105 0.763 0.014  0.202 0.903 
  n 14 14 18 22 22 22 
WBA (collagen) r -0.441 0.107 -0.185 -0.283 1 0.692** 
  p 0.114 0.715 0.464 0.202  0.000 
  n 14 14 18 22 22 22 
WBA (ADP) r -0.369 -0.294 -0.040 -0.028 0.692** 1 
  p 0.194 0.308 0.874 0.903 0.000  
  n 14 14 18 22 22 22 
r represents the Pearson correlation coefficient; * p < 0.05; ** p <  0.001.  
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Figure 6.7 Scatter plot of oxLDL and EPC number. There was no significant 
correlation between oxLDL and EPC number (CD34+/KDR+ cells) (r = 0.20, p = 0.52). 
 
 
Figure 6.8 Scatter plot of oxLDL and coronary endothelial function. There was no 
significant correlation between oxLDL and endothelial function (r = 0.45, p = 0.11). 
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Age was inversely correlated with number of circulating EPCs (Figure 6.9) and 
positively correlated with WBA in response to 20 µM ADP (Figure 6.10). 
Stepwise multiple linear regression analysis confirmed that the correlation 
between age and EPC number was independent of other cardiovascular risk 
factors (p = 0.05), however the correlation between age and WBA in response to 
ADP was no longer significant after correction for other cardiovascular risk 
factors (p = 0.08). The total number of cardiovascular risk factors (male gender, 
hypertension, hypercholesterolaemia, diabetes mellitus, current smoking, family 
history of premature CHD) did not correlate significantly with oxLDL, EPC 
number, endothelial function or either WBA result (data not shown). 
 
 
 
Figure 6.9 Scatter plot of age and EPC number. EPC number (CD34+/KDR+ cells) 
was inversely correlated with age (r = -0.47, p = 0.05). 
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Figure 6.10 Scatter plot of age and WBA in response to ADP. WBA in response to 
20 µM ADP was positively correlated with age (r = 0.46, p = 0.03). 
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6.4 Discussion  
 
This observational study in patients with stable CHD has demonstrated that 
coronary endothelial dysfunction was common and correlated with low levels of 
circulating EPCs. Plasma oxLDL concentration did not correlate significantly 
with EPCs, coronary endothelial function or WBA. 
 
6.4.1 Endothelial function in stable CHD 
The high prevalence of endothelial dysfunction in this population was consistent 
with other studies in patients with stable angina (324;327;329). Only 1 out of 22 
patients displayed significant coronary vasodilation (> 5 % increase in diameter) 
in response to acetylcholine, suggesting good endothelial function (in that 
artery). 7 patients exhibited a minimal response to acetylcholine (< 5 % change 
in diameter). In 14 patients, a definite constrictive response (> 5 % decrease in 
diameter) to acetylcholine occurred, due to direct muscarinic effects of 
acetylcholine predominating over acetylcholine-induced NO release from ECs, 
indicating significant endothelial dysfunction (324;326). These findings reflect 
the patients’ persistent exposure to cardiovascular risk factors and high 
probability of subclinical atherosclerosis in the study vessel, which cause 
endothelial dysfunction and reduced NO bioavailability.  
 
The incidence of clinical symptoms during the endothelial function studies was 
low and consistent with previous work using identical acetylcholine regimens 
(330). Aiming for a lower estimated final blood acetylcholine concentration 
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(between 10-8 and 10-6 M) may reduce the incidence of clinical symptoms 
further, as in other studies (331).  
 
6.4.2 EPCs and endothelial function 
The observation that circulating levels of EPCs in the peripheral blood are 
correlated with coronary endothelial function is a relatively novel finding. 
During the initial stages of this research, no studies had reported the relationship 
between circulating EPC levels and coronary endothelial function.  
 
Hill et al. (312) previously showed in 45 individuals without cardiovascular 
disease that peripheral vascular function (assessed by flow-mediated brachial 
artery reactivity) was significantly correlated with the number of EC colony 
forming units in culture, thought at the time to represent EPCs derived from 
peripheral blood. It has since been established that this widely cited study 
assessed an aspect of endothelial biology which did not reflect the number of 
EPCs present in the circulation (332;333). Uncertainty still surrounds the true 
identity of cells previously described as EPCs in the literature and, crucially, the 
most accurate way to identify and measure them. EPCs are widely believed to 
originate from haematopoietic stem cells, which are positive for CD34 (or the 
more immature marker protein CD133) and the EC antigen, KDR. These putative 
EPCs appear to make a valuable contribution to vessel formation (334). Hence, 
the measurement of CD34+/KDR+ cells is currently thought to be the most 
appropriate way to define circulating EPCs (333), as was the case in this study. A 
more detailed discussion on the controversies surrounding the identification and 
measurement of EPCs can be found elsewhere (176;332). 
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During the course of this research, Werner et al. (335) was the first to report a 
correlation between EPCs and coronary endothelial function. This landmark 
study in 90 patients with stable CHD measured the number of circulating EPCs 
in peripheral blood using flow cytometry to quantify CD34+/KDR+ and CD133+ 
cells. The ability of EPCs to produce endothelial colony forming units (described 
as EPC function) was also measured. It was found that levels of circulating EPCs 
(using CD34+/KDR+ and CD133+ methods) and EPC function correlated with 
coronary endothelial function, assessed invasively using serial acetylcholine 
infusions. CD34+/KDR+ cells were more strongly correlated with coronary 
endothelial function than CD133+ cells. After multivariate analysis, only the 
number of circulating EPCs correlated with coronary endothelial function 
independently of traditional cardiovascular risk factors. The failure of endothelial 
colony forming units to independently predict endothelial function probably 
relates to their dissociation with the number of circulating CD34+/KDR+ cells 
(333) and doubtful function in vascular regeneration (332).  
 
The work in this thesis therefore corroborates the novel findings by Werner et al. 
that EPCs (defined as CD34+/KDR+ cells) correlate with coronary endothelial 
function. Evidence is accumulating that suggests EPCs provide an important 
repair mechanism after vessel damage due to cardiovascular risk factors 
including hypertension, hyperlipidaemia, smoking and diabetes. Despite this, in 
many cases, progressive vessel injury progresses to the clinical manifestations of 
CHD, stroke and peripheral artery disease. The role of EPCs to repair the vessel 
injury caused by PCI is not well defined, but emerging as an important 
component of re-endothelialisation and restoration of vessel function (176). By 
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reducing the capacity of the endothelium to be repaired after vessel injury, an 
obvious link between circulating EPC numbers and coronary endothelial function 
exists. The confirmation herein and by Werner et al. (335) that lower numbers of 
EPCs are associated with impaired coronary endothelial function (and hence at 
risk of subsequent vascular events) provides a basis for the ability of EPCs to 
predict cardiovascular outcome (315;316). Furthermore, it also provides a 
valuable link between cardiovascular risk factors and endothelial dysfunction, 
which are both associated with fewer circulating EPCs. 
 
6.4.3 The role of oxLDL 
The relationship between EPCs and endothelial function was independent of 
traditional cardiovascular risk factors, which implied that EPCs may be causally 
involved in the regulation of endothelial function and are themselves regulated 
by other factors. In this study, plasma oxLDL levels were not correlated with the 
number of circulating EPCs or coronary endothelial function. Therefore, I have 
failed to demonstrate a biological explanation or peripheral biomarker for the 
deficiency of EPCs and associated severe coronary endothelial dysfunction in 
these patients, despite substantial evidence that oxLDL is toxic to EPCs 
(124;320;321;336-338). Besides the diverse methods to confirm EPC identity in 
laboratory studies, the absence of correlation in my results may relate to a 
number of issues.  
 
In previous studies, EPC dysfunction in vitro occurred at 1-10 µg/ml oxLDL 
(124;320) and marginally increased EPC apoptosis (5-10%) was present at 25 
µg/ml oxLDL or higher (321;337). Wang et al. reported a major reduction in 
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cultured EPCs (~50%) at 100 µg/ml (336). In my study, the mean (SD) plasma 
oxLDL concentration was 60.2 (18.3) IU, which was approximately 18.0 (5.5) 
µg/ml (personal communication from manufacturer), OxLDL levels were 
therefore lower than would be expected to significantly reduce EPC numbers in 
the circulation. Furthermore, the studies that investigated statin pre-treatment 
found that oxLDL-induced EPC dysfunction and senescence were both 
profoundly inhibited by 1 µM atorvastatin (124;320), possibly via activation of 
Akt (320;339). Thus, I speculate that the very high prevalence of statin therapy in 
this contemporary CHD population (90.9%) protected circulating EPCs against 
oxLDL-induced damage in the blood and may have masked a possible 
correlation with EPC levels. Further studies could address this relationship in 
statin-naïve patients; however, blood concentration may represent a blunt way to 
fully define the interaction between oxLDL and EPCs in vivo.  
 
This study was also underpowered to detect minor correlations between oxLDL 
and EPCs, due to the small number of patients with oxLDL results (n = 14). 
Nevertheless, there was no signal from the available data that plasma oxLDL was 
correlated with EPCs. I believe a much larger study would be required to confirm 
or exclude with confidence a relationship between plasma oxLDL and the 
number of circulating EPCs. A larger population would reduce the impact of 
important confounding factors such as co-existing medical conditions and drug 
treatments, both of which can influence oxLDL and EPC count and probably 
impaired the statistical validity of this component of my study. If an inverse 
correlation between oxLDL and EPCs was evident from a larger study, then the 
ability of oxLDL to predict cardiac events in patients with CHD (340) would 
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gain further mechanistic insights. Moreover, future directions for novel therapies 
may be possible, if they could provide EPCs with protection from oxLDL in vivo 
in a similar fashion to statin therapy. 
 
In this study, plasma oxLDL levels also failed to correlate with coronary 
endothelial function. I believe this relationship was similarly affected by (or 
possibly even more susceptible to) factors which accounted for the lack of 
correlation with EPCs; that is, the protective influence of statin therapy, the 
confounding effects of other risk factors and the relatively small sample size. 
Hein et al. (300) has shown that oxLDL specifically impaired NO-mediated 
endothelium-dependent vasodilation to shear stress and adenosine, but not 
bradykinin (a cytochrome P-450 monooxygenase activator) in isolated porcine 
coronary arterioles. A study of 15 CHD patients was first to report an inverse 
correlation between coronary endothelial function, represented by the vasomotor 
response to acetylcholine, and plasma oxLDL (328). Importantly, this small 
study excluded patients taking lipid-lowering therapy, which reinforces the 
potential role that statins may have played in my results. A larger study in 36 
cardiac transplant patients (17% were prescribed statins) demonstrated that 
coronary endothelial function was inversely related to oxLDL antibody levels, 
but not circulating oxLDL detected by monoclonal antibody EO6 (341). More 
recently, Matsumoto et al. (342) showed that impaired endothelium-dependent 
vasodilation in response to bradykinin was weakly correlated with oxLDL levels, 
measured by an immunosorbent assay. 
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6.4.4 Other predictors of EPCs and endothelial function 
In this study, age was inversely correlated with the number of circulating EPCs. 
This relationship was independent of traditional cardiovascular risk factors, 
suggesting that other age-related factors are responsible for the decline in EPCs 
in older patients. Older patients are likely to be more sedentary than younger 
patients and this may contribute to the reduction in EPCs, because physical 
activity increases EPC levels (307), even after a single episode of strenuous 
exercise (343). Another factor may be the lower use of medications that increase 
EPC levels, such as statins and ACE inhibitors. In this study, patients prescribed 
statin therapy were younger than those not prescribed statins (60.2 ± 2.0 years vs. 
74.0 ± 2.8 years, respectively, p < 0.05). Statin prescription was associated with 
more circulating EPCs (0.32 ± 0.08 CD34+/KDR+ cells/µl vs. 0.03 ± 0.03 
CD34+/KDR+ cells/µl, respectively, p = 0.25) and improved endothelial function 
(mean vessel response to acetylcholine -12.4 ± 3.6 % vs. -20.9 ± 5.9 %, p = 
0.33), but neither result was statistically significant due to the very small number 
of patients (two) not prescribed a statin. There were no discernable differences in 
any of these parameters for the prescription of ACE inhibitors. Aging per se may 
be associated with progressive exhaustion of bone marrow derived progenitor 
cells after several decades of exposure to cardiovascular risk factors and vascular 
damage (344). Even if not actually reduced in number, a decline in EPC function 
(345) is likely to make older patients more at risk of endothelial dysfunction and 
cardiovascular events. 
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6.4.5 Discussion of WBA results 
This study demonstrated that age was correlated with WBA in response to ADP, 
but not with collagen, in patients taking aspirin and clopidogrel. Since 
clopidogrel selectively and irreversibly inhibits the ADP receptor on platelets, 
this suggests a relative lack of clopidogrel response in older patients (346). 
Indeed, ADP-induced platelet aggregation is probably the gold standard 
technique to assess clopidogrel response. Variability in clopidogrel 
responsiveness is well recognised and known to be mediated by numerous 
clinical, cellular and genetic factors (346). To my knowledge, few studies have 
specifically reported the influence of age on clopidogrel responsiveness and have 
provided contrasting results (347;348). Since the correlation between age and 
ADP-induced WBA was not independent of cardiovascular risk factors, it is 
likely that other factors such as female gender (an independent predictor after 
multivariate adjustment in this study), diabetes and smoking are involved 
(346;348;349). 
 
6.4.6 Limitations 
As already discussed, a limitation of this study was the low statistical power to 
confidently determine the true relationship between plasma oxLDL and other 
study parameters. However, accurate assessment of these relationships may 
require a much larger population to avoid the influence of confounding factors. It 
is not known whether the specific oxLDL assay used in this study may have 
affected the results, as accurate quantification of oxLDL can be challenging. The 
method to identify EPCs in this study using specific haematopoietic and 
endothelial markers, CD34 and KDR respectively, is consistent with 
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contemporary recommended guidance (332), but the most accurate way to 
quantify EPCs currently remains speculative (176;333). It would also have been 
useful to assess EPC function, as this may have revealed an association with 
plasma oxLDL levels and provided further insights into the high prevalence of 
severe endothelial dysfunction in CHD patients. It was noted that QCA using 
automated edge detection software appeared to underestimate the change in 
lumen diameter for the most severe cases of endothelial dysfunction, compared 
to qualitative visual assessment, but this was unlikely to have greatly affected the 
correlations between variables. Despite a statistically significant correlation 
between EPCs and endothelial function, there was a wide variation in endothelial 
responses to acetylcholine. This variation is likely to be due to the influence of 
other mediators which contribute to vascular function, such as the presence of 
cardiovascular risk factors and other unknown factors. As a result, measurement 
of EPCs alone is likely to be a fairly blunt predictor of endothelial function in a 
tested individual. 
 
6.4.7 Conclusions  
This observational study has confirmed a high prevalence of coronary endothelial 
dysfunction in patients with chronic stable angina. Coronary endothelial function 
in this population was strongly correlated with the number of circulating EPCs, 
independent of traditional cardiovascular risk factors, which is a relatively novel 
finding and has only been reported by one other group (335). Plasma oxLDL did 
not correlate with EPC count or endothelial function, possibly due to the high 
prevalence of statin use, other confounding variables and insufficient sample 
size. Future studies should aim to define the specific reasons for a decline in 
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number and other functional aspects of EPCs in cases of severe endothelial 
dysfunction. This may aid the development of novel therapies which can protect 
or accelerate the vital endogenous processes required for rapid endothelial 
healing after vessel injury, including PCI. 
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Chapter 7 
 
Concluding discussion 
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7. 1 Basic concept of the thesis 
 
Oxidative stress plays an important role in vascular repair by influencing 
multiple targets after arterial injury. Oxidative stress is mediated by numerous 
ROS including the superoxide anion (O2-), which inactivates NO and leads to an 
accumulation of peroxynitrite (ONOO-), hydrogen peroxide (H2O2) and other 
potent oxidising secondary molecules. These ROS and others affect critical 
signalling pathways in platelets and vascular cells after PCI. The principal 
aspects of this include: 
 
• Stent thrombosis – modulation of platelet aggregation 
• Healing – endothelial regrowth and function, EPCs, inflammation 
• ISR – re-endothelialisation, neointimal growth, extracellular matrix  
 
The vascular processes modulated by oxidative stress are also closely inter-
related themselves. Stent thrombosis is mediated to a large extent by platelets, 
but it is also influenced by the presence of healthy ECs. The regrowth of ECs not 
only protects against stent thrombosis, it also restricts neointimal formation, the 
main cause of ISR. Inflammation is an important element of vascular healing, but 
it is also strongly related to ISR and can predispose to stent thrombosis. The 
research presented in this thesis aimed to investigate the effects of oxidative 
stress on several of these key processes and explore whether a strategy to target 
ROS would favourably modify vascular remodelling after PCI.  
 
 
 205 
7.2 Oxidative stress: effects on stent thrombosis 
 
7.2.1 Specific effects on thrombosis  
Many studies have reported diverse effects of ROS on platelet function and this 
is discussed in detail in Chapter 2 and by others (177). The overall conclusion 
from the literature is that ROS are heterogenous regulators of platelet function. 
Whilst some ROS appear to stimulate platelets, the actions of others may be 
inhibitory. Stent thrombosis is predominantly made up of platelets, but other 
factors in the circulation and in the vascular wall are also closely involved, so 
particular attention in this thesis was given to the effects of ROS on thrombus 
formation in whole blood and in the vicinity of ECs. The X/XO reaction was 
used to generate ROS in this thesis and although the formation of specific 
molecules was not characterised, this reaction is known to produce large amounts 
of O2- and H2O2 (238). The effect of oxidative stress in this setting was to inhibit 
thrombus formation in a concentration-dependent manner. This was an 
interesting finding, because ROS released by this reaction were expected to cause 
a stimulatory effect. This early conjecture was fortified by the assumption that 
ROS were uniformly prothrombotic molecules. By corroborating my results with 
the extensive literature, it is now clear that this supposition was inaccurate. I 
speculate that my experiments generated abundant ROS and secondary 
molecules, which were toxic to platelets and other aggregating factors in the 
blood. The ultimate effect of this “super-release” of ROS was a decrease in the 
rate of thrombosis. The addition of ECs to blood also impaired thrombus 
formation, which was consistent with the primary function of the endothelium. 
This effect was not significantly altered by the exogenous application of ROS, 
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suggesting that ROS would not greatly oppose the antithrombotic properties of 
nearby endothelium after PCI. Consistent with previous work, NO was partly 
responsible for the inhibitory effect of ECs. Although O2- may diminish this 
influence, the formation of inhibitory ROS appear to counterbalance the effect 
overall. Of course, whether this experimental situation approximates with the 
ROS generated by PCI is uncertain. Nevertheless, it would seem that non-
specific targeting of the acute effects of ROS on platelets and other aggregating 
factors in blood after PCI to lower the intrinsic risk of thrombosis may be 
ineffective. In fact, substantial release of ROS after PCI might even provide 
some protection against stent thrombosis. The widespread use of intensive 
antiplatelet medications has dramatically reduced the incidence of stent 
thrombosis during the first month after PCI to less than 1%, therefore novel 
approaches to reduce acute thrombotic events further would need to have 
substantial inhibitory effects on thrombosis. Unravelling the effects of oxidative 
stress on other vascular processes associated with late stent thrombosis and ISR 
(such as endothelial regeneration) may offer a more plausable strategy. 
 
7.2.2 Re-endothelialisation 
The movement of ECs to regenerate the endothelial monolayer is a critical 
component of vascular healing. The work presented by this thesis implies that 
EC migration may be inhibited by ROS, but it may also be antagonised by 
antioxidants. The explanation for this seemingly paradoxical observation may lie 
in the fact that pathological release of ROS can clearly disrupt important 
biological functions but, on the other hand, targeted physiological release of ROS 
often constitutes an essential component of normal cell activity. In this case, the 
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impact of ROS is not solely damaging to ECs, but necessary to support motility. 
The important role of ROS during normal EC migration has been reviewed 
comprehensively (258). This should guide future strategies away from near-total 
elimination ROS after PCI, as that may negatively influence some arterial 
healing processes. The ideal antioxidant to promote endothelial healing would 
oppose pathological ROS production, but permit lower level physiological ROS 
release. If this were achieved, antioxidant therapy could potentially accelerate 
endothelial regeneration. Some data in animal models suggest probucol may be 
successful for this purpose (149;150), although it would be gratifying if other 
groups could validate this work. It is not clear whether the reported effectiveness 
of probucol to promote re-endothelialisation is primarily due to its antioxidant 
effects or its effects on HO-1 (160;350;351). EPCs may represent another 
potential target to modify arterial healing after PCI. A major current limitation of 
this approach is the lack of clear understanding of the identity and precise role of 
these endothelial precursors. The work in this thesis has confirmed a crucial link 
between putative circulating EPCs (identified by haematopoietic and EC 
markers) and coronary endothelial function. This provides further impetus for 
future studies to fully characterise the role of these cells in vascular repair after 
PCI and the impact oxidative stress may exert.  
 
7.3 Antioxidants: prevention of ISR  
 
7.3.1 Nitrone D: the good, the bad and the ugly? 
The initial compound to be investigated in this thesis was the spin trapping agent, 
nitrone D, a potent antioxidant, but with relatively few supporting studies. I 
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found that nitrone D caused slight inhibition of whole blood aggregation. 
However, subsequent evaluation was abruptly terminated after nitrone D was 
found to cause a disturbing inhibitory effect on EC migration. Since acceleration 
of arterial healing was a primary aim of this thesis, there was no option other 
than to eliminate nitrone D from further investigation. This was disappointing, 
since nitrone D would have been an intriguing substance to take forward into 
preclinical assessment. Other than its antioxidant properties, nitrone D has other 
effects which may have influenced neointimal formation. Nitrone D decreases 
p21 expression (245), which may be problematic after stent injury because 
animal studies have indicated that p21 can attenuate neointimal thickening (352). 
Nitrone D also promotes SIRT 1 transcription, which is a negative regulator of 
p53 gene expression (245). Although this may be protective towards ECs (249) 
and EPCs (353), it may accelerate neointimal thickening (354;355). These 
studies emphasise the need to recognise potentially diverse effects of novel 
compounds as well as their primary intended action. Until nitrone-based 
compounds are tested in a preclinical stent model, it is not clear which effects 
would predominate and which tissue responses that would produce. 
 
7.3.2 Succinobucol: the end of the road? 
In contrast to nitrone D, succinobucol had tantalising supportive data which 
made it an exciting compound to test in a preclinical model. In many respects, 
the properties of succinobucol matched those of an ideal DES coating. 
Succinobucol shares many of its appealing properties with probucol, except it is 
more potent and is taken up more readily by cells (271;356). It also has 
additional anti-inflammatory effects on vascular adhesion molecules, which are 
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ideally suited to neointimal suppression. Despite these promising qualities, I 
found that succinobucol was damaging to arterial tissue after stenting, by 
increasing inflammation and neointimal growth. These two effects were probably 
inter-related. Speculation remains as to whether a lower dose would have 
improved the results. I am not convinced that simply coating a stent with a lower 
concentration of succinobucol solution would have provided beneficial effects. 
Based on my pharmacokinetic results, targeting a succinobucol tissue 
concentration in the range of favourable in vitro data (published by Atherogenics, 
who manufactured succinobucol) would be extremely difficult. Moreover, the 
cell culture data presented in this thesis suggests that succinobucol at low 
concentrations is toxic to ECs and SMCs. Of course, toxicity towards SMCs is 
not necessarily a negative characteristic of a DES, as this may limit neointimal 
proliferation, but the risk of inflammation and impaired healing would present a 
similar situation to that already offered by current DES, which are also uniformly 
toxic to vascular cells. Incidentally, the development of succinobucol as an oral 
medication to treat cardiovascular disease was suspended during the writing of 
this thesis after disappointing results in clinical trials. 
 
7.4 The antioxidant-eluting stent: still a worthwhile concept? 
 
This thesis investigated two novel antioxidant compounds, with ultimately 
negative effects. In fact, neither came close to providing promising data. In many 
respects, this contradicts the scientific literature that has broadly endorsed the 
potential role of antioxidants in vascular remodelling after PCI. The relevant 
studies have been reviewed in Chapter 1. Animal studies of probucol have 
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yielded the most positive results, yet this drug has not been effective in humans. 
Clinical studies of oral probucol which included IVUS measurements have 
consistently found that this drug has no effect on NIH (156;157;161). Oral 
succinobucol was identical in this regard (156). It was a central hypothesis of this 
thesis that local delivery of antioxidants would circumvent the obvious 
limitations of oral dosing in humans compared to animals, but no studies have 
reported a positive result for this strategy. Incorporation into dual DES 
technology may offer the only viable alternative. It is worth noting that 
successful reports of a probucol/rapamycin-eluting stent have conspicuously 
omitted probucol as a sole coating (264). The efficacy of a probucol- or 
succinobucol-eluting stent therefore seems improbable, so attention should 
probably be re-focussed on other antioxidant techniques.  
 
The obvious question relates to which antioxidant therapy holds most promise 
for human applications. Given that NADPH oxidase is the principal contributor 
to ROS production after PCI, it is conceivable that inhibitors of this enzyme 
might offer the greatest chance of success (143;144). Antioxidants that 
decompose O2- and H2O2 (both promote SMC proliferation) may be a worthwhile 
strategy and several animal studies using SOD with and without catalase have 
reported positive results (145;146;357-360). Unfortunately, the targeted delivery 
of these agents in humans provides significant challenges. Their ultra-short half-
life in the circulation presents their foremost limitation: the requirement for viral 
gene transfer. Viral transfer of eNOS (361) and VEGF (29) has been effective in 
animal models but suffers from the same disadvantage, which is significant. The 
concept of a gene-eluting stent has not been successfully translated to humans. 
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Accumulation of viral vectors in non-target tissues is a concern, given their 
relatively narrow therapeutic index and potentially harmful immune responses. 
Nevertheless, whilst gene-based therapy in general for cardiovascular diseases 
has so far provided limited successes, it offers the potential to make a major 
impact if translated to humans successfully. Ex vivo antioxidant gene transfer of 
progenitor cells may provide an alluring prospect in the future (362).  
 
Ultimately, will an antioxidant-based strategy ever be successful in improving 
clinical outcome after PCI? Innumerable animal models have provided satisfying 
results, whereas human studies have been universally disappointing. This 
situation unfortunately mirrors the use of antioxidants in cardiovascular disease 
in general. It is difficult to envisage that antioxidants will ever induce favourable 
vascular responses after PCI to rival the success of established devices. The 
arrival of new generation DES on the market will elevate the competition further. 
An antioxidant-based approach would need to be potent enough to inhibit 
profound tissue stimuli without causing toxicity. At the same time, it must permit 
ROS signalling which is necessary for normal vascular cell function. These 
challenges may prove insurmountable for an antioxidant, but future attempts are 
awaited with great interest.  
 
7.5 Final conclusions 
 
In conclusion, this thesis has examined the role of oxidative stress in platelet and 
EC function, known be important after PCI, and found this to be damaging. 
Despite this, the effects of a novel antioxidant-eluting stent were detrimental to 
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vascular repair. Coronary endothelial dysfunction was correlated with reduced 
circulating EPCs, but plasma oxLDL was not related to either parameter. These 
findings highlight the difficulties and complexities of targeting oxidative stress to 
improve outcome after PCI. I hope the work contained in this thesis will 
stimulate clinicians and scientists alike to continue with research in this exciting 
and rapidly progressing area of cardiovascular disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 213 
 
References 
 
 1.  British heart Foundation Statistics Website www.heartstats.org.  2010.  
Ref Type: Report 
 2.  Serruys PW, Morice MC, Kappetein AP et al. Percutaneous coronary 
intervention versus coronary-artery bypass grafting for severe coronary 
artery disease. N Engl J Med 2009;360:961-72. 
 3.  Dotter CT, Judkins MP. Transluminal Treatment of Arteriosclerotic 
Obstruction: Description of a New Technic and a Preliminary Report of 
Its Application. Circulation 1964;30:654-70. 
 4.  Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of 
coronary-artery stenosis: percutaneous transluminal coronary angioplasty. 
New England Journal of Medicine 301(2):61-8, 1979. 
 5.  Palmaz JC, Sibbitt RR, Reuter SR, Tio FO, Rice WJ. Expandable 
intraluminal graft: a preliminary study. Work in progress. Radiology 
156(1):73-7, 1985. 
 6.  Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular 
stents to prevent occlusion and restenosis after transluminal angioplasty. 
N Engl J Med 1987;316:701-6. 
 7.  NICE issues guidance to the NHS on Coronary Artery Stents. 
www.nice.org.uk.  2000.  
Ref Type: Report 
 8.  BCIS Audit Returns 2009 www.bcis.org.uk.  2010.  
Ref Type: Report 
 9.  Bucher HC, Hengstler P, Schindler C, Guyatt GH. Percutaneous 
transluminal coronary angioplasty versus medical treatment for non-acute 
coronary heart disease: meta-analysis of randomised controlled trials.[see 
comment]. BMJ 321(7253):73-7, 2000. 
 10.  Boden WE, O'Rourke RA, Teo KK et al. Optimal Medical Therapy with 
or without PCI for Stable Coronary Disease. N Engl J Med 
2007;356:1503-16. 
 214 
 11.  Hoffman SN, TenBrook JA, Wolf MP, Pauker SG, Salem DN, Wong JB. 
A meta-analysis of randomized controlled trials comparing coronary 
artery bypass graft with percutaneous transluminal coronary angioplasty: 
one- to eight-year outcomes. Journal of the American College of 
Cardiology 41(8):1293-304, 2003. 
 12.  Mehta SR, Cannon CP, Fox KA et al. Routine vs selective invasive 
strategies in patients with acute coronary syndromes: a collaborative 
meta-analysis of randomized trials.[see comment]. JAMA 293(23):2908-
17, 2005. 
 13.  Fox KA, Poole-Wilson P, Clayton TC et al. 5-year outcome of an 
interventional strategy in non-ST-elevation acute coronary syndrome: the 
British Heart Foundation RITA 3 randomised trial. Lancet 
366(9489):914-20, 2005;-16. 
 14.  Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous 
thrombolytic therapy for acute myocardial infarction: a quantitative 
review of 23 randomised trials.[see comment]. [Review] [41 refs]. Lancet 
361(9351):13-20, 2003. 
 15.  Sangiorgi G, Taylor AJ, Farb A et al. Histopathology of postpercutaneous 
transluminal coronary angioplasty remodeling in human coronary 
arteries. Am Heart J 1999;138:681-7. 
 16.  Hoffmann R, Mintz GS. Coronary in-stent restenosis--predictors, 
treatment and prevention. Eur Heart J 2000;21:1739-49. 
 17.  Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal 
stent restenosis is not a benign clinical entity. Am Heart J 2006;151:1260-
4. 
 18.  Welt FGP, Rogers C. Inflammation and Restenosis in the Stent Era. 
Arterioscler Thromb Vasc Biol 2002;22:1769-76. 
 19.  Moreno PR, Palacios IF, Leon MN, Rhodes J, Fuster V, Fallon JT. 
Histopathologic comparison of human coronary in-stent and post-balloon 
angioplasty restenotic tissue. Am J Cardiol 1999;84:462-6, A9. 
 20.  Coomber BL, Gotlieb AI. In vitro endothelial wound repair. Interaction 
of cell migration and proliferation. Arteriosclerosis 1990;10:215-22. 
 215 
 21.  Peiro C, Redondo J, Rodriguez-Martinez MA, Angulo J, Marin J, 
Sanchez-Ferrer CF. Influence of Endothelium on Cultured Vascular 
Smooth Muscle Cell Proliferation. Hypertension 1995;25:748-51. 
 22.  Scott-Burden T, Vanhoutte PM. The endothelium as a regulator of 
vascular smooth muscle cell proliferation. Circulation 1993;87:V51-V55. 
 23.  Werner N, Junk S, Laufs U et al. Intravenous Transfusion of Endothelial 
Progenitor Cells Reduces Neointima Formation After Vascular Injury. 
Circ Res 2003;93:17e-24. 
 24.  Aoki J, Serruys PW, van Beusekom H et al. Endothelial progenitor cell 
capture by stents coated with antibody against CD34: the HEALING-FIM 
(Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-
First In Man) Registry. Journal of the American College of Cardiology 
2005;45:1574-9. 
 25.  Beijk MA, Klomp M, Verouden NJ et al. Genous endothelial progenitor 
cell capturing stent vs. the Taxus Liberte stent in patients with de novo 
coronary lesions with a high-risk of coronary restenosis: a randomized, 
single-centre, pilot study. Eur Heart J 2010;31:1055-64. 
 26.  Asahara T, Chen D, Tsurumi Y et al. Accelerated Restitution of 
Endothelial Integrity and Endothelium-Dependent Function After 
phVEGF165 Gene Transfer. Circulation 1996;94:3291-302. 
 27.  Dulak J, Schwarzacher SP, Zwick RH et al. Effects of local gene transfer 
of VEGF on neointima formation after balloon injury in 
hypercholesterolemic rabbits. Vascular Medicine 2005;10:285-91. 
 28.  Hedman M, Hartikainen J, Syvanne M et al. Safety and Feasibility of 
Catheter-Based Local Intracoronary Vascular Endothelial Growth Factor 
Gene Transfer in the Prevention of Postangioplasty and In-Stent 
Restenosis and in the Treatment of Chronic Myocardial Ischemia: Phase 
II Results of the Kuopio Angiogenesis Trial (KAT). Circulation 
2003;107:2677-83. 
 29.  Walter DH, Cejna M, Diaz-Sandoval L et al. Local Gene Transfer of 
phVEGF-2 Plasmid by Gene-Eluting Stents: An Alternative Strategy for 
Inhibition of Restenosis. Circulation 2004;110:36-45. 
 30.  Swanson N, Hogrefe K, Javed Q, Malik N, Gershlick AH. Vascular 
endothelial growth factor (VEGF)-eluting stents: in vivo effects on 
 216 
thrombosis, endothelialization and intimal hyperplasia. J Invasive Cardiol 
2003;15:688-92. 
 31.  Widlansky ME, Gokce N, Keaney JF, Jr., Vita JA. The clinical 
implications of endothelial dysfunction. J Am Coll Cardiol 
2003;42:1149-60. 
 32.  Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial 
thrombosis. Circulation Research 2001;88:756-62. 
 33.  De La Cruz JP, Moreno A, Guerrero A, de La Cuesta FS. Antiplatelet 
effects of prostacyclin and nitric oxide in patients with type I diabetes and 
ischemic or edematous retinopathy. Platelets 2001;12:210-7. 
 34.  Marcus AJ, Broekman MJ, Drosopoulos JH, Pinsky DJ, Islam N, 
Maliszewsk CR. Inhibition of platelet recruitment by endothelial cell 
CD39/ecto-ADPase: significance for occlusive vascular diseases. Ital 
Heart J 2001 Nov ;2(11):824 -30 2001;2:824-30. 
 35.  Rosenberg RD, Aird WC. Vascular-bed--specific hemostasis and 
hypercoagulable states. N Engl J Med 1999;340:1555-64. 
 36.  Oliver JJ, Webb DJ, Newby DE. Stimulated tissue plasminogen activator 
release as a marker of endothelial function in humans. Arterioscler 
Thromb Vasc Biol 2005;25:2470-9. 
 37.  Ong AT, Hoye A, Aoki J et al. Thirty-day incidence and six-month 
clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, 
or paclitaxel stent implantation. J Am Coll Cardiol 2005;45:947-53. 
 38.  Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and 
outcome of thrombosis after successful implantation of drug-eluting 
stents. JAMA 2005;293:2126-30. 
 39.  Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent 
thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine 
clinical practice: data from a large two-institutional cohort study. Lancet 
2007;369:667-78. 
 40.  Wilson SH, Fasseas P, Orford JL et al. Clinical outcome of patients 
undergoing non-cardiac surgery in the two months following coronary 
stenting. J Am Coll Cardiol 2003;42:234-40. 
 217 
 41.  Cruden NL, Harding SA, Flapan AD et al. Previous coronary stent 
implantation and cardiac events in patients undergoing noncardiac 
surgery. Circ Cardiovasc Interv 2010;3:236-42. 
 42.  Luckie M, Khattar RS, Fraser D. Non-cardiac surgery and antiplatelet 
therapy following coronary artery stenting. Heart 2009;95:1303-8. 
 43.  Mauri L, Hsieh Wh, Massaro JM, Ho KKL, D'Agostino R, Cutlip DE. 
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents. 
N Engl J Med 2007;NEJMoa067731. 
 44.  Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A Pooled 
Analysis of Data Comparing Sirolimus-Eluting Stents with Bare-Metal 
Stents. N Engl J Med 2007;NEJMoa066633. 
 45.  Heestermans AA, van Werkum JW, Zwart B et al. Acute and subacute 
stent thrombosis after primary percutaneous coronary intervention for ST-
segment elevation myocardial infarction: incidence, predictors and 
clinical outcome. J Thromb Haemost 2010;8:2385-93. 
 46.  Cutlip DE, Windecker S, Mehran R et al. Clinical End Points in Coronary 
Stent Trials: A Case for Standardized Definitions. Circulation 
2007;115:2344-51. 
 47.  Uren NG, Schwarzacher SP, Metz JA et al. Predictors and outcomes of 
stent thrombosis: an intravascular ultrasound registry. Eur Heart J 
2002;23:124-32. 
 48.  Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, 
Serruys PW. Late angiographic stent thrombosis (LAST) events with 
drug-eluting stents. J Am Coll Cardiol 2005;45:2088-92. 
 49.  Kimura T, Morimoto T, Kozuma K et al. Comparisons of Baseline 
Demographics, Clinical Presentation, and Long-Term Outcome Among 
Patients With Early, Late, and Very Late Stent Thrombosis of Sirolimus-
Eluting Stents: Observations From the Registry of Stent Thrombosis for 
Review and Reevaluation (RESTART). Circulation 2010;122:52-61. 
 50.  Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and 
late coronary thrombosis secondary to a sirolimus-eluting stent: should 
we be cautious? Circulation 2004;109:701-5. 
 218 
 51.  Sousa JE, Costa MA, Abizaid A et al. Four-year angiographic and 
intravascular ultrasound follow-up of patients treated with sirolimus-
eluting stents. Circulation 2005;111:2326-9. 
 52.  Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a 
sirolimus-eluting stent with a standard stent for coronary 
revascularization. N Engl J Med 2002;346:1773-80. 
 53.  Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus 
standard stents in patients with stenosis in a native coronary artery. New 
England Journal of Medicine 349(14):1315-23, 2003. 
 54.  Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A 
hierarchical Bayesian meta-analysis of randomised clinical trials of drug-
eluting stents. Lancet 2004;364:583-91. 
 55.  Zahn R, Hamm CW, Schneider S et al. Incidence and predictors of target 
vessel revascularization and clinical event rates of the sirolimus-eluting 
coronary stent (results from the prospective multicenter German Cypher 
Stent Registry). Am J Cardiol 2005;95:1302-8. 
 56.  Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting 
stent in patients with coronary artery disease. New England Journal of 
Medicine 350(3):221-31, 2004. 
 57.  Kirtane AJ, Gupta A, Iyengar S et al. Safety and efficacy of drug-eluting 
and bare metal stents: comprehensive meta-analysis of randomized trials 
and observational studies. Circulation 2009;119:3198-206. 
 58.  Suzuki T, Kopia G, Hayashi Si et al. Stent-Based Delivery of Sirolimus 
Reduces Neointimal Formation in a Porcine Coronary Model. Circulation 
2001;104:1188-93. 
 59.  Zhou X, Li J, Kucik DF. The Microtubule Cytoskeleton Participates in 
Control of beta 2 Integrin Avidity. J Biol Chem 2001;276:44762-9. 
 60.  Parry TJ, Brosius R, Thyagarajan R et al. Drug-eluting stents: sirolimus 
and paclitaxel differentially affect cultured cells and injured arteries. 
European Journal of Pharmacology 2005;524:19-29. 
 61.  Butzal M, Loges S, Schweizer M et al. Rapamycin inhibits proliferation 
and differentiation of human endothelial progenitor cells in vitro. 
Experimental Cell Research 2004;300:65-71. 
 219 
 62.  Joner M, Finn AV, Farb A et al. Pathology of Drug-Eluting Stents in 
Humans: Delayed Healing and Late Thrombotic Risk. Journal of the 
American College of Cardiology 2006;48:193-202. 
 63.  Luscher TF, Steffel J, Eberli FR et al. Drug-Eluting Stent and Coronary 
Thrombosis: Biological Mechanisms and Clinical Implications. 
Circulation 2007;115:1051-8. 
 64.  Takano M, Ohba T, Inami S, Seimiya K, Sakai S, Mizuno K. 
Angioscopic differences in neointimal coverage and in persistence of 
thrombus between sirolimus-eluting stents and bare metal stents after a 6-
month implantation. Eur Heart J 2006;27:2189-95. 
 65.  Kotani Ji, Awata M, Nanto S et al. Incomplete Neointimal Coverage of 
Sirolimus-Eluting Stents: Angioscopic Findings. Journal of the American 
College of Cardiology 2006;47:2108-11. 
 66.  Oyabu J, Ueda Y, Ogasawara N, Okada K, Hirayama A, Kodama K. 
Angioscopic evaluation of neointima coverage: Sirolimus drug-eluting 
stent versus bare metal stent. American Heart Journal 2006;152:1168-74. 
 67.  Hong MK, Mintz GS, Lee CW et al. Late stent malapposition after drug-
eluting stent implantation: an intravascular ultrasound analysis with long-
term follow-up. Circulation 2006;113:414-9. 
 68.  Hofma SH, van der Giessen WJ, van Dalen BM et al. Indication of long-
term endothelial dysfunction after sirolimus-eluting stent implantation. 
Eur Heart J 2006;27:166-70. 
 69.  Moreno R, Fernandez C, Hernandez R et al. Drug-eluting stent 
thrombosis: Results from a pooled analysis including 10 randomized 
studies. J Am Coll Cardiol 2005;45:954-9. 
 70.  Pfisterer M, Brunner-La Rocca HP, Buser PT et al. Late Clinical Events 
After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting 
Stents: An Observational Study of Drug-Eluting Versus Bare-Metal 
Stents. J Am Coll Cardiol 2006;48:2584-91. 
 71.  Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled 
trials comparing drug-eluting vs. bare metal stents in coronary artery 
disease: a meta-analysis. Eur Heart J 2006;27:2784-814. 
 220 
 72.  Stone GW, Moses JW, Ellis SG et al. Safety and Efficacy of Sirolimus- 
and Paclitaxel-Eluting Coronary Stents. N Engl J Med 2007;356:998-
1008. 
 73.  Fajadet J, Wijns W, Laarman GJ et al. Randomized, Double-Blind, 
Multicenter Study of the Endeavor Zotarolimus-Eluting 
Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary 
Artery Lesions: Clinical and Angiographic Results of the ENDEAVOR II 
Trial. Circulation 2006;114:798-806. 
 74.  Kandzari DE, Leon MB, Popma JJ et al. Comparison of Zotarolimus-
Eluting and Sirolimus-Eluting Stents in Patients With Native Coronary 
Artery Disease: A Randomized Controlled Trial. Journal of the American 
College of Cardiology 2006;48:2440-7. 
 75.  Tsuchida K, Piek JJ, Neumann FJ et al. One-year results of a durable 
polymer everolimus-eluting stent in de novo coronary narrowings (The 
SPIRIT FIRST Trial). EuroIntervention 2005;1:266-72. 
 76.  Onuma Y, Serruys PW, Kukreja N et al. Randomized comparison of 
everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year 
clinical follow-up from the SPIRIT II and III trials. Eur Heart J 
2010;31:1071-8. 
 77.  Caixeta A, Lansky AJ, Serruys PW et al. Clinical follow-up 3 years after 
everolimus- and paclitaxel-eluting stents: a pooled analysis from the 
SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting 
Coronary Stent System in the Treatment of Patients With De Novo 
Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation 
of the Investigational Device XIENCE V Everolimus Eluting Coronary 
Stent System [EECSS] in the Treatment of Subjects With De Novo 
Native Coronary Artery Lesions) randomized trials. JACC Cardiovasc 
Interv 2010;3:1220-8. 
 78.  De Scheerder IK, Wilczek KL, Verbeken EV et al. Biocompatibility of 
polymer-coated oversized metallic stents implanted in normal porcine 
coronary arteries. Atherosclerosis 1995;114:105-14. 
 79.  Guagliumi G, Sirbu V, Bezerra H et al. Strut coverage and vessel wall 
response to zotarolimus-eluting and bare-metal stents implanted in 
patients with ST-segment elevation myocardial infarction: the OCTAMI 
(Optical Coherence Tomography in Acute Myocardial Infarction) Study. 
JACC Cardiovasc Interv 2010;3:680-7. 
 221 
 80.  Chin-Quee SL, Hsu SH, Nguyen-Ehrenreich KL et al. Endothelial cell 
recovery, acute thrombogenicity, and monocyte adhesion and activation 
on fluorinated copolymer and phosphorylcholine polymer stent coatings. 
Biomaterials 2010;31:648-57. 
 81.  Grube E, Sonoda S, Ikeno F et al. Six- and Twelve-Month Results From 
First Human Experience Using Everolimus-Eluting Stents With 
Bioabsorbable Polymer. Circulation 2004;109:2168-71. 
 82.  Tsuchiya Y, Lansky AJ, Costa RA et al. Effect of everolimus-eluting 
stents in different vessel sizes (from the pooled FUTURE I and II trials). 
Am J Cardiol 2006;98:464-9. 
 83.  Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with 
biodegradable polymer versus sirolimus-eluting stent with durable 
polymer for coronary revascularisation (LEADERS): a randomised non-
inferiority trial. Lancet 2008;372:1163-73. 
 84.  Barlis P, Regar E, Serruys PW et al. An optical coherence tomography 
study of a biodegradable vs. durable polymer-coated limus-eluting stent: 
a LEADERS trial sub-study. Eur Heart J 2010;31:165-76. 
 85.  John MC, Wessely R, Kastrati A et al. Differential healing responses in 
polymer- and nonpolymer-based sirolimus-eluting stents. JACC 
Cardiovasc Interv 2008;1:535-44. 
 86.  Swanson N, De Scheerder IK, Chevalier B, Camenzind E, Carver A, 
Gershlick A. Two-year clinical results of a polymer-free, paclitaxel-
eluting stent: the ELUTES trial. EuroIntervention 2007;3:109-12. 
 87.  Grube E, Gershlick A, Bartorelli A et al. Prospective non-randomized 
multi-centre evaluation of the non-polymer based ACHIEVE Paclitaxel 
Eluting Coronary Stent System in treatment of lesions with high risk of 
revascularization due to restenosis: the DELIVER II study. 
EuroIntervention 2006;1:385-90. 
 88.  Dibra A, Kastrati A, Mehilli J et al. Influence of stent surface topography 
on the outcomes of patients undergoing coronary stenting: a randomized 
double-blind controlled trial. Catheter Cardiovasc Interv 2005;65:374-80. 
 89.  Mehilli J, Kastrati A, Wessely R et al. Randomized Trial of a 
Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based 
 222 
Paclitaxel-Eluting Stent for the Reduction of Late Lumen Loss. 
Circulation 2006;113:273-9. 
 90.  Byrne RA, Kufner S, Tiroch K et al. Randomised trial of three 
rapamycin-eluting stents with different coating strategies for the 
reduction of coronary restenosis: 2-year follow-up results. Heart 
2009;95:1489-94. 
 91.  Steigerwald K, Merl S, Kastrati A et al. The pre-clinical assessment of 
rapamycin-eluting, durable polymer-free stent coating concepts. 
Biomaterials 2009;30:632-7. 
 92.  Byrne RA, Kastrati A, Tiroch K et al. 2-year clinical and angiographic 
outcomes from a randomized trial of polymer-free dual drug-eluting 
stents versus polymer-based Cypher and Endeavor [corrected] drug-
eluting stents. J Am Coll Cardiol 2010;55:2536-43. 
 93.  Lafont A. Bioresorbable stents: the next horizon after drug eluting stents? 
EuroIntervention 2007;3:21-3. 
 94.  Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-
eluting coronary stent system (ABSORB): 2-year outcomes and results 
from multiple imaging methods. Lancet 2009;373:897-910. 
 95.  Finn AV, Nakazawa G, Joner M, Virmani R. Everolimus eluting stents: 
beyond targeting restenosis! EuroIntervention 2006;2:277-9. 
 96.  Joner M, Nakazawa G, Finn AV et al. Endothelial cell recovery between 
comparator polymer-based drug-eluting stents. J Am Coll Cardiol 
2008;52:333-42. 
 97.  Mohacsi PJ, Tuller D, Hulliger B, Wijngaard PL. Different inhibitory 
effects of immunosuppressive drugs on human and rat aortic smooth 
muscle and endothelial cell proliferation stimulated by platelet-derived 
growth factor or endothelial cell growth factor. J Heart Lung Transplant 
1997;16:484-92. 
 98.  Steffel J, Latini RA, Akhmedov A et al. Rapamycin, but Not FK-506, 
Increases Endothelial Tissue Factor Expression: Implications for Drug-
Eluting Stent Design. Circulation 2005;112:2002-11. 
 99.  Tada N, Virmani R, Grant G et al. Polymer-free biolimus a9-coated stent 
demonstrates more sustained intimal inhibition, improved healing, and 
 223 
reduced inflammation compared with a polymer-coated sirolimus-eluting 
cypher stent in a porcine model. Circ Cardiovasc Interv 2010;3:174-83. 
 100.  Droge W. Free radicals in the physiological control of cell function. 
Physiol Rev 2002;82:47-95. 
 101.  Steinberg D. Lewis A. Conner Memorial Lecture: Oxidative Modification 
of LDL and Atherogenesis. Circulation 1997;95:1062-71. 
 102.  Navab M, Berliner JA, Watson AD et al. The Yin and Yang of Oxidation 
in the Development of the Fatty Streak: A Review Based on the 1994 
George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 
1996;16:831-42. 
 103.  Channon KM. Oxidative stress and coronary plaque stability. Arterioscler 
Thromb Vasc Biol 2002;22:1751-2. 
 104.  Harris A, Devaraj S, Jialal I. Oxidative stress, alpha-tocopherol therapy, 
and atherosclerosis. Curr Atheroscler Rep 2002;4:373-80. 
 105.  Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, 
Mitchinson MJ. Randomised controlled trial of vitamin E in patients with 
coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 
1996;347:781-6. 
 106.  Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E 
supplementation and cardiovascular events in high-risk patients. The 
Heart Outcomes Prevention Evaluation Study Investigators. N Engl J 
Med 2000;342:154-60. 
 107.   Dietary supplementation with n-3 polyunsaturated fatty acids and 
vitamin E after myocardial infarction: results of the GISSI-Prevenzione 
trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto 
miocardico. Lancet 1999;354:447-55. 
 108.   MRC/BHF Heart Protection Study of antioxidant vitamin 
supplementation in 20,536 high-risk individuals: a randomised placebo-
controlled trial. Lancet 2002;360:23-33. 
 109.  Jialal I, Devaraj S. Antioxidants and atherosclerosis: don't throw out the 
baby with the bath water. Circulation 2003;107:926-8. 
 224 
 110.  Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of 
oxidative stress in atherosclerosis. Am J Cardiol 2003;91:7A-11A. 
 111.  Souza HP, Souza LC, Anastacio VM et al. Vascular oxidant stress early 
after balloon injury: evidence for increased NAD(P)H oxidoreductase 
activity. Free Radic Biol Med 2000;28:1232-42. 
 112.  Shi Y, Niculescu R, Wang D, Patel S, Davenpeck KL, Zalewski A. 
Increased NAD(P)H oxidase and reactive oxygen species in coronary 
arteries after balloon injury. Arteriosclerosis, Thrombosis & Vascular 
Biology Vol 21(5)()(pp 739-745), 2001 2001;739-45. 
 113.  Iuliano L, Pratico D, Greco C et al. Angioplasty increases coronary sinus 
F2-isoprostane formation: evidence for in vivo oxidative stress during 
PTCA. Journal of the American College of Cardiology 2001;37:76-80. 
 114.  Fujii H, Shimizu M, Ino H et al. Acute increases in plasma oxidized low-
density lipoprotein immediately after percutaneous transluminal coronary 
angioplasty. Am J Cardiol 2001;87:102-3, A8. 
 115.  Tsimikas S, Lau HK, Han KR et al. Percutaneous coronary intervention 
results in acute increases in oxidized phospholipids and lipoprotein(a): 
short-term and long-term immunologic responses to oxidized low-density 
lipoprotein. Circulation 2004;109:3164-70. 
 116.  Basili S, Tanzilli G, Mangieri E et al. Intravenous Ascorbic Acid Infusion 
Improves Myocardial Perfusion Grade During Elective Percutaneous 
Coronary Intervention: Relationship With Oxidative Stress Markers. J 
Am Coll Cardiol Intv 2010;3:221-9. 
 117.  Azevedo LC, Pedro MA, Souza LC et al. Oxidative stress as a signaling 
mechanism of the vascular response to injury: the redox hypothesis of 
restenosis. Cardiovascular Research 2000;47:436-45. 
 118.  Janiszewski M, Pasqualucci CA, Souza LC, Pileggi F, da Luz PL, 
Laurindo M. Oxidized thiols markedly amplify the vascular response to 
balloon injury in rabbits through a redox active metal-dependent pathway. 
Cardiovascular Research 1998;39:327-38. 
 119.  Landry DB, Couper LL, Bryant SR, Lindner V. Activation of the NF-
kappa B and I kappa B system in smooth muscle cells after rat arterial 
injury. Induction of vascular cell adhesion molecule-1 and monocyte 
chemoattractant protein-1. Am J Pathol 1997;151:1085-95. 
 225 
 120.  Ohtani K, Egashira K, Nakano K et al. Stent-Based Local Delivery of 
Nuclear Factor-{kappa}B Decoy Attenuates In-Stent Restenosis in 
Hypercholesterolemic Rabbits. Circulation 2006;114:2773-9. 
 121.  Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of 
Protein Kinase Activity and Gene Expression by Reactive Oxygen 
Species and Their Role in Vascular Physiology and Pathophysiology. 
Arterioscler Thromb Vasc Biol 2000;20:2175-83. 
 122.  Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for 
Generation of H(2)O(2) for Platelet-Derived Growth Factor Signal Tran 
sduction. Science 1995;270:296-9. 
 123.  Nishi K, Itabe H, Uno M et al. Oxidized LDL in Carotid Plaques and 
Plasma Associates With Plaque Instability. Arterioscler Thromb Vasc 
Biol 2002;22:1649-54. 
 124.  Imanishi T, Hano T, Sawamura T, Nishio I. Oxidized low-density 
lipoprotein induces endothelial progenitor cell senescence, leading to 
cellular dysfunction. Clinical and Experimental Pharmacology and 
Physiology 2004;31:407-13. 
 125.  Fujii H, Li SH, Szmitko PE, Fedak PWM, Verma S. C-Reactive Protein 
Alters Antioxidant Defenses and Promotes Apoptosis in Endothelial 
Progenitor Cells. Arterioscler Thromb Vasc Biol 2006;26:2476-82. 
 126.  van Aalst JA, Zhang DM, Miyazaki K, Colles SM, Fox PL, Graham LM. 
Role of reactive oxygen species in inhibition of endothelial cell migration 
by oxidized low-density lipoprotein. J Vasc Surg 2004;40:1208-15. 
 127.  van Aalst JA, Burmeister W, Fox PL, Graham LM. Alpha-tocopherol 
preserves endothelial cell migration in the presence of cell-oxidized low-
density lipoprotein by inhibiting changes in cell membrane fluidity. J 
Vasc Surg 2004;39:229-37. 
 128.  Kuzuya M, Naito M, Funaki C et al. Antioxidants stimulate endothelial 
cell proliferation in culture. Artery 1991;18:115-24. 
 129.  Kuzuya M, Naito M, Funaki C, Hayashi T, Asai K, Kuzuya F. Probucol 
prevents oxidative injury to endothelial cells. J Lipid Res 1991;32:197-
204. 
 226 
 130.  Noiri E, Hu Y, Bahou WF, Keese CR, Giaever I, Goligorsky MS. 
Permissive role of nitric oxide in endothelin-induced migration of 
endothelial cells. J Biol Chem 1997;272:1747-52. 
 131.  Poppa V, Miyashiro JK, Corson MA, Berk BC. Endothelial NO Synthase 
Is Increased in Regenerating Endothelium After Denuding Injury of the 
Rat Aorta. Arterioscler Thromb Vasc Biol 1998;18:1312-21. 
 132.  Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from 
the reaction of nitric oxide with superoxide. Am J Physiol Lung Cell Mol 
Physiol 1995;268:L699-L722. 
 133.  Zou MH, Cohen R, Ullrich V. Peroxynitrite and vascular endothelial 
dysfunction in diabetes mellitus. Endothelium 2004;11:89-97. 
 134.  Loscalzo J. Oxidant stress: a key determinant of atherothrombosis. 
Biochem Soc Trans 2003;31:1059-61. 
 135.  Mabile L, Bruckdorfer KR, Rice-Evans C. Moderate supplementation 
with natural alpha-tocopherol decreases platelet aggregation and low-
density lipoprotein oxidation. Atherosclerosis 1999;147:177-85. 
 136.  Saldeen T, Li D, Mehta JL. Differential effects of alpha- and gamma-
tocopherol on low-density lipoprotein oxidation, superoxide activity, 
platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol 
1999;34:1208-15. 
 137.  Miyamoto S, Kawano H, Takazoe K et al. Vitamin E improves 
fibrinolytic activity in patients with coronary spastic angina. Thromb Res 
2004;113:345-51. 
 138.  Ghigliotti G, Mereto E, Eisenberg PR et al. N-acetyl-cysteine Reduces 
Neointimal Thickening and Procoagulant Activity after Balloon-induced 
Injury in Abdominal Aortae of New Zealand White Rabbits. Thrombosis 
and Haemostasis 2001;84:724-9. 
 139.  Hung CC, Tsai WJ, Kuo LM, Kuo YH. Evaluation of caffeic acid amide 
analogues as anti-platelet aggregation and anti-oxidative agents. Bioorg 
Med Chem 2005 Mar 1;13(5):1791 -7 2005;13:1791-7. 
 140.  Aviram M, Dornfeld L, Rosenblat M et al. Pomegranate juice 
consumption reduces oxidative stress, atherogenic modifications to LDL, 
and platelet aggregation: studies in humans and in atherosclerotic 
 227 
apolipoprotein E-deficient mice. Am J Clin Nutr 2000 May ;71 (5):1062 -
76 2000;71:1062-76. 
 141.  Wolfram RM, Oguogho A, Efthimiou Y, Budinsky AC, Sinzinger H. 
Effect of black tea on (iso-)prostaglandins and platelet aggregation in 
healthy volunteers. Prostaglandins Leukot Essent Fatty Acids 2002 May -
Jun ;66 (5-6 ):529 -33 2002;66:529-33. 
 142.  Salvemini D, Radziszewski W, Mollace V, Moore A, Willoughby D, 
Vane J. Diphenylene iodonium, an inhibitor of free radical formation, 
inhibits platelet aggregation. Eur J Pharmacol 1991;199:15-8. 
 143.  Jacobson GM, Dourron HM, Liu J et al. Novel NAD(P)H oxidase 
inhibitor suppresses angioplasty-induced superoxide and neointimal 
hyperplasia of rat carotid artery. Circ Res 2003;92:637-43. 
 144.  Dourron HM, Jacobson GM, Park JL et al. Perivascular gene transfer of 
NADPH oxidase inhibitor suppresses angioplasty-induced neointimal 
proliferation of rat carotid artery. American Journal of Physiology - Heart 
& Circulatory Physiology 2005;288:H946-H953. 
 145.  Laukkanen MO, Kivela A, Rissanen T et al. Adenovirus-mediated 
extracellular superoxide dismutase gene therapy reduces neointima 
formation in balloon-denuded rabbit aorta. Circulation 2002;106:1999-
2003. 
 146.  Durand E, Al Haj ZA, Addad F et al. Adenovirus-mediated gene transfer 
of superoxide dismutase and catalase decreases restenosis after balloon 
angioplasty. Journal of Vascular Research 2005;42:255-65. 
 147.  Schneider JE, Berk BC, Gravanis MB et al. Probucol decreases 
neointimal formation in a swine model of coronary artery balloon injury. 
A possible role for antioxidants in restenosis. Circulation 1993;88:628-
37. 
 148.  Miyauchi K, Aikawa M, Tani T et al. Effect of probucol on smooth 
muscle cell proliferation and dedifferentiation after vascular injury in 
rabbits: possible role of PDGF. Cardiovasc Drugs Ther 1998;12:251-60. 
 149.  Lau AK, Leichtweis SB, Hume P et al. Probucol promotes functional 
reendothelialization in balloon-injured rabbit aortas. Circulation 
2003;107:2031-6. 
 228 
 150.  Tanous D, Brasen JH, Choy K et al. Probucol inhibits in-stent thrombosis 
and neointimal hyperplasia by promoting re-endothelialization. 
Atherosclerosis 2006;189:342-9. 
 151.  Tardif JC, Cote G, Lesperance J et al. Probucol and multivitamins in the 
prevention of restenosis after coronary angioplasty. Multivitamins and 
Probucol Study Group. The New England Journal of Medicine 
1997;337:365-72. 
 152.  Yokoi H, Daida H, Kuwabara Y et al. Effectiveness of an antioxidant in 
preventing restenosis after percutaneous transluminal coronary 
angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll 
Cardiol 1997;30:855-62. 
 153.  Sekiya M, Funada J, Watanabe K, Miyagawa M, Akutsu H. Effects of 
probucol and cilostazol alone and in combination on frequency of 
poststenting restenosis. Am J Cardiol 1998;82:144-7. 
 154.  Kim MH, Cha KS, Han J-Y, Kim HJ, Kim JS. Effect of antioxidant 
probucol for preventing stent restenosis. Catheterization & 
Cardiovascular Interventions 2002;57:424-8. 
 155.  Wakeyama T, Ogawa H, Iida H et al. Effects of candesartan and probucol 
on restenosis after coronary stenting: results of insight of stent intimal 
hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) 
trial. Circ J 2003;67:519-24. 
 156.  Tardif JC, Gregoire J, Schwartz L et al. Effects of AGI-1067 and 
probucol after percutaneous coronary interventions. Circulation 
2003;107:552-8. 
 157.  Nunes GL, Abizaid AC, Theodoro MP et al. Role of probucol in 
inhibiting intimal hyperplasia after coronary stent implantation: a 
randomized study. Am Heart J 2006;152:914-7. 
 158.  Kim W, Jeong MH, Cha KS et al. Effect of anti-oxidant (carvedilol and 
probucol) loaded stents in a porcine coronary restenosis model. 
Circulation Journal 2005;69:101-6. 
 159.  Six I, Van Belle E, Bordet R et al. L-arginine and L-NAME have no 
effects on the reendothelialization process after arterial balloon injury. 
Cardiovasc Res 1999;43:731-8. 
 229 
 160.  Deng YM, Wu BJ, Witting PK, Stocker R. Probucol Protects Against 
Smooth Muscle Cell Proliferation by Upregulating Heme Oxygenase-1. 
Circulation 2004;110:1855-60. 
 161.  Cote G, Tardif JC, Lesperance J et al. Effects of probucol on vascular 
remodeling after coronary angioplasty. Multivitamins and Protocol Study 
Group. Circulation 1999;99:30-5. 
 162.  Kim MH, Cha KS, Han JY, Kim HJ, Kim JS. Effect of antioxidant 
probucol for preventing stent restenosis. Catheter Cardiovasc Interv 
2002;57:424-8. 
 163.  Kunsch C, Luchoomun J, Grey JY et al. Selective inhibition of 
endothelial and monocyte redox-sensitive genes by AGI-1067: a novel 
antioxidant and anti-inflammatory agent. J Pharmacol Exp Ther 
2004;308:820-9. 
 164.  Sundell CL, Somers PK, Meng CQ et al. AGI-1067: a multifunctional 
phenolic antioxidant, lipid modulator, anti-inflammatory and 
antiatherosclerotic agent. J Pharmacol Exp Ther 2003;305:1116-23. 
 165.  Meng CQ, Somers PK, Rachita CL et al. Novel phenolic antioxidants as 
multifunctional inhibitors of inducible VCAM-1 expression for use in 
atherosclerosis. Bioorg Med Chem Lett 2002;12:2545-8. 
 166.  Murata S, Sundell CL, Lijkwan MA et al. Effects of AGI-1096, a novel 
antioxidant compound with anti-inflammatory and antiproliferative 
properties, on rodent allograft arteriosclerosis. Transplantation 
2004;77:1494-500. 
 167.  Tardif JC, Gregoire J, L'Allier PL et al. Effects of the antioxidant 
succinobucol (AGI-1067) on human atherosclerosis in a randomized 
clinical trial. Atherosclerosis 2008;197:480-6. 
 168.  Cheng XW, Kuzuya M, Sasaki T et al. Green tea catechins inhibit 
neointimal hyperplasia in a rat carotid arterial injury model by TIMP-2 
overexpression. Cardiovascular Research 2004;62:594-602. 
 169.  Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition 
on restenosis: final results of the MARCATOR Study, a multicenter, 
double-blind, placebo-controlled trial of cilazapril. The Multicenter 
American Research Trial With Cilazapril After Angioplasty to Prevent 
 230 
Transluminal Coronary Obstruction and Restenosis (MARCATOR) 
Study Group. J Am Coll Cardiol 1995;25:362-9. 
 170.  Finn AV, Kolodgie FD, Harnek J et al. Differential response of delayed 
healing and persistent inflammation at sites of overlapping sirolimus- or 
paclitaxel-eluting stents. Circulation 2005;112:270-8. 
 171.  Farb A, Sangiorgi G, Carter AJ et al. Pathology of acute and chronic 
coronary stenting in humans. Circulation 1999;99:44-52. 
 172.  Carter AJ, Laird JR, Farb A, Kufs W, Wortham DC, Virmani R. 
Morphologic characteristics of lesion formation and time course of 
smooth muscle cell proliferation in a porcine proliferative restenosis 
model. J Am Coll Cardiol 1994;24:1398-405. 
 173.  Nakazawa G, Finn AV, Ladich E et al. Drug-eluting stent safety: findings 
from preclinical studies. Expert Rev Cardiovasc Ther 2008;6:1379-91. 
 174.  Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and 
drug-eluting stents: still important, still much to learn. J Am Coll Cardiol 
2004;44:1373-85. 
 175.  Schwartz RS, Edelman E, Virmani R et al. Drug-eluting stents in 
preclinical studies: updated consensus recommendations for preclinical 
evaluation. Circ Cardiovasc Interv 2008;1:143-53. 
 176.  Padfield GJ, Newby DE, Mills NL. Understanding the role of endothelial 
progenitor cells in percutaneous coronary intervention. J Am Coll Cardiol 
2010;55:1553-65. 
 177.  Krotz F, Sohn HY, Pohl U. Reactive oxygen species: players in the 
platelet game. Arterioscler Thromb Vasc Biol 2004;24:1988-96. 
 178.  Wachowicz B, Olas B, Zbikowska HM, Buczynski A. Generation of 
reactive oxygen species in blood platelets. Platelets 2002;13:175-82. 
 179.  Pearson JD. Endothelial cell function and thrombosis. Baillieres Best 
Pract Res Clin Haematol 1999;12:329-41. 
 180.  Rocca B, FitzGerald GA. Simply Read: Erythrocytes Modulate Platelet 
Function: Should We Rethink the Way We Give Aspirin? Circulation 
1997;95:11-3. 
 231 
 181.  Afshar-Kharghan V, Thiagarajan P. Leukocyte adhesion and thrombosis. 
Curr Opin Hematol 2006;13:34-9. 
 182.  Griffin JH, Fernandez JA, Deguchi H. Plasma lipoproteins, hemostasis 
and thrombosis. Thromb Haemost 2001;86:386-94. 
 183.  Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell 
interactions. J Thromb Haemost 2003;1:1335-42. 
 184.  El Omar MM, Islam N, Broekman MJ et al. The ratio of ADP- to ATP-
ectonucleotidase activity is reduced in patients with coronary artery 
disease. Thrombosis Research 2005;116:199-206. 
 185.  Li Y, Zhu H, Kuppusamy P, Roubaud V, Zweier JL, Trush MA. 
Validation of Lucigenin (Bis-N-methylacridinium) as a Chemilumigenic 
Probe for Detecting Superoxide Anion Radical Production by Enzymatic 
and Cellular Systems. J Biol Chem 1998;273:2015-23. 
 186.  Tarpey MM, White CR, Suarez E, Richardson G, Radi R, Freeman BA. 
Chemiluminescent detection of oxidants in vascular tissue. Lucigenin but 
not coelenterazine enhances superoxide formation. Circ Res 
1999;84:1203-11. 
 187.  Asai R, Nishino T, Matsumura T et al. Two Mutations Convert 
Mammalian Xanthine Oxidoreductase to Highly Superoxide-productive 
Xanthine Oxidase. J Biochem (Tokyo) 2007;141:525-34. 
 188.  Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide 
pathway present in human platelets regulates aggregation. Proc Natl Acad 
Sci U S A 1990;87:5193-7. 
 189.  Olas B, Wachowicz B. Role of reactive nitrogen species in blood platelet 
functions. Platelets 2007;18:555-65. 
 190.  Krotz F, Sohn HY, Gloe T et al. NAD(P)H oxidase-dependent platelet 
superoxide anion release increases platelet recruitment. Blood 2002 Aug 
1;100 (3):917 -24 2002;100:917-24. 
 191.  Handin RI, Karabin R, Boxer GJ. Enhancement of platelet function by 
superoxide anion. J Clin Invest 1977;59:959-65. 
 232 
 192.  Salvemini D, de Nucci G, Sneddon JM, Vane JR. Superoxide anions 
enhance platelet adhesion and aggregation. Br J Pharmacol 
1989;97:1145-50. 
 193.  De La Cruz JP, Garcia PJ, Sanchez dlC. Dipyridamole inhibits platelet 
aggregation induced by oxygen-derived free radicals. Thromb Res 
1992;66:277-85. 
 194.  Ambrosio G, Golino P, Pascucci I et al. Modulation of platelet function 
by reactive oxygen metabolites. Am J Physiol 1994;267:H308-H318. 
 195.  Belisario MA, Tafuri S, Di Domenico C et al. H(2)O(2) activity on 
platelet adhesion to fibrinogen and protein tyrosine phosphorylation. 
Biochim Biophys Acta 2000;1495:183-93. 
 196.  Stuart MJ, Holmsen H. Hydrogen peroxide, an inhibitor of platelet 
function: effect on adenine nucleotide metabolism, and the release 
reaction. Am J Hematol 1977;2:53-63. 
 197.  Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, Violi F. Hydrogen 
peroxide is involved in collagen-induced platelet activation. Blood 
1998;91:484-90. 
 198.  Pratico D, Iuliano L, Ghiselli A, Alessandri C, Violi F. Hydrogen 
peroxide as trigger of platelet aggregation. Haemostasis 1991;21:169-74. 
 199.  Moro MA, Darley-Usmar VM, Goodwin DA et al. Paradoxical fate and 
biological action of peroxynitrite on human platelets. Proc Natl Acad Sci 
U S A 1994;91:6702-6. 
 200.  Nowak P, Wachowicz B. Studies on pig blood platelet responses to 
peroxynitrite action. Platelets 2001;12:376-81. 
 201.  Nowak P, Wachowicz B. Peroxynitrite-mediated modification of 
fibrinogen affects platelet aggregation and adhesion. Platelets 
2002;13:293-9. 
 202.  Yin K, Lai PS, Rodriguez A, Spur BW, Wong PY. Antithrombotic effects 
of peroxynitrite: inhibition and reversal of aggregation in human platelets. 
Prostaglandins 1995;50:169-78. 
 233 
 203.  Brown AS, Moro MA, Masse JM, Cramer EM, Radomski M, Darley-
Usmar V. Nitric oxide-dependent and independent effects on human 
platelets treated with peroxynitrite. Cardiovasc Res 1998;40:380-8. 
 204.  Maalej N, Albrecht R, Loscalzo J, Folts JD. The potent platelet inhibitory 
effects of S-nitrosated albumin coating of artificial surfaces. J Am Coll 
Cardiol 1999;33:1408-14. 
 205.  Ware JA, Heistad DD. Platelet-Endothelium Interactions. N Engl J Med 
1993;328:628-35. 
 206.  Marcus AJ, Broekman MJ, Drosopoulos JH et al. The endothelial cell 
ecto-ADPase responsible for inhibition of platelet function is CD39. J 
Clin Invest 1997;99:1351-60. 
 207.  Marcus A, Broekman M, Drosopoulos J et al. Thromboregulation by 
endothelial cells: significance for occlusive vascular diseases. 
Arteriosclerosis, Thrombosis, and Vascular Biology 2001;21:178-82. 
 208.  Krotz F, Sohn HY, Keller M et al. Depolarization of endothelial cells 
enhances platelet aggregation through oxidative inactivation of 
endothelial NTPDase. Arterioscler Thromb Vasc Biol 2002 Dec 1;22 (12 
):2003 -9 2002;22:2003-9. 
 209.  Lindner V, Majack RA, Reidy MA. Basic fibroblast growth factor 
stimulates endothelial regrowth and proliferation in denuded arteries. J 
Clin Invest 1990;85:2004-8. 
 210.  Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes 
and smooth muscle cells: activation of a latent transforming growth 
factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol 
1989;109:309-15. 
 211.  Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-
cyclic guanosine monophosphate inhibit mitogenesis and proliferation of 
cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-7. 
 212.  Bell L, Madri JA. Influence of the angiotensin system on endothelial and 
smooth muscle cell migration. Am J Pathol 1990;137:7-12. 
 213.  Casscells W. Migration of smooth muscle and endothelial cells. Critical 
events in restenosis. Circulation 1992;86:723-9. 
 234 
 214.  Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular 
endothelial growth factor is a secreted angiogenic mitogen. Science 
1989;246:1306-9. 
 215.  Ishikawa F, Miyazono K, Hellman U et al. Identification of angiogenic 
activity and the cloning and expression of platelet-derived endothelial cell 
growth factor. Nature 1989;338:557-62. 
 216.  Oviedo PJ, Sobrino A, Laguna-Fernandez A et al. Estradiol induces 
endothelial cell migration and proliferation through estrogen receptor-
enhanced RhoA/ROCK pathway. Mol Cell Endocrinol 2010. 
 217.  Cattaneo MG, Chini B, Vicentini LM. Oxytocin stimulates migration and 
invasion in human endothelial cells. Br J Pharmacol 2008;153:728-36. 
 218.  Mueller SN, Thomas KA, Di Salvo J, Levine EM. Stabilization by 
heparin of acidic fibroblast growth factor mitogenicity for human 
endothelial cells in vitro. J Cell Physiol 1989;140:439-48. 
 219.  Morbidelli L, Orlando C, Maggi CA, Ledda F, Ziche M. Proliferation and 
migration of endothelial cells is promoted by endothelins via activation of 
ETB receptors. Am J Physiol 1995;269:H686-H695. 
 220.  Pankonin G, Teuscher E. Stimulation of endothelial cell migration by 
thrombin. Biomed Biochim Acta 1991;50:1073-8. 
 221.  Inyang AL, Tobelem G. Tissue-plasminogen activator stimulates 
endothelial cell migration in wound assays. Biochem Biophys Res 
Commun 1990;171:1326-32. 
 222.  Seetharam D, Mineo C, Gormley AK et al. High-density lipoprotein 
promotes endothelial cell migration and reendothelialization via 
scavenger receptor-B type I. Circ Res 2006;98:63-72. 
 223.  Sprague EA, Luo J, Palmaz JC. Human aortic endothelial cell migration 
onto stent surfaces under static and flow conditions. J Vasc Interv Radiol 
1997;8:83-92. 
 224.  Morales-Ruiz M, Fulton D, Sowa G et al. Vascular endothelial growth 
factor-stimulated actin reorganization and migration of endothelial cells is 
regulated via the serine/threonine kinase Akt. Circ Res 2000;86:892-6. 
 235 
 225.  Ziche M, Morbidelli L, Masini E et al. Nitric oxide mediates angiogenesis 
in vivo and endothelial cell growth and migration in vitro promoted by 
substance P. J Clin Invest 1994;94:2036-44. 
 226.  Pyriochou A, Vassilakopoulos T, Zhou Z, Papapetropoulos A. cGMP-
dependent and -independent angiogenesis-related properties of nitric 
oxide. Life Sci 2007;81:1549-54. 
 227.  Bulotta S, Ierardi MV, Maiuolo J et al. Basal nitric oxide release 
attenuates cell migration of HeLa and endothelial cells. Biochem Biophys 
Res Commun 2009;386:744-9. 
 228.  Lau YT, Ma WC. Nitric oxide inhibits migration of cultured endothelial 
cells. Biochem Biophys Res Commun 1996;221:670-4. 
 229.  Kipshidze N, Dangas G, Tsapenko M et al. Role of the endothelium in 
modulating neointimal formation: Vasculoprotective approaches to 
attenuate restenosis after percutaneous coronary interventions. Journal of 
the American College of Cardiology 2004;44:733-9. 
 230.  Watt J, Wadsworth R, Kennedy S, Oldroyd KG. Pro-healing drug-eluting 
stents: a role for antioxidants? Clin Sci (Lond) 2008;114:265-73. 
 231.  Burk RR. A factor from a transformed cell line that affects cell migration. 
Proc Natl Acad Sci U S A 1973;70:369-72. 
 232.  Steinberg D. Lewis A. Conner Memorial Lecture. Oxidative modification 
of LDL and atherogenesis. Circulation 1997;95:1062-71. 
 233.  Channon KM. Oxidative Stress and Coronary Plaque Stability. 
Arterioscler Thromb Vasc Biol 2002;22:1751-2. 
 234.  Cominacini L, Garbin U, Pasini AF et al. Oxidized low-density 
lipoprotein increases the production of intracellular reactive oxygen 
species in endothelial cells: inhibitory effect of lacidipine. J Hypertens 
1998;16:1913-9. 
 235.  Murugesan G, Chisolm GM, Fox PL. Oxidized low density lipoprotein 
inhibits the migration of aortic endothelial cells in vitro. J Cell Biol 
1993;120:1011-9. 
 236 
 236.  Chavakis E, Dernbach E, Hermann C, Mondorf UF, Zeiher AM, 
Dimmeler S. Oxidized LDL inhibits vascular endothelial growth factor-
induced endothelial cell migration by an inhibitory effect on the 
Akt/endothelial nitric oxide synthase pathway. Circulation 
2001;103:2102-7. 
 237.  Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide 
production contributes to the angiogenic properties of vascular 
endothelial growth factor in human endothelial cells. J Clin Invest 
1997;100:3131-9. 
 238.  Porras AG, Olson JS, Palmer G. The reaction of reduced xanthine oxidase 
with oxygen. Kinetics of peroxide and superoxide formation. J Biol Chem 
1981;256:9096-103. 
 239.  Clements MK, Siemsen DW, Swain SD et al. Inhibition of actin 
polymerization by peroxynitrite modulates neutrophil functional 
responses. J Leukoc Biol 2003;73:344-55. 
 240.  Sato E, Koyama S, Camhi SL, Nelson DK, Robbins RA. Reactive oxygen 
and nitrogen metabolites modulate fibronectin-induced fibroblast 
migration in vitro. Free Radic Biol Med 2001;30:22-9. 
 241.  Kuzuya M, Kuzuya F. Probucol as an antioxidant and antiatherogenic 
drug. Free Radical Biology and Medicine 1993;14:67-77. 
 242.  Ok E, Basnakian AG, Apostolov EO, Barri YM, Shah SV. Carbamylated 
low-density lipoprotein induces death of endothelial cells: A link to 
atherosclerosis in patients with kidney disease. Kidney Int 2005;68:173-8. 
 243.  Shi Y, Niculescu R, Wang D, Patel S, Davenpeck KL, Zalewski A. 
Increased NAD(P)H Oxidase and Reactive Oxygen Species in Coronary 
Arteries After Balloon Injury. Arterioscler Thromb Vasc Biol 
2001;21:739-45. 
 244.  Hay A, Burkitt MJ, Jones CM, Hartley RC. Development of a new EPR 
spin trap, DOD-8C (N-[4-dodecyloxy-2-(7'-carboxyhept-1'-
yloxy)benzylidene]-N-tert-butylamine N-oxide), for the trapping of lipid 
radicals at a predetermined depth within biological membranes. Arch 
Biochem Biophys 2005;435:336-46. 
 237 
 245.  Sklavounou E, Hay A, Ashraf N et al. The use of telomere biology to 
identify and develop superior nitrone based anti-oxidants. Biochem 
Biophys Res Commun 2006;347:420-7. 
 246.  Michan S, Sinclair D. Sirtuins in mammals: insights into their biological 
function. Biochem J 2007;404:1-13. 
 247.  Potente M, Dimmeler S. Emerging roles of SIRT1 in vascular endothelial 
homeostasis. Cell Cycle 2008;7:2117-22. 
 248.  Zu Y, Liu L, Lee MYK et al. SIRT1 Promotes Proliferation and Prevents 
Senescence Through Targeting LKB1 in Primary Porcine Aortic 
Endothelial Cells. Circ Res 2010;106:1384-93. 
 249.  Ota H, Eto M, Kano MR et al. Induction of Endothelial Nitric Oxide 
Synthase, SIRT1, and Catalase by Statins Inhibits Endothelial Senescence 
Through the Akt Pathway. Arterioscler Thromb Vasc Biol 
2010;ATVBAHA. 
 250.  Ota H, Eto M, Ako J et al. Sirolimus and Everolimus Induce Endothelial 
Cellular Senescence Via Sirtuin 1 Down-Regulation: Therapeutic 
Implication of Cilostazol After Drug-Eluting Stent Implantation. Journal 
of the American College of Cardiology 2009;53:2298-305. 
 251.  Mehran R, Nikolsky E, Camenzind E et al. An Internet-based registry 
examining the efficacy of heparin coating in patients undergoing 
coronary stent implantation. Am Heart J 2005;150:1171-6. 
 252.  Lin Q, Yan J, Qiu F, Song X, Fu G, Ji J. Heparin/collagen multilayer as a 
thromboresistant and endothelial favorable coating for intravascular stent. 
J Biomed Mater Res A 2011;96:132-41. 
 253.  Ota H, Akishita M, Eto M, Iijima K, Kaneki M, Ouchi Y. Sirt1 modulates 
premature senescence-like phenotype in human endothelial cells. Journal 
of Molecular and Cellular Cardiology 2007;43:571-9. 
 254.  Potente M, Dimmeler S. NO Targets SIRT1: A Novel Signaling Network 
in Endothelial Senescence. Arterioscler Thromb Vasc Biol 2008;28:1577-
9. 
 255.  Kiosses WB, Daniels RH, Otey C, Bokoch GM, Schwartz MA. A role for 
p21-activated kinase in endothelial cell migration. J Cell Biol 
1999;147:831-44. 
 238 
 256.  Moldovan L, Moldovan NI, Sohn RH, Parikh SA, Goldschmidt-Clermont 
PJ. Redox changes of cultured endothelial cells and actin dynamics. Circ 
Res 2000;86:549-57. 
 257.  Ikeda S, Yamaoka-Tojo M, Hilenski L et al. IQGAP1 regulates reactive 
oxygen species-dependent endothelial cell migration through interacting 
with Nox2. Arterioscler Thromb Vasc Biol 2005;25:2295-300. 
 258.  Moldovan L, Mythreye K, Goldschmidt-Clermont PJ, Satterwhite LL. 
Reactive oxygen species in vascular endothelial cell motility. Roles of 
NAD(P)H oxidase and Rac1. Cardiovasc Res 2006;71:236-46. 
 259.  Paniccia R, Antonucci E, Maggini N et al. Assessment of platelet 
function on whole blood by multiple electrode aggregometry in high-risk 
patients with coronary artery disease receiving antiplatelet therapy. Am J 
Clin Pathol 2009;131:834-42. 
 260.  Breet NJ, van Werkum JW, Bouman HJ et al. Comparison of platelet 
function tests in predicting clinical outcome in patients undergoing 
coronary stent implantation. JAMA 2010;303:754-62. 
 261.  Luscher TF, Steffel J, Eberli FR et al. Drug-eluting stent and coronary 
thrombosis: biological mechanisms and clinical implications. Circulation 
2007;115:1051-8. 
 262.  Tanaka K, Hayashi K, Shingu T, Kuga Y, Nomura K, Kajiyama G. 
Probucol inhibits neointimal formation in carotid arteries of 
normocholesterolemic rabbits and the proliferation of cultured rabbit 
vascular smooth muscle cells. Cardiovascular Drugs & Therapy 
1998;12:19-28. 
 263.  Steigerwald K, Merl S, Kastrati A et al. The pre-clinical assessment of 
rapamycin-eluting, durable polymer-free stent coating concepts. 
Biomaterials 2009;30:632-7. 
 264.  Byrne RA, Mehilli J, Iijima R et al. A polymer-free dual drug-eluting 
stent in patients with coronary artery disease: a randomized trial vs. 
polymer-based drug-eluting stents. Eur Heart J 2009;30:923-31. 
 265.  Mehilli J, Byrne RA, Wieczorek A et al. Randomized trial of three 
rapamycin-eluting stents with different coating strategies for the 
reduction of coronary restenosis. Eur Heart J 2008;29:1975-82. 
 239 
 266.  Schober A, Weber C. Mechanisms of monocyte recruitment in vascular 
repair after injury. Antioxid Redox Signal 2005;7:1249-57. 
 267.  Bhoday J, de Silva S, Xu Q. The molecular mechanisms of vascular 
restenosis: Which genes are crucial? Curr Vasc Pharmacol 2006;4:269-
75. 
 268.  Serebruany V, Malinin A, Scott R. The in vitro effects of a novel vascular 
protectant, AGI-1067, on platelet aggregation and major receptor 
expression in subjects with multiple risk factors for vascular disease. J 
Cardiovasc Pharmacol Ther 2006;11:191-6. 
 269.  Tardif JC, McMurray JJ, Klug E et al. Effects of succinobucol (AGI-
1067) after an acute coronary syndrome: a randomised, double-blind, 
placebo-controlled trial. Lancet 2008;371:1761-8. 
 270.  Neklesa TK, Davis RW. Superoxide anions regulate TORC1 and its 
ability to bind Fpr1:rapamycin complex. Proceedings of the National 
Academy of Sciences 2008;105:15166-71. 
 271.  Muldrew KM, Franks AM. Succinobucol: review of the metabolic, 
antiplatelet and cardiovascular effects. Expert Opin Investig Drugs 
2009;18:531-9. 
 272.  Wessely R, Hausleiter J, Michaelis C et al. Inhibition of neointima 
formation by a novel drug-eluting stent system that allows for dose-
adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc 
Biol 2005;25:748-53. 
 273.  Hausleiter J, Kastrati A, Wessely R et al. Prevention of restenosis by a 
novel drug-eluting stent system with a dose-adjustable, polymer-free, on-
site stent coating. Eur Heart J 2005;26:1475-81. 
 274.  Schwartz RS, Edelman ER, Carter A et al. Drug-Eluting Stents in 
Preclinical Studies: Recommended Evaluation From a Consensus Group. 
Circulation 2002;106:1867-73. 
 275.  Kanellakis P, Pomilio G, Walker C et al. A novel antioxidant 3,7-
dihydroxy-isoflav-3-ene (DHIF) inhibits neointimal hyperplasia after 
vessel injury attenuating reactive oxygen species and nuclear factor-
kappaB signaling. Atherosclerosis 2009;204:66-72. 
 240 
 276.  Lee HM, Jeon BH, Won KJ et al. Gene Transfer of Redox Factor-1 
Inhibits Neointimal Formation: Involvement of Platelet-Derived Growth 
Factor-{beta} Receptor Signaling via the Inhibition of the Reactive 
Oxygen Species-Mediated Syk Pathway. Circ Res 2009;104:219-27. 
 277.  Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent 
restenosis: contributions of inflammatory responses and arterial injury to 
neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-30. 
 278.  Granada JF, Inami S, Aboodi MS et al. Development of a novel 
prohealing stent designed to deliver sirolimus from a biodegradable 
abluminal matrix. Circ Cardiovasc Interv 2010;3:257-66. 
 279.  Grube E, Schofer J, Hauptmann KE et al. A novel paclitaxel-eluting stent 
with an ultrathin abluminal biodegradable polymer 9-month outcomes 
with the JACTAX HD stent. JACC Cardiovasc Interv 2010;3:431-8. 
 280.  Grube E, Buellesfeld L. BioMatrix Biolimus A9-eluting coronary stent: a 
next-generation drug-eluting stent for coronary artery disease. Expert Rev 
Med Devices 2006;3:731-41. 
 281.  Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP Inhibits 
Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells. 
Circ Res 1995;76:412-7. 
 282.  Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment 
and neointimal hyperplasia in rabbits. Coupled inhibitory effects of 
heparin. Arterioscler Thromb Vasc Biol 1996;16:1312-8. 
 283.  Kearney M, Pieczek A, Haley L et al. Histopathology of In-Stent 
Restenosis in Patients With Peripheral Artery Disease. Circulation 
1997;95:1998-2002. 
 284.  Virmani R, Liistro F, Stankovic G et al. Mechanism of late in-stent 
restenosis after implantation of a paclitaxel derivate-eluting polymer stent 
system in humans. Circulation 2002;106:2649-51. 
 285.  Bayes-Genis A, Campbell JH, Carlson PJ, Holmes DR, Jr., Schwartz RS. 
Macrophages, myofibroblasts and neointimal hyperplasia after coronary 
artery injury and repair. Atherosclerosis 2002;163:89-98. 
 241 
 286.  Sherman LA, Lee JL, Stewart CC. Release of fibrinolytic enzymes by 
macrophages in response to soluble fibrin. J Reticuloendothel Soc 
1981;30:317-29. 
 287.  Kaluza GL, Raizner AE, Mazur W et al. Long-term effects of 
intracoronary beta-radiation in balloon- and stent-injured porcine 
coronary arteries. Circulation 2001;103:2108-13. 
 288.  Tyurina YY, Tyurin VA, Yalowich JC et al. Phenoxyl radicals of 
etoposide (VP-16) can directly oxidize intracellular thiols: protective 
versus damaging effects of phenolic antioxidants. Toxicol Appl 
Pharmacol 1995;131:277-88. 
 289.  Kagan VE, Tyurina YY. Recycling and redox cycling of phenolic 
antioxidants. Ann N Y Acad Sci 1998;854:425-34. 
 290.  Rosner D, McCarthy N, Bennett M. Rapamycin inhibits human in stent 
restenosis vascular smooth muscle cells independently of pRB 
phosphorylation and p53. Cardiovasc Res 2005;66:601-10. 
 291.  Ako J, Morino Y, Honda Y et al. Late incomplete stent apposition after 
sirolimus-eluting stent implantation: a serial intravascular ultrasound 
analysis. J Am Coll Cardiol 2005;46:1002-5. 
 292.  Foley DP, Melkert R, Serruys PW. Influence of coronary vessel size on 
renarrowing process and late angiographic outcome after successful 
balloon angioplasty. Circulation 1994;90:1239-51. 
 293.  Jeong MH, Owen WG, Staab ME et al. Porcine model of stent 
thrombosis: platelets are the primary component of acute stent closure. 
Cathet Cardiovasc Diagn 1996;38:38-43. 
 294.  Yokoyama T, Miyauchi K, Kurata T, Sato H, Daida H. Effect of probucol 
on neointimal thickening in a stent porcine restenosis model. Japanese 
Heart Journal 2004;45:305-13. 
 295.  Farb A, Heller PF, Shroff S et al. Pathological analysis of local delivery 
of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-9. 
 296.  Kastrati A, Schomig A, Dirschinger J et al. Increased Risk of Restenosis 
After Placement of Gold-Coated Stents : Results of a Randomized Trial 
Comparing Gold-Coated With Uncoated Steel Stents in Patients With 
Coronary Artery Disease. Circulation 2000;101:2478-83. 
 242 
 297.  Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vliestra RE, 
Holmes DR. Restenosis after balloon angioplasty. A practical 
proliferative model in porcine coronary arteries. Circulation 
1990;82:2190-200. 
 298.  Grech ED, Dodd NJ, Jackson MJ, Morrison WL, Faragher EB, Ramsdale 
DR. Evidence for free radical generation after primary percutaneous 
transluminal coronary angioplasty recanalization in acute myocardial 
infarction. Am J Cardiol 1996;77:122-7. 
 299.  Iuliano L, Pratico D, Greco C et al. Angioplasty increases coronary sinus 
F2-isoprostane formation: evidence for in vivo oxidative stress during 
PTCA. Journal of the American College of Cardiology 2001;37:76-80. 
 300.  Hein TW, Liao JC, Kuo L. oxLDL specifically impairs endothelium-
dependent, NO-mediated dilation of coronary arterioles. Am J Physiol 
Heart Circ Physiol 2000;278:H175-H183. 
 301.  Takahashi T, Kalka C, Masuda H et al. Ischemia- and cytokine-induced 
mobilization of bone marrow-derived endothelial progenitor cells for 
neovascularization. Nat Med 1999;5:434-8. 
 302.  Shintani S, Murohara T, Ikeda H et al. Mobilization of Endothelial 
Progenitor Cells in Patients With Acute Myocardial Infarction. 
Circulation 2001;103:2776-9. 
 303.  Massa M, Rosti V, Ferrario M et al. Increased circulating hematopoietic 
and endothelial progenitor cells in the early phase of acute myocardial 
infarction. Blood 2005;105:199-206. 
 304.  Bonello L, Basire A, Sabatier F, Paganelli F, Dignat-George F. 
Endothelial injury induced by coronary angioplasty triggers mobilization 
of endothelial progenitor cells in patients with stable coronary artery 
disease. J Thromb Haemost 2006;4:979-81. 
 305.  Kalka C, Masuda H, Takahashi T et al. Vascular Endothelial Growth 
Factor165 Gene Transfer Augments Circulating Endothelial Progenitor 
Cells in Human Subjects. Circ Res 2000;86:1198-202. 
 306.  Aicher A, Heeschen C, Mildner-Rihm C et al. Essential role of 
endothelial nitric oxide synthase for mobilization of stem and progenitor 
cells. Nat Med 2003;9:1370-6. 
 243 
 307.  Laufs U, Werner N, Link A et al. Physical Training Increases Endothelial 
Progenitor Cells, Inhibits Neointima Formation, and Enhances 
Angiogenesis. Circulation 2004;109:220-6. 
 308.  Vasa M, Fichtlscherer S, Adler K et al. Increase in Circulating 
Endothelial Progenitor Cells by Statin Therapy in Patients With Stable 
Coronary Artery Disease. Circulation 2001;103:2885-90. 
 309.  Walter DH, Rittig K, Bahlmann FH et al. Statin Therapy Accelerates 
Reendothelialization: A Novel Effect Involving Mobilization and 
Incorporation of Bone Marrow-Derived Endothelial Progenitor Cells. 
Circulation 2002;105:3017-24. 
 310.  Min TQ, Zhu CJ, Xiang WX, Hui ZJ, Peng SY. Improvement in 
Endothelial Progenitor Cells from Peripheral Blood by Ramipril Therapy 
in Patients with Stable Coronary Artery Disease. Cardiovascular Drugs 
and Therapy 2004;18:203-9. 
 311.  Vasa M, Fichtlscherer S, Aicher A et al. Number and Migratory Activity 
of Circulating Endothelial Progenitor Cells Inversely Correlate With Risk 
Factors for Coronary Artery Disease. Circ Res 2001;89:1e-7. 
 312.  Hill JM, Zalos G, Halcox JPJ et al. Circulating Endothelial Progenitor 
Cells, Vascular Function, and Cardiovascular Risk. N Engl J Med 
2003;348:593-600. 
 313.  Eizawa T, Ikeda U, Murakami Y et al. Decrease in circulating endothelial 
progenitor cells in patients with stable coronary artery disease. Heart 
2004;90:685-6. 
 314.  Thum T, Tsikas D, Stein S et al. Suppression of Endothelial Progenitor 
Cells in Human Coronary Artery Disease by the Endogenous Nitric 
Oxide Synthase Inhibitor Asymmetric Dimethylarginine. Journal of the 
American College of Cardiology 2005;46:1693-701. 
 315.  Werner N, Kosiol S, Schiegl T et al. Circulating Endothelial Progenitor 
Cells and Cardiovascular Outcomes. N Engl J Med 2005;353:999-1007. 
 316.  Schmidt-Lucke C, Rossig L, Fichtlscherer S et al. Reduced Number of 
Circulating Endothelial Progenitor Cells Predicts Future Cardiovascular 
Events: Proof of Concept for the Clinical Importance of Endogenous 
Vascular Repair. Circulation 2005;111:2981-7. 
 244 
 317.  He T, Peterson TE, Holmuhamedov EL et al. Human endothelial 
progenitor cells tolerate oxidative stress due to intrinsically high 
expression of manganese superoxide dismutase.[see comment]. 
Arteriosclerosis, Thrombosis & Vascular Biology 24(11):2021-7, 2004. 
 318.  Dernbach E, Urbich C, Brandes RP, Hofmann WK, Zeiher AM, 
Dimmeler S. Antioxidative stress-associated genes in circulating 
progenitor cells: evidence for enhanced resistance against oxidative 
stress. Blood 2004;104:3591-7. 
 319.  Ingram DA, Krier TR, Mead LE et al. Clonogenic Endothelial Progenitor 
Cells Are Sensitive to Oxidative Stress. Stem Cells 2007;25:297-304. 
 320.  Imanishi T, Hano T, Matsuo Y, Nishio I. Oxidized low-density 
lipoprotein inhibits vascular endothelial growth factor-induced 
endothelial progenitor cell differentiation. Clinical and Experimental 
Pharmacology and Physiology 2003;30:665-70. 
 321.  Ma FX, Zhou B, Chen Z et al. Oxidized low density lipoprotein impairs 
endothelial progenitor cells by regulation of endothelial nitric oxide 
synthase. J Lipid Res 2006;47:1227-37. 
 322.  Manoharan A, Gemmell R, Brighton T, Dunkley S, Lopez K, Kyle P. 
Thrombosis and bleeding in myeloproliferative disorders: identification 
of at-risk patients with whole blood platelet aggregation studies. Br J 
Haematol 1999;105:618-25. 
 323.  Dyszkiewicz-Korpanty A, Olteanu H, Frenkel EP, Sarode R. Clopidogrel 
anti-platelet effect: an evaluation by optical aggregometry, impedance 
aggregometry, and the platelet function analyzer (PFA-100). Platelets 
2007;18:491-6. 
 324.  Ludmer PL, Selwyn AP, Shook TL et al. Paradoxical vasoconstriction 
induced by acetylcholine in atherosclerotic coronary arteries. N Engl J 
Med 1986;315:1046-51. 
 325.  Ganz W, Tamura K, Marcus HS, Donoso R, Yoshida S, Swan HJ. 
Measurement of coronary sinus blood flow by continuous thermodilution 
in man. Circulation 1971;44:181-95. 
 326.  Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and 
dysfunction: testing and clinical relevance. Circulation 2007;115:1285-
95. 
 245 
 327.  The E, I. Effect of Nifedipine and Cerivastatin on Coronary Endothelial 
Function in Patients With Coronary Artery Disease: The ENCORE I 
Study (Evaluation of Nifedipine and Cerivastatin On Recovery of 
coronary Endothelial function). Circulation 2003;107:422-8. 
 328.  Nakaishi T, Tamura A, Watanabe T, Mikuriya Y, Nasu M. Relationship 
between plasma oxidized low-density lipoprotein and the coronary 
vasomotor response to acetylcholine in patients with coronary artery 
disease. Jpn Circ J 2000;64:856-60. 
 329.  Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G. 
Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase 
inhibition on coronary endothelial function. Circ Res 2003;93:e98-103. 
 330.  Luscher TF, Pieper M, Tendera M et al. A randomized placebo-controlled 
study on the effect of nifedipine on coronary endothelial function and 
plaque formation in patients with coronary artery disease: the ENCORE 
II study. Eur Heart J 2009;30:1590-7. 
 331.  Mancini GBJ, Henry GC, Macaya C et al. Angiotensin-Converting 
Enzyme Inhibition With Quinapril Improves Endothelial Vasomotor 
Dysfunction in Patients With Coronary Artery Disease: The TREND 
(Trial on Reversing ENdothelial Dysfunction) Study. Circulation 
1996;94:258-65. 
 332.  Yoder MC, Mead LE, Prater D et al. Redefining endothelial progenitor 
cells via clonal analysis and hematopoietic stem/progenitor cell 
principals. Blood 2007;109:1801-9. 
 333.  George J, Shmilovich H, Deutsch V, Miller H, Keren G, Roth A. 
Comparative Analysis of Methods for Assessment of Circulating 
Endothelial Progenitor Cells. Tissue Engineering 2006;12:331-5. 
 334.  Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and 
role in vascular biology. Circ Res 2004;95:343-53. 
 335.  Werner N, Wassmann S, Ahlers P et al. Endothelial progenitor cells 
correlate with endothelial function in patients with coronary artery 
disease. Basic Res Cardiol 2007;102:565-71. 
 336.  Wang X, Chen J, Tao Q, Zhu J, Shang Y. Effects of ox-LDL on number 
and activity of circulating endothelial progenitor cells. Drug Chem 
Toxicol 2004;27:243-55. 
 246 
 337.  Ma FX, Ren Q, Han ZC. [Effects of oxidized low-density lipoprotein on 
endothelial progenitor cells survival and activity mediated by lectin-like 
oxidized low density lipoprotein receptor]. Zhongguo Yi Xue Ke Xue 
Yuan Xue Bao 2007;29:336-41. 
 338.  Di Santo S, Diehm N, Ortmann J et al. Oxidized low density lipoprotein 
impairs endothelial progenitor cell function by downregulation of E-
selectin and integrin alpha(v)beta5. Biochem Biophys Res Commun 
2008;373:528-32. 
 339.  Llevadot J, Murasawa S, Kureishi Y et al. HMG-CoA reductase inhibitor 
mobilizes bone marrow-derived endothelial progenitor cells. Journal of 
Clinical Investigation 2001;108:399-405. 
 340.  Shimada K, Mokuno H, Matsunaga E et al. Circulating oxidized low-
density lipoprotein is an independent predictor for cardiac event in 
patients with coronary artery disease. Atherosclerosis 2004;174:343-7. 
 341.  Fang JC, Kinlay S, Behrendt D et al. Circulating autoantibodies to 
oxidized LDL correlate with impaired coronary endothelial function after 
cardiac transplantation. Arterioscler Thromb Vasc Biol 2002;22:2044-8. 
 342.  Matsumoto T, Takashima H, Ohira N et al. Plasma level of oxidized low-
density lipoprotein is an independent determinant of coronary 
macrovasomotor and microvasomotor responses induced by bradykinin. J 
Am Coll Cardiol 2004;44:451-7. 
 343.  Rehman J, Li J, Parvathaneni L et al. Exercise acutely increases 
circulating endothelial progenitor cells and monocyte-/macrophage-
derived angiogenic cells. J Am Coll Cardiol 2004;43:2314-8. 
 344.  Rauscher FM, Goldschmidt-Clermont PJ, Davis BH et al. Aging, 
progenitor cell exhaustion, and atherosclerosis. Circulation 
2003;108:457-63. 
 345.  Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C. Impaired 
Progenitor Cell Activity in Age-Related Endothelial Dysfunction. Journal 
of the American College of Cardiology 2005;45:1441-8. 
 346.  Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in 
individual responsiveness to clopidogrel: clinical implications, 
management, and future perspectives. J Am Coll Cardiol 2007;49:1505-
16. 
 247 
 347.  Denninger MH, Necciari J, Serre-Lacroix E, Sissmann J. Clopidogrel 
antiplatelet activity is independent of age and presence of atherosclerosis. 
Semin Thromb Hemost 1999;25 Suppl 2:41-5. 
 348.  Hobson AR, Qureshi Z, Banks P, Curzen N. Gender and responses to 
aspirin and clopidogrel: insights using short thrombelastography. 
Cardiovasc Ther 2009;27:246-52. 
 349.  Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review 
of the evidence. Journal of the American College of Cardiology 
2005;45:1157-64. 
 350.  Stocker R, Perrella MA. Heme oxygenase-1: a novel drug target for 
atherosclerotic diseases? Circulation 2006;114:2178-89. 
 351.  Wu BJ, Midwinter RG, Cassano C et al. Heme oxygenase-1 increases 
endothelial progenitor cells. Arterioscler Thromb Vasc Biol 
2009;29:1537-42. 
 352.  Andres V. Unexpected proatherogenic properties of p21: beyond cell 
cycle control? Circulation 2004;110:3749-52. 
 353.  Rosso A, Balsamo A, Gambino R et al. p53 Mediates the Accelerated 
Onset of Senescence of Endothelial Progenitor Cells in Diabetes. Journal 
of Biological Chemistry 2006;281:4339-47. 
 354.  Sata M, Tanaka K, Ishizaka N, Hirata Y, Nagai R. Absence of p53 leads 
to accelerated neointimal hyperplasia after vascular injury. Arterioscler 
Thromb Vasc Biol 2003;23:1548-52. 
 355.  Mayr U, Mayr M, Li C et al. Loss of p53 accelerates neointimal lesions 
of vein bypass grafts in mice. Circ Res 2002;90:197-204. 
 356.  Stocker R. Molecular mechanisms underlying the antiatherosclerotic and 
antidiabetic effects of probucol, succinobucol, and other probucol 
analogues. Curr Opin Lipidol 2009;20:227-35. 
 357.  Shi M, Yang H, Motley ED, Guo Z. Overexpression of Cu/Zn-superoxide 
dismutase and/or catalase in mice inhibits aorta smooth muscle cell 
proliferation. American Journal of Hypertension 17(5 Pt 1):450-6, 2004. 
 248 
 358.  Kuo MD, Bright IJ, Wang DS et al. Local resistance to oxidative stress by 
overexpression of copper-zinc superoxide dismutase limits neointimal 
formation after angioplasty. Journal of Endovascular Therapy: Official 
Journal of the International Society of Endovascular Specialists 
11(6):585-94, 2004. 
 359.  Ozumi K, Tasaki H, Takatsu H et al. Extracellular superoxide dismutase 
overexpression reduces cuff-induced arterial neointimal formation. 
Atherosclerosis 181(1):55-62, 2005. 
 360.  Brasen JH, Leppanen O, Inkala M et al. Extracellular superoxide 
dismutase accelerates endothelial recovery and inhibits in-stent restenosis 
in stented atherosclerotic Watanabe heritable hyperlipidemic rabbit aorta. 
J Am Coll Cardiol 2007;50:2249-53. 
 361.  Sharif F, Hynes SO, Cooney R et al. Gene-eluting Stents: Adenovirus-
mediated Delivery of eNOS to the Blood Vessel Wall Accelerates Re-
endothelialization and Inhibits Restenosis. Mol Ther 2008;16:1674-80. 
 362.  Levonen AL, Vahakangas E, Koponen JK, Yla-Herttuala S. Antioxidant 
Gene Therapy for Cardiovascular Disease: Current Status and Future 
Perspectives. Circulation 2008;117:2142-50. 
 
 
 
